

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2014**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Cumulative Supplement 11

November 2014

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

**CUMULATIVE SUPPLEMENT 11
November 2014**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
CLONMEL HEALTHCARE LTD (CLONMEL)	DAVA PHARMACEUTICALS INC (DAVA PHARMS INC)
CLONMEL HEALTHCARE (CLONMEL HLTHCARE)	DAVA PHARMACEUTICALS INC (DAVA PHARMS INC)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS)	ACTAVIS LABORATORIES INC (ACTAVIS LABS FL INC)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885	15823	15974	
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)	2516 (15.9%)	2536 (15.9%)	
MULTISOURCE	13194 (84.0%)	13345 (84.0%)	13307 (84.1%)	13438 (84.1%)	
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)	13169 (83.2%)	13304 (83.3%)	
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)	138 (0.9%)	134 (0.8%)	
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)	77 (0.5%)	
NEW MOLECULAR ENTITIES APPROVED	20	12	6	17	
NUMBER OF APPLICANTS	866	873	889	899	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL
TRIUMEQ

+ VIIV HLTHCARE EQ 600MG BASE;EQ 50MG BASE;300MG N205551 001 Aug 22, 2014 Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM

AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACARBOSE

TABLET;ORAL
ACARBOSE

AB STRIDES PHARMA 25MG A090912 001 Jul 27, 2011 Aug CAHN
AB 50MG A090912 002 Jul 27, 2011 Aug CAHN
AB 100MG A090912 003 Jul 27, 2011 Aug CAHN

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE

@ WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995 May DISC
@ EQ 400MG BASE A074007 002 Oct 18, 1995 May DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
PHRENILIN FORTE

@ VALEANT 650MG;50MG A088831 001 Jun 19, 1985 Apr DISC

TABLET;ORAL
BUTAPAP

@ MIKART 650MG;50MG A089988 001 Oct 26, 1992 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
ESGIC-PLUS

@ MIKART 500MG;50MG;40MG A040085 001 Mar 28, 1996 Apr DISC

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIKART 750MG;50MG;40MG A040496 001 Dec 23, 2003 Apr DISC
@ MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar DISC
AA + VINTAGE PHARMS 325MG;50MG;40MG A040511 001 Aug 27, 2003 Mar CRLD
@ 500MG;50MG;40MG A040513 001 Aug 25, 2003 Apr DISC
@ WATSON LABS 500MG;50MG;40MG A040267 001 Jul 30, 1998 Jan DISC
ESGIC-PLUS
@ MIKART 500MG;50MG;40MG A089451 001 May 23, 1988 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB HIKMA INTL PHARMS 325MG;50MG;40MG;30MG A075618 001 Mar 23, 2001 Sep CAHN
PHRENILIN WITH CAFFEINE AND CODEINE
@ VALEANT 325MG;50MG;40MG;30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

>A> WRASER PHARMS LLC 320.5MG;30MG;16MG A204785 001 Nov 26, 2014 Nov NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG/15ML;7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC
@ MIKART 500MG/15ML;7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC
@ PHARM ASSOC 500MG/15ML;7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC
AA VINTAGE PHARMS 325MG/15ML;7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN
@ 500MG/15ML;7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC

TABLET;ORAL

ANEXSIA

@ MALLINCKRODT 500MG;5MG A089160 001 Apr 23, 1987 Jan DISC
@ 750MG;10MG A040468 001 Oct 31, 2002 Jan DISC

TABLET; ORAL

ANEXSIA 7.5/650					
@ MALLINCKRODT	650MG; 7.5MG	A 089725	001	Sep 30, 1987	Jan DISC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
@ AMNEAL PHARMS NY	500MG; 5MG	A 040729	001	Aug 25, 2006	Apr DISC
@	500MG; 7.5MG	A 040748	001	Aug 25, 2006	Apr DISC
@	500MG; 10MG	A 040813	001	Feb 23, 2007	Apr DISC
@	650MG; 7.5MG	A 040754	001	Aug 25, 2006	Apr DISC
@	650MG; 10MG	A 040757	001	Aug 25, 2006	Apr DISC
@	750MG; 7.5MG	A 040769	001	Aug 28, 2006	Apr DISC
@ CARACO	500MG; 5MG	A 090265	001	Dec 23, 2008	Apr DISC
@	500MG; 7.5MG	A 090265	002	Dec 23, 2008	Apr DISC
@	500MG; 10MG	A 090265	003	Dec 23, 2008	Apr DISC
@	650MG; 7.5MG	A 090380	001	Dec 23, 2008	Apr DISC
@	650MG; 10MG	A 090380	002	Dec 23, 2008	Apr DISC
@	660MG; 10MG	A 090380	003	Dec 23, 2008	Apr DISC
@	750MG; 7.5MG	A 090380	004	Dec 23, 2008	Apr DISC
@ MALLINCKRODT	500MG; 5MG	A 040084	002	Jun 01, 1995	Jan DISC
@	500MG; 7.5MG	A 040201	001	Feb 27, 1998	Jan DISC
@	500MG; 10MG	A 040201	002	Feb 27, 1998	Jan DISC
@	650MG; 10MG	A 040084	004	Oct 16, 1996	Jan DISC
@	660MG; 10MG	A 040084	003	Jul 29, 1996	Jan DISC
@	750MG; 7.5MG	A 040084	001	Jun 01, 1995	Jan DISC
@ MIKART	500MG; 7.5MG	A 089699	001	Aug 25, 1989	Apr DISC
@	650MG; 7.5MG	A 089689	001	Jun 29, 1988	Apr DISC
@	650MG; 10MG	A 081223	001	May 29, 1992	Apr DISC
AA SUN PHARM INDS INC	325MG; 5MG	A 090118	001	Dec 23, 2008	Jun CAHN
AA	325MG; 7.5MG	A 090118	002	Dec 23, 2008	Jun CAHN
AA	325MG; 10MG	A 090118	003	Dec 23, 2008	Jun CAHN
AA VINTAGE PHARMS	300MG; 5MG	A 090415	001	Jan 24, 2011	Feb CAHN
AA	300MG; 7.5MG	A 090415	002	Jan 24, 2011	Feb CAHN
AA	300MG; 10MG	A 090415	003	Jan 24, 2011	Feb CAHN
@	500MG; 2.5MG	A 040144	002	Apr 25, 1997	Apr DISC
@	500MG; 5MG	A 089971	001	Dec 02, 1988	Apr DISC
@	500MG; 7.5MG	A 040144	001	Feb 22, 1996	Apr DISC
@	500MG; 10MG	A 040356	001	May 31, 2000	Apr DISC
@	650MG; 7.5MG	A 040155	001	Apr 14, 1997	Jan DISC
@	650MG; 10MG	A 040143	001	Feb 22, 1996	Apr DISC
@	660MG; 10MG	A 040358	001	May 31, 2000	Apr DISC
@	750MG; 7.5MG	A 040157	001	Apr 12, 1996	Jan DISC
@ WATSON LABS	500MG; 2.5MG	A 081079	001	Aug 30, 1991	Apr DISC
@	500MG; 5MG	A 089883	001	Dec 01, 1988	Apr DISC
@	500MG; 7.5MG	A 081080	001	Aug 30, 1991	Jan DISC
@	650MG; 7.5MG	A 040094	001	Sep 29, 1995	Apr DISC
@	650MG; 10MG	A 040094	002	Sep 29, 1995	Apr DISC
@	660MG; 10MG	A 040094	003	Aug 08, 2000	Apr DISC
@	750MG; 7.5MG	A 081083	001	Aug 30, 1991	Jan DISC
@	750MG; 10MG	A 040094	004	Mar 22, 1999	Apr DISC
@ WATSON LABS FLORIDA	660MG; 10MG	A 040495	001	May 28, 2003	Apr DISC
LORTAB					
@ UCB INC	500MG; 5MG	A 087722	001	Jul 09, 1982	Apr DISC
@	500MG; 10MG	A 040100	001	Jan 26, 1996	Apr DISC
ZYDONE					
@ VINTAGE PHARMS LLC	400MG; 5MG	A 040288	001	Nov 27, 1998	Apr DISC
@	400MG; 7.5MG	A 040288	002	Nov 27, 1998	Apr DISC
@	400MG; 10MG	A 040288	003	Nov 27, 1998	Apr DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

@ ACTAVIS ELIZABETH	500MG; 5MG	A 040199	001	Dec 30, 1998	Aug CAHN
@ DURAMED PHARMS BARR	500MG; 5MG	A 040289	001	Mar 16, 1999	Apr DISC
@ MALLINCKRODT	500MG; 5MG	A 040257	001	Aug 04, 1998	Jan DISC
@ VINTAGE PHARMS	500MG; 5MG	A 040106	001	Jul 30, 1996	Apr DISC
@ WATSON LABS	500MG; 5MG	A 040234	001	Oct 30, 1997	Jan DISC

ROXILOX

@ ROXANE	500MG; 5MG	A 040061	001	Jul 03, 1995	Apr DISC
----------	------------	----------	-----	--------------	----------

TYLOX

@ JANSSEN PHARMS	500MG; 5MG	A 088790	001	Dec 12, 1984	Apr DISC
------------------	------------	----------	-----	--------------	----------

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

@ ACTAVIS ELIZABETH	325MG; 5MG	A 040203	001	Mar 15, 1999	Sep CAHN
@	325MG; 7.5MG	A 040800	001	Apr 03, 2012	Sep CAHN

TABLET; ORAL									
OXYCODONE AND ACETAMINOPHEN									
	@	325MG; 10MG	A040800	002	Apr 03, 2012	Sep	CAHN		
	@ ACTAVIS TOTOWA	325MG; 7.5MG	A040800	001	Apr 03, 2012	Aug	DISC		
	@	325MG; 10MG	A040800	002	Apr 03, 2012	Aug	DISC		
	@ AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007	Apr	DISC		
	@	650MG; 10MG	A040789	002	Nov 27, 2007	Apr	DISC		
	@ COASTAL PHARMS	500MG; 7.5MG	A090177	005	Oct 20, 2008	Apr	DISC		
	@	650MG; 10MG	A090177	006	Oct 20, 2008	Apr	DISC		
	@ MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004	Apr	DISC		
	@	650MG; 10MG	A040550	002	Jun 30, 2004	Apr	DISC		
	@ MIKART	400MG; 5MG	A040687	001	Apr 27, 2006	Apr	DISC		
	@	400MG; 7.5MG	A040698	001	Apr 27, 2006	Apr	DISC		
	@	400MG; 10MG	A040692	001	Apr 27, 2006	Apr	DISC		
	@	500MG; 10MG	A040676	001	Apr 19, 2006	Apr	DISC		
AA	RHODES PHARMS	325MG; 5MG	A201278	001	Aug 28, 2014	Aug	NEWA		
AA		325MG; 7.5MG	A201278	002	Aug 28, 2014	Aug	NEWA		
AA		325MG; 10MG	A201278	003	Aug 28, 2014	Aug	NEWA		
AA	SUN PHARM INDS INC	325MG; 2.5MG	A090535	001	Dec 26, 2013	Jul	CAHN		
AA		325MG; 5MG	A090535	002	Dec 26, 2013	Jul	CAHN		
AA		325MG; 7.5MG	A090535	003	Dec 26, 2013	Jul	CAHN		
AA		325MG; 10MG	A090535	004	Dec 26, 2013	Jul	CAHN		
	@ WATSON LABS	500MG; 7.5MG	A040371	001	Dec 29, 2000	Jan	DISC		
	@	650MG; 10MG	A040371	002	Dec 29, 2000	Jan	DISC		
PERCOCET									
	@ VINTAGE PHARMS LLC	500MG; 7.5MG	A040341	001	Jul 26, 1999	Jan	DISC		
	@	650MG; 10MG	A040341	002	Jul 26, 1999	Jan	DISC		
TABLET, EXTENDED RELEASE; ORAL									
XARTEMIS XR									
+	MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014	Mar	NEWA		
<u>ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE</u>									
TABLET; ORAL									
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE									
	@ GAVIS PHARMS	650MG; EQ 25MG BASE	A076202	001	Aug 02, 2002	Apr	DISC		
	@ WATSON LABS	650MG; EQ 25MG BASE	A074699	001	Mar 24, 2000	Apr	DISC		
<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE</u>									
TABLET; ORAL									
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN									
AB	ALLIED PHARMA INC	325MG; 37.5MG	A202076	001	Mar 30, 2012	Apr	CAHN		
AB	APOTEX INC	325MG; 37.5MG	A078778	001	Apr 07, 2014	Mar	NEWA		
AB	SUN PHARM INDS INC	325MG; 37.5MG	A077184	001	Dec 16, 2005	Jul	CAHN		
	@ WATSON LABS	325MG; 37.5MG	A076914	001	Jul 26, 2006	May	DISC		
<u>ACETAZOLAMIDE SODIUM</u>									
INJECTABLE; INJECTION									
ACETAZOLAMIDE SODIUM									
AP	EUROHLTH INTL	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Aug	CAHN		
<u>ACETOHEXAMIDE</u>									
TABLET; ORAL									
ACETOHEXAMIDE									
	@ WATSON LABS	250MG	A071893	001	Nov 25, 1987	May	DISC		
	@	500MG	A071894	001	Nov 25, 1987	May	DISC		
<u>ACETYLCYSTEINE</u>									
SOLUTION; INHALATION, ORAL									
ACETYLCYSTEINE									
AN	INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014	Jan	NEWA		
	@ ROXANE	10%	A072323	001	Apr 30, 1992	Aug	DISC		
AN		10%	A072323	001	Apr 30, 1992	Jun	CAHN		
	@	20%	A072324	001	Apr 30, 1992	Aug	DISC		
AN		20%	A072324	001	Apr 30, 1992	Jun	CAHN		
<u>ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
SEMPREX-D									
+	AUXILIUM PHARMS LLC	8MG; 60MG	N019806	001	Mar 25, 1994	Apr	CAHN		

ACYCLOVIR

CAPSULE;ORAL							
ACYCLOVIR							
AB	CADILA PHARMS LTD	200MG	A201445	001	Mar 06, 2014	Feb	NEWA
ZOVIRAX							
AB	+ DELCOR ASSET	200MG	N018828	001	Jan 25, 1985	Jun	CAHN
OINTMENT;TOPICAL							
ACYCLOVIR							
AB	AMNEAL PHARMS	5%	A204605	001	Jun 18, 2014	Jun	NEWA
TABLET;BUCCAL							
SITAVIG							
	+ INNOCUTIS HOLDINGS	50MG	N203791	001	Apr 12, 2013	Apr	CMFD
	+	50MG	N203791	001	Apr 12, 2013	Apr	CAHN
TABLET;ORAL							
ACYCLOVIR							
AB	ZYDUS PHARMS USA INC	400MG	A204314	001	Aug 19, 2014	Aug	NEWA
AB		800MG	A204314	002	Aug 19, 2014	Aug	NEWA
ZOVIRAX							
AB	DELCOR ASSET	400MG	N020089	001	Apr 30, 1991	Jun	CAHN
AB	+	800MG	N020089	002	Apr 30, 1991	Jun	CAHN

ACYCLOVIR SODIUM

INJECTABLE;INJECTION							
ACYCLOVIR SODIUM							
	+ BEDFORD	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CRLD
	@ HIKMA MAPLE	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997	Feb	DISC
	@	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997	Feb	DISC

ADAPALENE

GEL;TOPICAL							
ADAPALENE							
AB	ACTAVIS MID ATLANTIC	0.3%	A201000	001	Oct 27, 2014	Oct	NEWA

ADENOSINE

INJECTABLE;INJECTION							
ADENOSINE							
AP	AGILA SPECLTS	3MG/ML	A078640	001	Mar 21, 2014	Mar	NEWA
AP		3MG/ML	A078686	001	May 13, 2009	Feb	CAHN
AP	HOSPIRA INC	3MG/ML	A203883	001	Mar 24, 2014	Mar	NEWA
AP	SAGENT STRIDES	3MG/ML	A090212	001	Mar 28, 2014	Mar	NEWA
SOLUTION;IV (INFUSION)							
ADENOSCAN							
AP	+ ASTELLAS	3MG/ML	N020059	001	May 18, 1995	Sep	CDFR
AP	+	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Sep	CPOT
AP	+	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Sep	NEWA
ADENOSINE							
AP	AKORN	60MG/20ML (3MG/ML)	A090450	001	Oct 02, 2014	Sep	NEWA
AP		90MG/30ML (3MG/ML)	A090450	002	Oct 02, 2014	Sep	NEWA
AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Sep	NEWA
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Sep	NEWA
AP	HOSPIRA INC	3MG/ML	A203883	001	Mar 24, 2014	Sep	CDFR
AP		60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Sep	CPOT
AP		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Sep	NEWA
AP	SAGENT STRIDES	3MG/ML	A090212	001	Mar 28, 2014	Sep	CDFR
AP		60MG/20ML (3MG/ML)	A090212	001	Mar 28, 2014	Sep	CPOT
AP		90MG/30ML (3MG/ML)	A090212	002	Mar 28, 2014	Sep	NEWA
AP	TEVA PHARMS USA	3MG/ML	A077425	001	Aug 29, 2013	Sep	CDFR
AP		60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Sep	CPOT
AP		90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Sep	NEWA

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION							
VENTOLIN HFA							
BX	+ GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	Sep	CAHN
SOLUTION;INHALATION							
ACCUNEB							
AN	+ MYLAN SPECLT	EQ 0.021% BASE	N020949	002	Apr 30, 2001	May	CAHN
AN	+	EQ 0.042% BASE	N020949	001	Apr 30, 2001	May	CAHN

	TABLET; ORAL		ALBUTEROL SULFATE																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
--	--------------	--	-------------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

AMBENONIUM CHLORIDETABLET; ORAL
MYTELEASE

@ SANOFI AVENTIS US	10MG	N010155	002		Jun	DISC
---------------------	------	---------	-----	--	-----	------

AMIFOSTINEINJECTABLE; INJECTION
ETHYOL

>A>	@ CLINIGEN HLTHCARE	375MG/VIAL	N020221	002	Sep 10, 1999	Nov CAHN
>A> AP	+	500MG/VIAL	N020221	001	Dec 08, 1995	Nov CAHN
>D>	@ MEDIMMUNE	375MG/VIAL	N020221	002	Sep 10, 1999	Nov CAHN
>D> AP	+	500MG/VIAL	N020221	001	Dec 08, 1995	Nov CAHN

AMIKACIN SULFATEINJECTABLE; INJECTION
AMIKACIN SULFATE

AP	+	EUROHLTH INTL	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Aug CAHN
AP	+		EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Aug CAHN

AMINO ACIDSINJECTABLE; INJECTION
HEPATASOL 8%

@ BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996	Jul	DISC
RENAMIN W/O ELECTROLYTES						
@ BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982	Jul	DISC
TRAVASOL 10% W/O ELECTROLYTES						
@ BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006		Jul	DISC
TRAVASOL 5.5% W/O ELECTROLYTES						
@ BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004		Jul	DISC
TRAVASOL 8.5% W/O ELECTROLYTES						
@ BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005		Jul	DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; IV (INFUSION)

KABIVEN IN PLASTIC CONTAINER

FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014	Aug	NEWA
	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)	N200656	005	Aug 25, 2014	Aug	NEWA
	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)	N200656	006	Aug 25, 2014	Aug	NEWA
+	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)	N200656	007	Aug 25, 2014	Aug	NEWA

PERIKABIVEN IN PLASTIC CONTAINER

FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML)	N200656	001	Aug 25, 2014	Aug	NEWA
	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1920ML)	N200656	002	Aug 25, 2014	Aug	NEWA
	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Aug	NEWA

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% W/ ELECTROLYTES

@ BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493	003		Jul	DISC
-------------------	--	---------	-----	--	-----	------

TRAVASOL 5.5% W/ ELECTROLYTES

@ BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001		Jul	DISC
-------------------	--	---------	-----	--	-----	------

TRAVASOL 8.5% W/ ELECTROLYTES

@ BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;	N017493	002		Jul	DISC
-------------------	-------------------------------	---------	-----	--	-----	------

INJECTABLE; INJECTION
 TRAVASOL 8.5% W/ ELECTROLYTES
 594MG/100ML; 154MG/100ML

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION
 AMINOHIPPURATE SODIUM
 @ MERCK 20%

N005619 001 Jun DISC

AMINOPHYLLINE

TABLET; ORAL
 AMINOPHYLLINE
 @ HIKMA INTL PHARMS 100MG
 @ 200MG

A084540 001 Oct CAHN
 A085003 001 Oct CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
 AMIODARONE HYDROCHLORIDE
 @ PAR STERILE PRODUCTS 50MG/ML

A076394 001 Apr 25, 2003 May CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
 AMITRIPTYLINE HYDROCHLORIDE

AB MUTUAL PHARM 10MG
 AB 50MG
 AB 75MG
 AB 100MG
 AB 100MG
 AB 150MG
 AB SUN PHARM INDS INC 10MG
 AB 25MG
 AB 50MG
 AB 75MG
 AB 100MG
 AB 150MG

A089399 002 Jul 14, 1987 Jun CMS1
 A089399 003 Jul 14, 1987 Jun CMS1
 A089399 004 Jul 14, 1987 Jun CMS1
 A089399 005 Jul 14, 1987 Jun CMS1
 A089399 006 Jul 14, 1987 Jun CMS1
 A089399 006 Jul 14, 1987 Jul CPOT
 A040816 002 Jun 27, 2008 Jul CAHN
 A040816 001 Jun 27, 2008 Jul CAHN
 A040816 003 Jun 27, 2008 Jul CAHN
 A040816 004 Jun 27, 2008 Jul CAHN
 A040816 005 Jun 27, 2008 Jul CAHN
 A040816 006 Jun 27, 2008 Jul CAHN

AMITRIPTYLINE HYDROCHORIDE

AB ACCORD HLTHCARE 10MG
 AB 25MG
 AB 50MG
 AB 75MG
 AB 100MG
 AB 150MG

A202446 001 Jun 04, 2014 May NEWA
 A202446 002 Jun 04, 2014 May NEWA
 A202446 003 Jun 04, 2014 May NEWA
 A202446 004 Jun 04, 2014 May NEWA
 A202446 005 Jun 04, 2014 May NEWA
 A202446 006 Jun 04, 2014 May NEWA

AMLODIPINE BESYLATE

TABLET; ORAL
 AMLODIPINE BESYLATE

@ PURACAP PHARM EQ 2.5MG BASE
 @ EQ 5MG BASE
 @ EQ 10MG BASE
 AB SUN PHARM INDS INC EQ 2.5MG BASE
 AB EQ 5MG BASE
 AB EQ 10MG BASE
 AB VIVIMED LABS EQ 2.5MG BASE
 AB EQ 5MG BASE
 AB EQ 10MG BASE

A078131 001 Sep 04, 2007 Feb DISC
 A078131 002 Sep 04, 2007 Feb DISC
 A078131 003 Sep 04, 2007 Feb DISC
 A078231 001 Nov 30, 2007 Jul CAHN
 A078231 002 Nov 30, 2007 Jul CAHN
 A078231 003 Nov 30, 2007 Jul CAHN
 A077516 001 Jul 11, 2007 Apr CAHN
 A077516 002 Jul 11, 2007 Apr CAHN
 A077516 003 Jul 11, 2007 Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB DR REDDYS LABS LTD EQ 2.5MG BASE; EQ 10MG BASE
 AB EQ 2.5MG BASE; EQ 20MG BASE
 AB EQ 2.5MG BASE; EQ 40MG BASE
 AB EQ 5MG BASE; EQ 10MG BASE
 AB EQ 5MG BASE; EQ 20MG BASE
 AB EQ 5MG BASE; EQ 40MG BASE
 AB EQ 5MG BASE; EQ 80MG BASE
 AB EQ 10MG BASE; EQ 10MG BASE
 AB EQ 10MG BASE; EQ 20MG BASE
 AB EQ 10MG BASE; EQ 40MG BASE
 AB EQ 10MG BASE; EQ 80MG BASE

A203874 001 Mar 07, 2014 Feb NEWA
 A203874 002 Mar 07, 2014 Feb NEWA
 A203874 003 Mar 07, 2014 Feb NEWA
 A203874 004 Mar 07, 2014 Feb NEWA
 A203874 005 Mar 07, 2014 Feb NEWA
 A203874 006 Mar 07, 2014 Feb NEWA
 A203874 007 Mar 07, 2014 Feb NEWA
 A203874 008 Mar 07, 2014 Feb NEWA
 A203874 009 Mar 07, 2014 Feb NEWA
 A203874 010 Mar 07, 2014 Feb NEWA
 A203874 011 Mar 07, 2014 Feb NEWA

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

AB	MYLAN PHARMS INC	EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Aug NEWA
AB		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Aug NEWA
AB		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Aug NEWA
AB		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Aug NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	BRIGHAM WOMENS HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203783	001	Oct 30, 2014	Oct NEWA
AP	GLOBAL ISOTOPES LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Oct NEWA
AP	JOHNS HOPKINS UNIV	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204514	001	Aug 19, 2014	Aug NEWA
>A> AP	MIPS CRF	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204535	001	Nov 20, 2014	Nov NEWA
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366	001	Sep 19, 2014	Sep NEWA
AP	UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204496	001	Mar 28, 2014	Mar NEWA
AP	UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014	Jun NEWA
AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB	AUROBINDO PHARMA LTD	125MG/5ML	A204030	001	Sep 15, 2014	Sep NEWA
AB		250MG/5ML	A204030	002	Sep 15, 2014	Sep NEWA

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008	Apr CAHN
---	-------------------	-------	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	SANDOZ	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A202588	001	Mar 04, 2014	Feb NEWA
----	--------	--	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	GASTROENTERO	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 20MG	N050824	001	Feb 08, 2011	Mar CDFR
---	--------------	--	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG; 1.25MG; 1.25MG; 1.25MG	A040456	001	May 06, 2003	Sep CAHN
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A040456	002	May 06, 2003	Sep CAHN
AB		5MG; 5MG; 5MG; 5MG	A040456	003	May 06, 2003	Sep CAHN
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A040456	004	May 06, 2003	Sep CAHN
AB	WATSON LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A040456	001	May 06, 2003	Apr CMFD
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A040456	002	May 06, 2003	Apr CMFD
AB		5MG; 5MG; 5MG; 5MG	A040456	003	May 06, 2003	Apr CMFD
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A040456	004	May 06, 2003	Apr CMFD

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Sep CAHN
+		10MG	A200166	002	Aug 09, 2012	Sep CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Mar NEWA
AP	ANTIBIOTICE	EQ 1GM BASE/VIAL	A090354	003	Dec 28, 2009	Jun CMFD
AP		EQ 2GM BASE/VIAL	A090354	004	Dec 28, 2009	Jun CMFD
AP		EQ 250MG BASE/VIAL	A090354	001	Dec 28, 2009	Jun CMFD
AP		EQ 500MG BASE/VIAL	A090354	002	Dec 28, 2009	Jun CMFD
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb CAHN
AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb CAHN
AP		EQ 10GM BASE/VIAL	A201404	001	Dec 20, 2013	Jan CPOT
AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb CAHN
AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb CAHN

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb CAHN
AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Mar NEWA
AP		EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Mar NEWA
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Mar NEWA

POWDER; INTRAVENOUS
AMPICILLIN SODIUM

AP	+ SANDOZ	EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987	Sep CRLD
AP		EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987	Sep CDFR
AP	+	EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987	Sep CRLD
AP		EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987	Sep CDFR

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Mar NEWA
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Mar NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005	Feb CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005	Feb CAHN
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006	Feb CAHN
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	May CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	May CAHN

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE

>A>	AB	CIPLA LTD	1MG	A091164	001	Jun 28, 2010	Nov CAHN
>D>	AB	THREE RIVERS PHARMS	1MG	A091164	001	Jun 28, 2010	Nov CAHN
		@ WATSON LABS	1MG	A078984	001	Jun 28, 2010	May DISC

APREMILAST

TABLET; ORAL
OTEZLA

		CELGENE CORP	10MG	N205437	001	Mar 21, 2014	Mar NEWA
			20MG	N205437	002	Mar 21, 2014	Mar NEWA
	+		30MG	N205437	003	Mar 21, 2014	Mar NEWA

ARGATROBAN

INJECTABLE; INJECTION
ARGATROBAN

AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626	001	Jun 30, 2014	Jun NEWA
AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665	001	Jun 30, 2014	Jun NEWA

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ABILIFY MAINTENA KIT

		OTSUKA PHARM CO LTD	300MG	N202971	003	Sep 29, 2014	Oct NEWA
			400MG	N202971	004	Sep 29, 2014	Oct NEWA

ARMODAFINIL

TABLET; ORAL
ARMODAFINIL

		@ MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Oct DISC
		@	150MG	A200043	002	Jun 01, 2012	Oct DISC
		@	250MG	A200043	003	Jun 01, 2012	Oct DISC
		@ WATSON LABS INC	100MG	A200156	002	Aug 29, 2012	Oct DISC
		@	200MG	A200156	004	Aug 29, 2012	Oct DISC
AB			200MG	A200156	004	Aug 29, 2012	May CTEC
		NUVIGIL					
		CEPHALON	50MG	N021875	001	Jun 15, 2007	Oct CTEC
			150MG	N021875	003	Jun 15, 2007	Oct CTEC
			200MG	N021875	005	Mar 26, 2009	Oct CTEC
AB			200MG	N021875	005	Mar 26, 2009	May CMFD
	+		250MG	N021875	004	Jun 15, 2007	Oct CTEC

ASENAPINE MALEATETABLET;SUBLINGUAL
SAPHRISFOREST LABS INC EQ 5MG BASE
+ EQ 10MG BASEN022117 001 Aug 13, 2009 Feb CAHN
N022117 002 Aug 13, 2009 Feb CAHNASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA + HIKMA INTL PHARMS 325MG;50MG;40MG

A086162 002 Feb 16, 1984 Aug CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ WATSON LABS 325MG;50MG;40MG;30MG

A074359 001 Aug 31, 1995 Mar DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

@ STEVENS J 385MG;30MG;25MG

A074988 001 Apr 30, 1999 Mar DISC

@ 770MG;60MG;50MG

A074988 002 Apr 30, 1999 Mar DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@ MIRROR PHARMS 325MG;200MG;16MG

A040860 001 Jan 07, 2010 Mar DISC

@ PROSAM LABS 325MG;200MG;16MG

A040283 001 Dec 29, 1998 Mar DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ WATSON LABS 325MG;4.5MG;0.38MG

A040255 001 Feb 27, 1998 May DISC

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

TEVA PHARMS USA EQ 100MG BASE

A091673 001 Apr 22, 2014 Aug CTEC

AB EQ 100MG BASE

A091673 001 Apr 22, 2014 Apr NEWA

AB EQ 150MG BASE

A091673 002 Apr 22, 2014 Apr NEWA

AB EQ 200MG BASE

A091673 003 Apr 22, 2014 Apr NEWA

AB EQ 300MG BASE

A091673 004 Apr 22, 2014 Apr NEWA

REYATAZ

@ BRISTOL MYERS SQUIBB EQ 100MG BASE

N021567 001 Jun 20, 2003 Aug DISC

AB EQ 100MG BASE

N021567 001 Jun 20, 2003 Apr CFTG

AB EQ 150MG BASE

N021567 002 Jun 20, 2003 Apr CFTG

AB EQ 200MG BASE

N021567 003 Jun 20, 2003 Apr CFTG

AB + EQ 300MG BASE

N021567 004 Oct 16, 2006 Apr CFTG

POWDER;ORAL

REYATAZ

+ BRISTOL MYERS SQUIBB EQ 50MG BASE/PACKET

N206352 001 Jun 02, 2014 Jun NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB MYLAN 50MG

A073457 003 Jan 24, 1992 Apr CMS1

AB SUN PHARM INDS INC 25MG

A078210 001 Jul 10, 2007 Jul CAHN

AB 50MG

A078210 002 Jul 10, 2007 Jul CAHN

AB 100MG

A078210 003 Jul 10, 2007 Jul CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB AMNEAL PHARMS 750MG/5ML

A202960 001 Mar 18, 2014 Mar NEWA

MEPRON

AB + GLAXOSMITHKLINE LLC 750MG/5ML

N020500 001 Feb 08, 1995 Mar CFTG

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	MYLAN PHARMS INC	62.5MG;25MG	A202362	001	May 27, 2014	May NEWA
AB		250MG;100MG	A202362	002	May 27, 2014	May NEWA
	MALARONE PEDIATRIC					
AB	GLAXOSMITHKLINE	62.5MG;25MG	N021078	002	Jul 14, 2000	May CTEC

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+ EUROHLTH INTL	10MG/ML	A074901	001	Jul 18, 1997	Aug CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	+ EUROHLTH INTL	10MG/ML	A074900	001	Jul 18, 1997	Aug CAHN

ATROPINE SULFATE

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+ HOSPIRA 0.05MG/ML

N021146 002 Jul 09, 2001 May CRLD

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

AKORN 1%

N206289 001 Jul 18, 2014 Jul NEWA

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+ EUROHLTH INTL EQ 100MG BASE/VIAL

A074419 001 Mar 31, 1995 Aug CAHN

AZELASTINE HYDROCHLORIDE

SPRAY; NASAL

AZELASTINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743	001	May 08, 2014	Apr NEWA
----	----------------	------------------------	---------	-----	--------------	----------

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743	001	May 08, 2014	Jun CDFR
AB	ROXANE	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014	Oct NEWA

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

ARBOR PHARMS IRELAND EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Feb CAHN

+ EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Feb CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

ARBOR PHARMS IRELAND EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011 Feb CAHN

+ EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011 Feb CAHN

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP	EUROHLTH INTL	1GM/VIAL	A065286	001	Mar 23, 2011	Aug CAHN
AP		2GM/VIAL	A065286	002	Mar 23, 2011	Aug CAHN

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

AP	XELLIA PHARMS APS	50,000 UNITS/VIAL	A203177	001	Aug 25, 2014	Aug NEWA
----	-------------------	-------------------	---------	-----	--------------	----------

OINTMENT; OPHTHALMIC

BACITRACIN

	+ PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Feb CTEC
--	------------------------	--------------	---------	-----	--	----------

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	SUN PHARM INDS INC	20MG	A077862	002	Aug 14, 2006	Jul CAHN
----	--------------------	------	---------	-----	--------------	----------

BELINOSTATPOWDER; IV (INFUSION)
BELEODAQ

+ SPECTRUM PHARMS 500MG/VIAL N206256 001 Jul 03, 2014 Jul NEWA

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	5MG; 6.25MG	A078794	001	Aug 21, 2014	Aug NEWA
AB		10MG; 12.5MG	A078794	002	Aug 21, 2014	Aug NEWA
AB		20MG; 12.5MG	A078794	003	Aug 21, 2014	Aug NEWA
AB		20MG; 25MG	A078794	004	Aug 21, 2014	Aug NEWA

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

AB	MYLAN	5MG; 40MG	A078688	001	Feb 15, 2008	Jan CTNA
AB		5MG; 80MG	A078688	002	Feb 15, 2008	Jan CTNA

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	MIKART	150MG	A040851	002	Nov 09, 2009	Sep CTEC
AA	SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008	Jun CAHN
AA		200MG	A040587	002	Mar 19, 2008	Jun CAHN
AA	+ THE PHARMA NETWORK	100MG	A040627	001	Mar 30, 2007	Oct CRLD
AA	+	200MG	A040749	001	Jul 25, 2007	Oct CRLD
AA	+ THEPHARMANETWORK LLC	150MG	A201209	001	Sep 24, 2014	Oct CRLD
AA		150MG	A201209	001	Sep 24, 2014	Sep NEWA
	TESSALON					
AA	PFIZER	100MG	N011210	001		Oct CRLD
	@	200MG	N011210	003	Jun 25, 1999	Oct DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

>D>	+ DOW PHARM	2.5%; 1.2%	N050819	001	Oct 23, 2008	Nov CPOT
>A>	+	2.5%; EQ 1.2% BASE	N050819	001	Oct 23, 2008	Nov CPOT
	BENZACLIN					
AB	+ VALEANT BERMUDA	5%; EQ 1% BASE	N050756	001	Dec 21, 2000	Mar CRLD
	@	5%; EQ 1% BASE	N050756	002	Apr 20, 2007	Jul DISC
	+	5%; EQ 1% BASE	N050756	002	Apr 20, 2007	Mar CTEC
	ONEXTON					
>A>	DOW PHARM	3.75%; EQ 1.2% BASE	N050819	002	Nov 24, 2014	Nov NEWA

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+ BAUSCH AND LOMB INC 1.5% N022288 001 Sep 08, 2009 Apr CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

LOTRISONE

AB + MERCK SHARP DOHME EQ 0.05% BASE; 1% N020010 001 Dec 08, 2000 Jan CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT IGI LABS INC EQ 0.5% BASE A075630 001 Apr 12, 2001 Sep CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

	@ ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004	Jul CAHN
	@	10MG	A040553	001	Oct 28, 2004	Jul CAHN
	@	25MG	A040554	001	Oct 28, 2004	Jul CAHN
	@	50MG	A040551	001	Oct 28, 2004	Jul CAHN
AA	SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009	Jun CAHN
AA		10MG	A040897	002	Apr 22, 2009	Jun CAHN
AA		25MG	A040897	003	Apr 22, 2009	Jun CAHN
AA		50MG	A040897	004	Apr 22, 2009	Jun CAHN

TABLET;ORAL

DUVOID

@ WELLSRING PHARM

10MG

A086262 001

Mar DISC

@

25MG

A086263 001

Mar DISC

@

50MG

A085882 003

Mar DISC

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

@ BANNER PHARMACAPS

75MG

A203174 001 Aug 12, 2014

Aug DISC

AB

75MG

A203174 001 Aug 12, 2014

Jul NEWA

TARGRETIN

+ VALEANT LUXEMBOURG

75MG

N021055 001 Dec 29, 1999

Aug CTEC

AB

+

75MG

N021055 001 Dec 29, 1999

Jul CFTG

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB ACTAVIS ELIZABETH

50MG

A078634 001 Aug 28, 2009

Aug CAHN

AB ACTAVIS TOTOWA

50MG

A078634 001 Aug 28, 2009

Oct CAHN

@ ROXANE

50MG

A078285 001 Mar 24, 2011

Jun DISC

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

>A>

>A> AT

APOTEX INC

0.03%

A201894 001 Dec 01, 2014

Nov NEWA

LATISSE

>D>

>A> AT

+ ALLERGAN

0.03%

N022369 001 Dec 24, 2008

Nov CFTG

+ ALLERGAN

0.03%

N022369 001 Dec 24, 2008

Nov CFTG

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

HALFLYTELY

@ BRAINTREE

5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2

N021551 003 Jul 16, 2010

Sep DISC

AA

+

.86GM;N/A,5.6GM

N021551 003 Jul 16, 2010

Aug CFTG

5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2

N021551 003 Jul 16, 2010

Aug CFTG

.86GM;N/A,5.6GM

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

+ NOVEL LABS INC

5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2

A202217 001 Aug 20, 2014

Sep CRLD

.86GM;N/A,5.6GM

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, AND BISACODYL

AA NOVEL LABS INC

5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2

A202217 001 Aug 20, 2014

Aug NEWA

.86GM;N/A,5.6GM

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

+ FOREST LABS INC

140MG;125MG;125MG

N050786 001 Sep 28, 2006

Apr CAHN

+ FOREST RES INST INC

140MG;125MG;125MG

N050786 001 Sep 28, 2006

Mar CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

@ PROMETHEUS LABS

262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,

N050719 001 Aug 15, 1996

Aug DISC

N/A,500MG

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS

2.5MG;6.25MG

A075469 001 Sep 25, 2000

May DISC

@

5MG;6.25MG

A075469 002 Sep 25, 2000

May DISC

@

10MG;6.25MG

A075469 003 Sep 25, 2000

May DISC

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP EUROLTH INTL

EQ 15 UNITS BASE/VIAL

A065042 002 Oct 17, 2001

Aug CAHN

AP

EQ 30 UNITS BASE/VIAL

A065042 001 Oct 17, 2001

Aug CAHN

BRIMONIDINE TARTRATESOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

>A>	AT	INDOCO REMEDIES	0.2%	A091691	001	Nov 18, 2014	Nov NEWA
-----	----	-----------------	------	---------	-----	--------------	----------

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMDAY

AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr CAHN
AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan CFTG
BROMFENAC SODIUM							
AT1		APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun NEWA
AT			EQ 0.09% ACID	A202620	001	Jun 23, 2014	Jun NEWA
AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan CTEC
AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan NEWA
AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan CTEC
XIBROM							
	@	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	+	WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun CTEC
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE							
AA		PADDOCK LLC	2MG/5ML;10MG/5ML;30MG/5ML	A205292	001	Jul 15, 2014	Jun NEWA
AA		VINTAGE PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202940	001	Jul 21, 2014	Jul NEWA

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

>D>	+	SALIX PHARMS INC	2MG	N205613	001	Oct 07, 2014	Nov CPOT
>A>	+		2MG/ACTUATION	N205613	001	Oct 07, 2014	Nov CPOT
	+		2MG	N205613	001	Oct 07, 2014	Oct NEWA

CAPSULE;ORAL

BUDESONIDE

AB		BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar NEWA
SPRAY, METERED;NASAL							
BUDESONIDE							
AB		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Apr NEWA
RHINOCORT							
AB	+	ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999	Apr CFTG
TABLET, EXTENDED RELEASE;ORAL							
UCERIS							
	+	SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Feb CAHN
	+	SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

@ HOSPIRA 0.75%

A070587 001 Mar 03, 1987 Jul DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUTRANS

PURDUE PHARMA LP 7.5MCG/HR

N021306 005 Jun 30, 2014 Jun NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP		EUROHLTH INTL	EQ 0.3MG BASE/ML	A076931	001	Mar 02, 2005	Aug CAHN
----	--	---------------	------------------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL

BUNAVAIL

BIODELIVERY SCI INTL EQ 2.1MG BASE;EQ 0.3MG BASE

N205637 001 Jun 06, 2014 Jun NEWA

EQ 4.2MG BASE;EQ 0.7MG BASE

N205637 002 Jun 06, 2014 Jun NEWA

+ EQ 6.3MG BASE;EQ 1MG BASE

N205637 003 Jun 06, 2014 Jun NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ROXANE	EQ 2MG BASE;EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Jun NEWA
----	--	--------	---------------------------	---------	-----	--------------	----------

TABLET;SUBLINGUALBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		EQ 8MG BASE;EQ 2MG BASE	A203326	002	Jun 27, 2014	Jun NEWA
AB	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Aug NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014	Aug NEWA

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORALBUPROPION HYDROCHLORIDE

AB1	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Jul CAHN
AB1		150MG	A202774	002	Oct 11, 2013	Jul CAHN
AB2		150MG	A202775	001	Oct 11, 2013	Aug CAHN
AB1		200MG	A202774	003	Oct 11, 2013	Jul CAHN
AB1	TORRENT PHARMS LTD	100MG	A203969	001	Oct 31, 2014	Oct NEWA
AB1		150MG	A203969	002	Oct 31, 2014	Oct NEWA
AB1		200MG	A203969	003	Oct 31, 2014	Oct NEWA
AB3	ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORALCONTRAVE

+	TAKEDA PHARMS USA	90MG;8MG	N200063	001	Sep 10, 2014	Sep NEWA
---	-------------------	----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDETABLET;ORALBUSPIRONE HYDROCHLORIDE

AB	STRIDES ARCOLAB LTD	5MG	A202330	001	Aug 25, 2014	Aug NEWA
AB		10MG	A202330	002	Aug 25, 2014	Aug NEWA
AB		15MG	A202330	003	Aug 25, 2014	Aug NEWA
AB		30MG	A202330	004	Aug 25, 2014	Aug NEWA
AB	ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan NEWA
AB		10MG	A078888	002	Feb 07, 2014	Jan NEWA
AB		15MG	A078888	003	Feb 07, 2014	Jan NEWA
AB		30MG	A078888	004	Feb 07, 2014	Jan NEWA

BUTENAFINE HYDROCHLORIDECREAM;TOPICALMENTAX-TC

@	MYLAN	1%	N021408	001	Oct 17, 2002	Jun DISC
---	-------	----	---------	-----	--------------	----------

BUTOCONAZOLE NITRATECREAM;VAGINALGYNAZOLE-1

>A>	@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	Nov CAHN
>D>	@	LUMARA HEALTH INC	2%	N019881	001	Feb 07, 1997	Nov CAHN
	@		2%	N019881	001	Feb 07, 1997	May CAHN

BUTORPHANOL TARTRATEINJECTABLE;INJECTIONBUTORPHANOL TARTRATE

@	HIKMA FARMACEUTICA	2MG/ML	A078247	001	Apr 29, 2009	May DISC
---	--------------------	--------	---------	-----	--------------	----------

CAFFEINE CITRATESOLUTION;INTRAVENOUSCAFCIT

AP	+	EUROHLTH INTL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Aug CAHN
		CAFFEINE CITRATE					
AP		EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006	Feb CAHN
		SOLUTION;ORAL					
		CAFCIT					
AA	+	EUROHLTH INTL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Aug CAHN
		CAFFEINE CITRATE					
AA		EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Feb CAHN

CAFFEINE; ERGOTAMINE TARTRATETABLET;ORALERGOTAMINE TARTRATE AND CAFFEINE

AA		HIKMA INTL PHARMS	100MG;1MG	A040510	001	Sep 17, 2004	Sep CAHN
----	--	-------------------	-----------	---------	-----	--------------	----------

CALCIPOTRIENE

SOLUTION;TOPICAL							
CALCIPOTRIENE							
	@ HI TECH PHARMA	0.005%	A077579	001	Nov 19, 2009	May	DISC
AT	+ TOLMAR	0.005%	A077029	001	Nov 20, 2009	Apr	CRLD

CALCITONIN SALMON

INJECTABLE;INJECTION							
MIACALCIN							
	@ SEBELA IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Sep	CAHN
	+	200 IU/ML	N017808	002	Mar 29, 1991	Sep	CAHN
SPRAY, METERED;NASAL							
MIACALCIN							
AB	+ SEBELA IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Sep	CAHN

CALCITRIOL

INJECTABLE;INJECTION							
CALCITRIOL							
	@ TEVA PARENTERAL	0.002MG/ML	A075823	002	Mar 31, 2003	Feb	DISC

CALCIUM ACETATE

CAPSULE;ORAL							
CALCIUM ACETATE							
AB	AMNEAL PHARMS	EQ 169MG CALCIUM	A201658	001	Oct 06, 2014	Sep	NEWA

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION							
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER							
	@ BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N016695	001		Jul	DISC

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL							
INVOKAMET							
	JANSSEN PHARMS	50MG;500MG	N204353	001	Aug 08, 2014	Aug	NEWA
		50MG;1GM	N204353	002	Aug 08, 2014	Aug	NEWA
		150MG;500MG	N204353	003	Aug 08, 2014	Aug	NEWA
	+	150MG;1GM	N204353	004	Aug 08, 2014	Aug	NEWA

CAPECITABINE

TABLET;ORAL							
CAPECITABINE							
AB	MYLAN PHARMS INC	150MG	A090943	001	Aug 08, 2014	Jul	NEWA
AB		500MG	A090943	002	Aug 08, 2014	Jul	NEWA

CAPTOPRIL

TABLET;ORAL							
CAPTOPRIL							
	@ DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996	May	CAHN
	@	25MG	A074423	002	Feb 13, 1996	May	CAHN
	@	50MG	A074423	003	Feb 13, 1996	May	CAHN
	@	100MG	A074423	004	Feb 13, 1996	May	CAHN
	@ WATSON LABS	12.5MG	A074451	001	Feb 13, 1996	Mar	DISC
	@	25MG	A074451	002	Feb 13, 1996	Mar	DISC
	@	50MG	A074451	003	Feb 13, 1996	Mar	DISC
	@	100MG	A074451	004	Feb 13, 1996	Mar	DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL							
CAPOZIDE 25/15							
	@ APOTHECON	25MG;15MG	N018709	001	Oct 12, 1984	Mar	DISC
CAPOZIDE 25/25							
	@ APOTHECON	25MG;25MG	N018709	002	Oct 12, 1984	Mar	DISC
CAPOZIDE 50/15							
	@ APOTHECON	50MG;15MG	N018709	004	Oct 12, 1984	Mar	DISC
CAPOZIDE 50/25							
	@ APOTHECON	50MG;25MG	N018709	003	Oct 12, 1984	Mar	DISC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
AB	+ MYLAN	25MG;25MG	A074896	002	Dec 29, 1997	Mar	CRLD
AB	+	50MG;15MG	A074896	004	Dec 29, 1997	Mar	CRLD

CARBIDOPATABLET; ORAL
CARBIDOPA

AB		AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb NEWA
		LODOSYN					
AB	+	ATON	25MG	N017830	001		Feb CFTG

CARBIDOPA; LEVODOPATABLET, ORALLY DISINTEGRATING; ORAL
CARBIDOPA AND LEVODOPA

		@ IMPAX LABS	10MG; 100MG	A090631	001	Jun 08, 2010	Aug DISC
		@	25MG; 100MG	A090631	002	Jun 08, 2010	Aug DISC
		@	25MG; 250MG	A090631	003	Jun 08, 2010	Aug DISC
AB	+	MYLAN	25MG; 250MG	A078893	003	Sep 18, 2008	Aug CRLD
		PARCOPA					
		@ UCB INC	10MG; 100MG	A076699	001	Aug 27, 2004	Aug DISC
		@	25MG; 100MG	A076699	002	Aug 27, 2004	Aug DISC
		@	25MG; 250MG	A076699	003	Aug 27, 2004	Aug DISC

CARBINOXAMINE MALEATESOLUTION; ORAL
CARBINOXAMINE MALEATE

AA		VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN
		TABLET; ORAL					
		CARBINOXAMINE MALEATE					
AA		MISSION PHARMACAL CO	4MG	A090756	001	May 27, 2011	Sep CAHN
AA		VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN

CARBOPLATININJECTABLE; INJECTION
CARBOPLATIN

		@ BEDFORD	50MG/VIAL	A076099	001	Oct 14, 2004	May DISC
		@	150MG/VIAL	A076099	002	Oct 14, 2004	May DISC
		@	450MG/VIAL	A076099	003	Oct 14, 2004	May DISC
		@ CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	May DISC
		@	150MG/VIAL	A077383	002	Jan 27, 2006	May DISC
		@	450MG/VIAL	A077383	003	Jan 27, 2006	May DISC
		@ EUROHLTH INTL	50MG/VIAL	A076099	001	Oct 14, 2004	Aug CAHN
		@	150MG/VIAL	A076099	002	Oct 14, 2004	Aug CAHN
		@	450MG/VIAL	A076099	003	Oct 14, 2004	Aug CAHN
		@ FRESENIUS KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004	May DISC
		@	150MG/VIAL	A076235	002	Oct 14, 2004	May DISC
		@	450MG/VIAL	A076235	003	Oct 14, 2004	May DISC
		@ ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May DISC
		@	150MG/VIAL	A091510	002	May 29, 2012	May DISC
		@	450MG/VIAL	A091510	003	May 29, 2012	May DISC
		@ SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005	May DISC
		@	150MG/VIAL	A076959	002	Mar 18, 2005	May DISC
		@	450MG/VIAL	A076959	003	Mar 18, 2005	May DISC
		@ WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004	May DISC
		@	150MG/VIAL	A076162	002	Oct 14, 2004	May DISC
		@	450MG/VIAL	A076162	003	Oct 14, 2004	May DISC

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP		ACTAVIS ELIZABETH	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Aug CAHN
AP			150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Aug CAHN
AP			450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Aug CAHN
AP			600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Aug CAHN
AP		ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Oct CAHN
AP			150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Oct CAHN
AP			450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Oct CAHN
AP			600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Oct CAHN
AP		EUROHLTH INTL	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	Aug CAHN
AP			150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	Aug CAHN
AP			450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	Aug CAHN
AP			600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	Aug CAHN
AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN
AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN
AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN
AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

	@ HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Oct CAHN
AA	NATCO PHARMA LTD	350MG	A090988	001	Oct 28, 2014	Oct NEWA
AA	ORIENT PHARMA CO LTD	350MG	A205085	001	Oct 28, 2014	Oct NEWA
AA	SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA

CARVEDILOL

TABLET; ORAL

CARVEDILOL

AB	SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007	Jul CAHN
AB		6.25MG	A077346	001	Sep 05, 2007	Jul CAHN
AB		12.5MG	A077346	002	Sep 05, 2007	Jul CAHN
AB		25MG	A077346	003	Sep 05, 2007	Jul CAHN

CEFACLOL

FOR SUSPENSION; ORAL

CEFACLOL

AB	+ YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan CRLD
----	-------------------	-------------------	---------	-----	--------------	----------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

	@ ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan CAHN
	@	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan CAHN
	@	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan CAHN
	@	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan CAHN
	@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014	Aug NEWA
	@ STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+ COVIS INJECTABLES	1GM/VIAL	N050578	002	Jul 19, 1985	May CAHN
AP	+	2GM/VIAL	N050578	003	Jul 19, 1985	May CAHN
AP	+	6GM/VIAL	N050578	004	Jul 19, 1985	May CAHN
AP	+	500MG/VIAL	N050578	001	Jul 19, 1985	May CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

	@ COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr CAHN
+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr CAHN
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr CAHN

CEFTIBUTEN DIHYDRATE

FOR SUSPENSION; ORAL

CEDAX

+	PERNIX THERAP	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Oct CMFD
---	---------------	-------------------	---------	-----	--------------	----------

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

	@ AGILA SPECCLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Aug DISC
AP		EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb CAHN
	SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014	Apr NEWA
	CEFTRIAXONE IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005	Sep CRLD
+		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005	Sep CRLD

CEFUROXIME SODIUMINJECTABLE;INJECTION
ZINACEF

AP	+	COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr CAHN
		ZINACEF IN PLASTIC CONTAINER					
	@	COVIS INJECTABLES	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN

CELECOXIBCAPSULE;ORAL
CELEBREX

AB		GD SEARLE	50MG	N020998	004	Dec 15, 2006	May CFTG
AB			100MG	N020998	001	Dec 31, 1998	May CFTG
AB			200MG	N020998	002	Dec 31, 1998	May CFTG
AB	+		400MG	N020998	003	Aug 29, 2002	May CFTG
		CELECOXIB					
AB		LUPIN LTD	50MG	A202240	001	Oct 29, 2014	Oct NEWA
AB		MYLAN PHARMS INC	50MG	A078857	001	May 30, 2014	May NEWA
AB		TEVA	50MG	A076898	001	May 30, 2014	May NEWA
AB			100MG	A076898	002	May 30, 2014	May NEWA
AB			200MG	A076898	003	May 30, 2014	May NEWA
AB			400MG	A076898	004	May 30, 2014	May NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

	@	FACTA FARMA	EQ 250MG BASE	A062118	001		Jun DISC
	@		EQ 500MG BASE	A062118	002		Jun DISC
	@	STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar DISC
		FOR SUSPENSION;ORAL					
		CEPHALEXIN					
	@	FACTA FARMA	EQ 125MG BASE/5ML	A062117	002		Jun DISC
	@		EQ 250MG BASE/5ML	A062117	003		Jun DISC
	@	HIKMA PHARMS	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009	Sep DISC
	@		EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009	Sep DISC
	@	RANBAXY	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Oct DISC
	@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Oct DISC
AB	+	TEVA	EQ 250MG BASE/5ML	A062703	002	Feb 13, 1987	Sep CRLD
	@	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336	001	Jul 25, 2007	Sep DISC
	@		EQ 250MG BASE/5ML	A065336	002	Jul 25, 2007	Sep DISC

CERITINIBCAPSULE;ORAL
ZYKADIA

+	NOVARTIS PHARMS CORP	150MG	N205755	001	Apr 29, 2014	Apr NEWA
---	----------------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDESYRUP;ORAL
CETIRIZINE HYDROCHLORIDE

AA		SUN PHARM INDS INC	5MG/5ML	A090191	001	Nov 12, 2009	Sep CAHN
----	--	--------------------	---------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDECAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE

AB		PACK PHARMS LLC	30MG	A203775	001	Jun 04, 2014	May NEWA
----	--	-----------------	------	---------	-----	--------------	----------

CHLORDIAZEPOXIDE HYDROCHLORIDECAPSULE;ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE

@	WATSON LABS	5MG	A086383	001		May DISC
@		10MG	A086294	001		May DISC
@		25MG	A086382	001		May DISC

CHLOROPROCAINE HYDROCHLORIDEINJECTABLE;INJECTION
CHLOROPROCAINE HYDROCHLORIDE

AP		EUROHLTH INTL	2%	A040273	001	Sep 09, 1998	Aug CAHN
AP			3%	A040273	002	Sep 09, 1998	Aug CAHN

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

@ HIKMA INTL PHARMS

250MG

A086028 001 Jul 14, 1982 Oct CAHN

@

500MG

A087736 001 Jul 14, 1982 Oct CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP MYLAN INSTITUTIONAL EQ 500MG BASE/VIAL

A202493 001 Jun 18, 2014 Jun NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> AA

TRIS PHARMA INC

4MG/5ML; 5MG/5ML; 60MG/5ML

A203838 001 Nov 26, 2014 Nov NEWA

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA

PADDOCK LLC

4MG/5ML; 5MG/5ML; 60MG/5ML

A204627 001 Apr 29, 2014 Apr NEWA

ZUTRIPRO

AA

+ CYPRESS PHARM

4MG/5ML; 5MG/5ML; 60MG/5ML

N022439 001 Jun 08, 2011 Apr CFTG

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

ECR PHARMA

EQ 4MG MALEATE; EQ 5MG BITARTRATE

A077273 002 Sep 24, 2007 Jul CAHN

+

EQ 8MG MALEATE; EQ 10MG BITARTRATE

A077273 001 Sep 24, 2007 Jul CAHN

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB

NEOS THERAP INC

EQ 8MG MALEATE/5ML; EQ 10MG
BITARTRATE/5ML

A091671 001 Jun 29, 2012 Sep CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC

100MG

A088768 001 Oct 11, 1984 Jan CAHN

@

100MG

A088812 001 Oct 19, 1984 Jan CAHN

@

100MG

A088840 001 Oct 25, 1984 Feb CAHN

@

100MG

A088918 001 Oct 16, 1984 Jan CAHN

AB

@

100MG

A088921 001 Apr 12, 1985 Jan CAHN

@

100MG

A089446 001 Nov 17, 1986 Jan CAHN

@

250MG

A088813 001 Oct 19, 1984 Jan CAHN

@

250MG

A088919 001 Oct 16, 1984 Jan CAHN

AB

@

250MG

A088922 001 Apr 12, 1985 Jan CAHN

@

250MG

A089447 001 Nov 17, 1986 Jan CAHN

@ TEVA PHARMS USA

250MG

A087353 001 Apr CAHN

GLUCAMIDE

@ ANI PHARMS INC

250MG

A088641 001 Oct 11, 1984 Jan CAHN

@ TEVA PHARMS USA

250MG

A088641 001 Oct 11, 1984 Apr CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ ACTAVIS ELIZABETH

250MG

A088928 001 May 08, 1987 Jun CAHN

@

500MG

A040113 001 Sep 29, 1995 Aug CAHN

@ WATSON LABS

500MG

A040137 001 Aug 09, 1996 May DISC

@

500MG

A081040 001 Aug 22, 1989 May DISC

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB

TARO

0.77%

A076790 001 Apr 12, 2005 Mar CMFD

@

0.77%

A076790 001 Apr 12, 2005 Feb DISC

GEL; TOPICAL

LOPROX

AB

+ CNTY LINE PHARMS

0.77%

N020519 001 Jul 21, 1997 Jul CAHN

SHAMPOO; TOPICAL

CICLOPIROX

AT

ACTAVIS MID ATLANTIC

1%

A090490 001 Nov 24, 2009 Aug CAHN

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION							
PRIMAXIN							
	@ MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	A062756	001	Jan 08, 1987	Sep	DISC
	@	EQ 500MG BASE/VIAL; 500MG/VIAL	A062756	002	Jan 08, 1987	Sep	DISC
POWDER; INTRAMUSCULAR							
PRIMAXIN							
	MERCK	EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990	Sep	CTEC
AP		EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990	Sep	CDFR
	@	EQ 750MG BASE/VIAL; 750MG/VIAL	N050630	002	Dec 14, 1990	Sep	CDFR
POWDER; INTRAVENOUS							
IMIPENEM AND CILASTATIN							
AP	ACS DOBFAR	EQ 250MG BASE/VIAL; 250MG/VIAL	A090577	001	Dec 21, 2011	Sep	CDFR
AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A090577	002	Dec 21, 2011	Sep	CDFR
AP	HOSPIRA INC	EQ 250MG BASE/VIAL; 250MG/VIAL	A090825	001	Nov 16, 2011	Sep	CDFR
AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011	Sep	CDFR
AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011	Sep	CDFR
PRIMAXIN							
AP	+ MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	N050587	001	Nov 26, 1985	Sep	CDFR
AP	+	EQ 500MG BASE/VIAL; 500MG/VIAL	N050587	002	Nov 26, 1985	Sep	CDFR

CILOSTAZOL

TABLET; ORAL							
CILOSTAZOL							
	@ ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004	Aug	CAHN

CIMETIDINE

TABLET; ORAL							
CIMETIDINE							
	@ CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994	Sep	CAHN
	@	400MG	A074361	002	Dec 23, 1994	Sep	CAHN
	@	800MG	A074371	001	Dec 23, 1994	Sep	CAHN
	@ DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995	Jul	DISC
	@	400MG	A074340	002	Jun 23, 1995	Jul	DISC
	@	800MG	A074339	001	Jun 23, 1995	Sep	DISC
	@ IVAX SUB TEVA PHARMS	200MG	A074424	001	Jul 28, 1995	Jul	DISC
	@	300MG	A074424	002	Jul 28, 1995	Jul	DISC
	@	400MG	A074424	003	Jul 28, 1995	Jul	DISC
	@	800MG	A074424	004	Jul 28, 1995	Jul	DISC
AB	+ MYLAN	800MG	A074246	004	May 17, 1994	Jul	CRLD
	@ PLIVA	200MG	A074568	001	Feb 27, 1997	Jul	DISC
	@	300MG	A074568	002	Feb 27, 1997	Jul	DISC
	@	400MG	A074568	003	Feb 27, 1997	Jul	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL							
CIMETIDINE HYDROCHLORIDE							
AA	ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN
	@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN
	@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN
	@ CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997	Sep	CAHN

CIPROFLOXACIN

FOR SUSPENSION; ORAL							
CIPRO							
AB	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
AB	+	500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG
CIPROFLOXACIN							
AB	LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb	NEWA
AB		500MG/5ML	A200563	002	Mar 05, 2014	Feb	NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
CIPROFLOXACIN HYDROCHLORIDE							
AT	IGI LABS INC	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Sep	CAHN
AT	WATSON LABS INC	EQ 0.3% BASE	A076673	001	Jan 21, 2005	Apr	CAHN

CISPLATININJECTABLE;INJECTION
CISPLATIN

AP	EUROHLTH INTL	1MG/ML	A075036	001	Nov 07, 2000	Aug CAHN
AP	PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb CAHN

CITALOPRAM HYDROBROMIDETABLET;ORAL
CITALOPRAM HYDROBROMIDE

AB	SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004	Jul CAHN
AB		EQ 20MG BASE	A077032	002	Nov 12, 2004	Jul CAHN
AB		EQ 40MG BASE	A077032	003	Nov 12, 2004	Jul CAHN
	@ WATSON LABS	EQ 10MG BASE	A077034	001	Jun 30, 2005	May DISC
	@	EQ 20MG BASE	A077034	002	Jun 30, 2005	May DISC
	@	EQ 40MG BASE	A077034	003	Jun 30, 2005	May DISC

CLADRIBINEINJECTABLE;INJECTION
CLADRIBINE

AP	EUROHLTH INTL	1MG/ML	A075405	001	Feb 28, 2000	Aug CAHN
----	---------------	--------	---------	-----	--------------	----------

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb NEWA
----	---------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATECREAM;VAGINAL
CLINDESSE

>A>	+	ELAN PHARMA INTL LTD	EQ 2% BASE	N050793	001	Nov 30, 2004	Nov CAHN
>D>	+	LUMARA HEALTH INC	EQ 2% BASE	N050793	001	Nov 30, 2004	Nov CAHN
	+		EQ 2% BASE	N050793	001	Nov 30, 2004	May CAHN

SOLUTION;TOPICAL
CLINDAMYCIN PHOSPHATE

AB	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Apr CMFD
AT	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jun CTC
AB		EQ 1% BASE	A062811	001	Sep 01, 1988	May CAHN
	@ VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb CAHN

CLOBETASOL PROPIONATEAEROSOL, FOAM;TOPICAL
OLUX

AB1	+	DELCOR ASSET	0.05%	N021142	001	May 26, 2000	Jun CAHN
-----	---	--------------	-------	---------	-----	--------------	----------

CLONAZEPAMTABLET;ORAL
CLONAZEPAM

AB	SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001	Jul CAHN
AB		1MG	A075423	002	Apr 27, 2001	Jul CAHN
AB		2MG	A075423	003	Apr 27, 2001	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
CLONAZEPAM

AB	SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Aug NEWA
AB		0.25MG	A078654	002	Aug 27, 2014	Aug NEWA
AB		0.5MG	A078654	003	Aug 27, 2014	Aug NEWA
AB		1MG	A078654	004	Aug 27, 2014	Aug NEWA
AB		2MG	A078654	005	Aug 27, 2014	Aug NEWA

CLONIDINEFILM, EXTENDED RELEASE;TRANSDERMAL
CLONIDINE

AB	WATSON LABS INC	0.1MG/24HR	A090873	001	May 06, 2014	Apr NEWA
AB		0.2MG/24HR	A090873	002	May 06, 2014	Apr NEWA
AB		0.3MG/24HR	A090873	003	May 06, 2014	Apr NEWA

CLONIDINE HYDROCHLORIDEINJECTABLE;INJECTION
CLONIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb NEWA
AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb NEWA

TABLET;ORAL							
CLONIDINE HYDROCHLORIDE							
AB	CARACO	0.1MG	A090329	001	Jul 03, 2014	Jun	NEWA
AB		0.2MG	A090329	002	Jul 03, 2014	Jun	NEWA
AB		0.3MG	A090329	003	Jul 03, 2014	Jun	NEWA
AB	SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014	Jul	CAHN
AB		0.2MG	A090329	002	Jul 03, 2014	Jul	CAHN
AB		0.3MG	A090329	003	Jul 03, 2014	Jul	CAHN
	@ WATSON LABS	0.3MG	A070963	001	Jul 08, 1986	May	DISC
TABLET, EXTENDED RELEASE;ORAL							
CLONIDINE HYDROCHLORIDE							
AB	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar	NEWA
AB		0.2MG	A202983	002	Apr 02, 2014	Mar	NEWA
<u>CLOPIDOGREL</u>							
TABLET;ORAL							
CLOPIDOGREL							
AB	AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar	NEWA
<u>CLOPIDOGREL BISULFATE</u>							
TABLET;ORAL							
CLOPIDOGREL BISULFATE							
AB	ACTAVIS ELIZABETH	EQ 75MG BASE	A090307	001	May 28, 2013	Aug	CAHN
AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Oct	CAHN
AB	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb	NEWA
AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan	NEWA
AB	SCIEGEN PHARMS INC	EQ 75MG BASE	A204165	001	Sep 15, 2014	Sep	NEWA
AB		EQ 300MG BASE	A204165	002	Sep 15, 2014	Sep	NEWA
<u>CLORAZEPATE DIPOTASSIUM</u>							
TABLET;ORAL							
CLORAZEPATE DIPOTASSIUM							
	@ WATSON LABS	3.75MG	A071852	001	Feb 09, 1988	May	DISC
	@	7.5MG	A071853	001	Feb 09, 1988	May	DISC
	@	15MG	A071854	001	Feb 09, 1988	May	DISC
<u>CLOZAPINE</u>							
TABLET;ORAL							
CLOZAPINE							
AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
AB		200MG	A076809	001	Dec 16, 2005	Mar	CTEC
AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar	NEWA
AB		50MG	A075417	004	Apr 15, 2010	Mar	NEWA
AB		200MG	A075417	005	Apr 15, 2010	Mar	NEWA
AB	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Jul	CAHN
AB		50MG	A075713	003	Aug 19, 2005	Jul	CAHN
AB		100MG	A075713	002	Nov 15, 2002	Jul	CAHN
<u>COBICISTAT</u>							
TABLET;ORAL							
TYBOST							
+	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Sep	NEWA
<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>							
SYRUP;ORAL							
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE							
AA	SUN PHARM INDS INC	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Sep	CAHN
<u>CODEINE SULFATE</u>							
TABLET;ORAL							
CODEINE SULFATE							
AB	LANNETT HOLDINGS INC	15MG	A203046	001	Jun 13, 2014	Jun	NEWA
AB		30MG	A203046	002	Jun 13, 2014	Jun	NEWA
AB		60MG	A203046	003	Jun 13, 2014	Jun	NEWA
AB	ROXANE	15MG	N022402	001	Jul 16, 2009	Jun	CFTG
AB		30MG	N022402	002	Jul 16, 2009	Jun	CFTG
AB	+	60MG	N022402	003	Jul 16, 2009	Jun	CFTG

COLCHICINECAPSULE;ORAL
MITIGARE

HIKMA PHARMS LLC

0.6MG

N204820 001 Sep 26, 2014 Sep NEWA

COLISTIMETHATE SODIUMINJECTABLE;INJECTION
COLISTIMETHATE SODIUMAP SAGENT PHARMS EQ 150MG BASE/VIAL
COLY-MYCIN M

A201365 001 Feb 19, 2014 Feb NEWA

AP + PAR STERILE PRODUCTS EQ 150MG BASE/VIAL

N050108 002 Apr CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS;OTIC
COLY-MYCIN S+ PAR STERILE PRODUCTS EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG
BASE/ML;0.5MG/ML

N050356 001 Apr CAHN

CONIVAPTAN HYDROCHLORIDEINJECTABLE;IV (INFUSION)
VAPRISOL

@ CUMBERLAND PHARMS 20MG/4ML (5MG/ML)

N021697 001 Dec 29, 2005 Feb CAHN

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+ CUMBERLAND PHARMS 20MG/100ML (0.2MG/ML)

N021697 002 Oct 08, 2008 Feb CAHN

CORTISONE ACETATE

TABLET;ORAL

CORTISONE ACETATE

+ HIKMA INTL PHARMS 25MG

A080776 002 Sep CAHN

COSYNTROPINSOLUTION;INTRAVENOUS
COSYNTROPIN

@ SANDOZ 0.25MG/ML (0.25MG/ML)

N022028 001 Feb 21, 2008 Sep DISC

CROMOLYN SODIUMSOLUTION;INHALATION
CROMOLYN SODIUMAN MYLAN SPECLT 10MG/ML
@ WATSON LABS 10MG/MLA074209 001 Apr 26, 1994 May CAHN
A076469 001 Jun 17, 2005 May DISCSOLUTION/DROPS;OPHTHALMIC
CROMOLYN SODIUMAT + AKORN 4%
OPTICROM

A074706 001 Apr 29, 1998 Jun CRLD

@ ALLERGAN 4%

N018155 001 Oct 03, 1984 Jun DISC

CYCLOPHOSPHAMIDEINJECTABLE;INJECTION
CYCLOPHOSPHAMIDEAP JIANGSU HENGRUI MED 1GM/VIAL
AP 2GM/VIAL
AP 500MG/VIALA204555 002 Oct 31, 2014 Oct NEWA
A204555 003 Oct 31, 2014 Oct NEWA
A204555 001 Oct 31, 2014 Oct NEWA

NEOSAR

@ BEDFORD 1GM/VIAL

A087442 004 Jul 08, 1983 Sep CAHN

@ 2GM/VIAL

A087442 005 Mar 30, 1989 Sep CAHN

@ 100MG/VIAL

A087442 001 Feb 16, 1982 Sep CAHN

@ 200MG/VIAL

A087442 002 Feb 16, 1982 Sep CAHN

@ 500MG/VIAL

A087442 003 Feb 16, 1982 Sep CAHN

CYCLOSPORINEINJECTABLE;INJECTION
CYCLOSPORINE

AP EUROHLTH INTL 50MG/ML

A065004 001 Oct 29, 1999 Aug CAHN

CYSTEAMINE BITARTRATECAPSULE, DELAYED RELEASE;ORAL
PROCYSBI

RAPTOR INC

EQ 25MG BASE

N203389 001 Apr 30, 2013 Aug CAHN

+ EQ 75MG BASE

N203389 002 Apr 30, 2013 Aug CAHN

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

AP	EUROHLTH INTL	1GM/VIAL	A074245	001	Aug 31, 1994	Aug CAHN
AP		2GM/VIAL	A074245	002	Aug 31, 1994	Aug CAHN
AP		100MG/VIAL	A071471	001	Aug 02, 1989	Aug CAHN
AP		500MG/VIAL	A071472	001	Aug 02, 1989	Aug CAHN

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE

AP	EUROHLTH INTL	200MG/VIAL	A075812	001	Jun 15, 2001	Aug CAHN
AP		500MG/VIAL	A075812	002	Oct 31, 2002	Aug CAHN

DACTINOMYCIN

INJECTABLE; INJECTION
DACTINOMYCIN

AP	EUROHLTH INTL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Aug CAHN
----	---------------	------------	---------	-----	--------------	----------

DALBAVANCIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)
DALVANCE

+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	May NEWA
---	---------------------	--------------------	---------	-----	--------------	----------

DANAPAROID SODIUM

INJECTABLE; INJECTION
ORGARAN

>A>	@ AGI	750 UNITS/0.6ML	N020430	001	Dec 24, 1996	Nov CAHN
>D>	@ ORGANON USA INC	750 UNITS/0.6ML	N020430	001	Dec 24, 1996	Nov CAHN

DANTROLENE SODIUM

CAPSULE; ORAL
DANTRIUM

AB	PAR STERILE PRODUCTS	25MG	N017443	001		Mar CAHN
AB		50MG	N017443	003		Mar CAHN
AB	+	100MG	N017443	002		Mar CAHN

FOR SUSPENSION; INTRAVENOUS
RYANODEX

EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014	Jul NEWA
--------------	------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
DANTRIUM

AP	+	PAR STERILE PRODUCTS	20MG/VIAL	N018264	001	Apr CAHN
AP		REVONTO				
AP		US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007
						Mar CTNA

DAPAGLIFLOZIN

TABLET; ORAL
FARXIGA

ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb CAHN
+	10MG	N202293	002	Jan 08, 2014	Feb CAHN
BRISTOL MYERS SQUIBB	5MG	N202293	001	Jan 08, 2014	Jan NEWA
+	10MG	N202293	002	Jan 08, 2014	Jan NEWA

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
XIGDUO XR

ASTRAZENECA AB	5MG; 1GM	N205649	002	Oct 29, 2014	Oct NEWA
	5MG; 500MG	N205649	001	Oct 29, 2014	Oct NEWA
+	10MG; 1GM	N205649	004	Oct 29, 2014	Oct NEWA
	10MG; 500MG	N205649	003	Oct 29, 2014	Oct NEWA

DAPTOMYCIN

INJECTABLE; IV (INFUSION)
CUBICIN

AP	+	CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Sep CFTG
AP		DAPTOMYCIN					
AP		HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Sep NEWA

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
CERUBIDINE

AP	+	EUROHLTH INTL	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Aug CAHN
AP	+	EUROHLTH INTL	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Aug CAHN

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

AP		SANDOZ	50MG/VIAL	A202969	001	Aug 28, 2014	Aug NEWA
		POWDER; INTRAVENOUS DECITABINE					
	+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Jan NEWA

DEFEROXAMINE MESYLATEINJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

AP		EUROHLTH INTL	2GM/VIAL	A078086	002	May 30, 2007	Aug CAHN
AP			500MG/VIAL	A078086	001	May 30, 2007	Aug CAHN
	@	WATSON LABS	2GM/VIAL	A076806	002	Mar 31, 2006	May DISC
	@		500MG/VIAL	A076806	001	Mar 31, 2006	May DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	10MG	A074430	001	Feb 09, 1996	Aug CAHN
AB			25MG	A071601	001	Jun 05, 1987	Aug CAHN
AB			50MG	A071588	001	Jun 05, 1987	Aug CAHN
AB			75MG	A071602	001	Oct 05, 1987	Aug CAHN
AB			100MG	A071766	001	Oct 05, 1987	Aug CAHN
AB			150MG	A074430	002	Feb 09, 1996	Aug CAHN
AB		ACTAVIS TOTOWA	10MG	A074430	001	Feb 09, 1996	Oct CAHN
AB			25MG	A071601	001	Jun 05, 1987	Oct CAHN
AB			50MG	A071588	001	Jun 05, 1987	Oct CAHN
AB			75MG	A071602	001	Oct 05, 1987	Oct CAHN
AB			100MG	A071766	001	Oct 05, 1987	Oct CAHN
AB			150MG	A074430	002	Feb 09, 1996	Oct CAHN
	@	ANI PHARMS INC	25MG	A071800	001	Dec 08, 1987	Jan CAHN
	@		50MG	A071801	001	Dec 08, 1987	Jan CAHN
	@		75MG	A071802	001	Dec 08, 1987	Jan CAHN
	@		100MG	A071803	001	May 29, 1997	Feb CAHN
	@		150MG	A071804	001	May 29, 1997	Feb CAHN

DESLORATADINESOLUTION; ORAL
CLARINEX

	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	May CDFR
--	---	-------------------	----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATEINJECTABLE; INJECTION
DDAVP

AP	+	FERRING PHARMS INC	0.004MG/ML	N018938	001	Mar 30, 1984	Oct CAHN
	@		0.015MG/ML	N018938	002	Apr 25, 1995	Oct CAHN

SOLUTION; NASAL
DDAVP

AB	+	FERRING PHARMS INC	0.01%	N017922	001		Oct CAHN
----	---	--------------------	-------	---------	-----	--	----------

SPRAY, METERED; NASAL
DDAVP

	@	FERRING PHARMS INC	0.01MG/SPRAY	N017922	002	Feb 06, 1989	Oct CAHN
		DDAVP (NEEDS NO REFRIGERATION)					

AB	+	FERRING PHARMS INC	0.01MG/SPRAY	N017922	003	Aug 07, 1996	Oct CAHN
		DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)					

AB		SUN PHARMA GLOBAL	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Jan CMS2
----	--	-------------------	--------------	---------	-----	--------------	----------

TABLET; ORAL

DESMOPRESSIN ACETATE

AB		MYLAN PHARMS INC	0.1MG	A200653	001	Jun 27, 2014	Jun NEWA
AB			0.2MG	A200653	002	Jun 27, 2014	Jun NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28							
KARIVA							
AB	+	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Oct CTEC
	+		0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Sep CRLD
	MIRCETTE						
	@	TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG	N020713	001	Apr 22, 1998	Sep DISC

DESONIDE

AEROSOL, FOAM; TOPICAL							
VERDESO							
	+	AQUA PHARMS	0.05%	N021978	001	Sep 19, 2006	May CAHN
LOTION; TOPICAL							
DESONIDE							
AB		TARO	0.05%	A202161	001	Oct 31, 2014	Oct NEWA

DESOXIMETASONE

OINTMENT; TOPICAL							
DESOXIMETASONE							
AB		VERSAPHARM INC	0.25%	A201005	001	Apr 24, 2014	Apr NEWA

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL							
DESVENLAFAXINE							
BC		SUN PHARMA GLOBAL	50MG	N205583	001	Jan 28, 2014	Jan NEWA
BC	+		100MG	N205583	002	Jan 28, 2014	Jan NEWA

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL							
DESVENLAFAXINE							
	+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun CTNA
	+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun CTNA
	@	TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013	Jun DISC
	+		EQ 50MG BASE	N205208	001	Oct 11, 2013	Jun CTNA
	@		EQ 100MG BASE	N205208	002	Oct 11, 2013	Jun DISC
	+		EQ 100MG BASE	N205208	002	Oct 11, 2013	Jun CTNA
DESVENLAFAXINE FUMARATE							
	+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CTEC
	+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CTEC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL							
PRISTIQ							
		WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Oct NEWA

DEXCHLORPHENIRAMINE MALEATE

TABLET; ORAL							
DEXCHLORPHENIRAMINE MALEATE							
	@	ANI PHARMS INC	2MG	A088682	001	Jan 17, 1986	Jan CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL							
DEXILANT							
		TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009	Jun CAHN
	+		60MG	N022287	002	Jan 30, 2009	Jun CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION							
DEXMEDETOMIDINE HYDROCHLORIDE							
>A>	AP	AKORN INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202585	001	Nov 24, 2014	Nov NEWA
	AP	MYLAN INSTITUTIONAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202881	001	Aug 18, 2014	Aug NEWA
	AP	PAR STERILE PRODUCTS	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203972	001	Aug 18, 2014	Aug NEWA
PRECEDEX							
	+	HOSPIRA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	N021038	001	Dec 17, 1999	Aug CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	TEVA PHARMS USA	15MG	A078908	004	May 19, 2014	May NEWA
AB		30MG	A202731	003	May 19, 2014	May NEWA
AB	WATSON LABS INC	15MG	A079108	003	May 19, 2014	May NEWA

DEXRAZOXANE HYDROCHLORIDEINJECTABLE;INJECTION
DEXRAZOXANE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Aug CAHN
AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Aug CAHN

DEXTROAMPHETAMINE SULFATETABLET;ORAL
DEXTROAMPHETAMINE SULFATE

AA	COREPHARMA	5MG	A090652	001	Mar 07, 2014	Feb NEWA
AA		10MG	A090652	002	Mar 07, 2014	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDESYRUP;ORAL
PROMETH W/ DEXTROMETHORPHAN

	@ ACTAVIS MID ATLANTIC	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	Sep DISC
	PROMETHAZINE DM					
AA	+ VINTAGE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Sep CRLD
	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
	@ AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011	Sep DISC
	@ TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012	Sep DISC

DIAZEPAMCONCENTRATE;ORAL
DIAZEPAM

AA	LANNETT HOLDINGS INC	5MG/ML	A204433	001	Apr 14, 2014	Mar NEWA
	DIAZEPAM INTENSOL					
AA	+ ROXANE	5MG/ML	A071415	001	Apr 03, 1987	Mar CFTG

GEL;RECTAL
DIASTAT

>D>	VALEANT	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Nov CAHN
>D>	@	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Nov CAHN
>D>	@	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Nov CAHN
>D>	@	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Nov CAHN
>D>	@	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Nov CAHN
>A>	VALEANT PHARMS NORTH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Nov CAHN
>A>	@	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Nov CAHN
>A>	@	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Nov CAHN
>A>	@	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Nov CAHN
>A>	@	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Nov CAHN
	DIASTAT ACUDIAL					
>D>	VALEANT	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Nov CAHN
>D>	+	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Nov CAHN
>A>	VALEANT PHARMS NORTH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Nov CAHN
>A>	+	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Nov CAHN

TABLET;ORAL
DIAZEPAM

	@ DAVA PHARMS INC	2MG	A070226	001	Sep 26, 1985	Mar DISC
--	-------------------	-----	---------	-----	--------------	----------

DICLOFENAC POTASSIUMFOR SOLUTION;ORAL
CAMBIA

+	DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Jan CAHN
---	-------------	------	---------	-----	--------------	----------

DICLOFENAC SODIUMSOLUTION;TOPICAL
DICLOFENAC SODIUM

AT	APOTEX INC	1.5%	A202027	001	May 27, 2014	May NEWA
>A> AT	PADDOCK LLC	1.5%	A202393	001	Nov 24, 2014	Nov NEWA
>A> AT	TARO	1.5%	A203818	001	Nov 26, 2014	Nov NEWA
>A> AT	WATSON LABS INC	1.5%	A202852	001	Nov 24, 2014	Nov NEWA
	PENNSAID					
AT	+ MALLINCKRODT	1.5%	N020947	001	Nov 04, 2009	May CFTG
	+ MALLINCKRODT INC	2%	N204623	001	Jan 16, 2014	Jan NEWA

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar	NEWA
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar	NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

AB	+ FOREST LABS INC	10MG	N007409	003	Oct 15, 1984	Apr	CAHN
----	-------------------	------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

BENTYL

AP	+ FOREST LABS INC	10MG/ML	N008370	001	Oct 15, 1984	Apr	CAHN
	BENTYL PRESERVATIVE FREE						

AP	+ FOREST LABS INC	10MG/ML	N008370	002	Oct 15, 1984	Apr	CAHN
	DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)						

AP	EUROHLTH INTL	10MG/ML	A040465	001	Jun 30, 2003	Aug	CAHN
----	---------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

BENTYL

AB	+ FOREST LABS INC	20MG	N007409	001	Oct 15, 1984	Apr	CAHN
----	-------------------	------	---------	-----	--------------	-----	------

DIGOXIN

INJECTABLE;INJECTION

LANOXIN

AP	+ COVIS INJECTABLES	0.25MG/ML	N009330	002		Apr	CAHN
	LANOXIN PEDIATRIC						

	+ COVIS INJECTABLES	0.1MG/ML	N009330	004		Apr	CAHN
--	---------------------	----------	---------	-----	--	-----	------

TABLET;ORAL

DIGOXIN

AB	HIKMA INTL PHARMS	0.125MG	A077002	002	Oct 30, 2007	Sep	CAHN
AB		0.25MG	A077002	001	Oct 30, 2007	Sep	CAHN

	MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Sep	CMFD
--	------------------	---------	---------	-----	--------------	-----	------

		0.25MG	A040282	002	Dec 23, 1999	Sep	CMFD
--	--	--------	---------	-----	--------------	-----	------

@	SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Jul	CAHN
---	--------------------	---------	---------	-----	--------------	-----	------

@		0.25MG	A076363	002	Jan 31, 2003	Jul	CAHN
---	--	--------	---------	-----	--------------	-----	------

LANOXIN

	COVIS PHARMA	0.0625MG	N020405	001	Sep 30, 1997	Jan	CMFD
--	--------------	----------	---------	-----	--------------	-----	------

		0.1875MG	N020405	003	Sep 30, 1997	Jan	CMFD
--	--	----------	---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB3	ACTAVIS ELIZABETH	360MG	A202463	001	Dec 07, 2012	Sep	CAHN
-----	-------------------	-------	---------	-----	--------------	-----	------

@	NESHER PHARMS	120MG	A076563	002	Sep 12, 2006	Mar	DISC
---	---------------	-------	---------	-----	--------------	-----	------

@		180MG	A076563	003	Sep 12, 2006	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

@		240MG	A076563	004	Sep 12, 2006	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

@		300MG	A076563	005	Sep 12, 2006	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

@		360MG	A076563	006	Sep 12, 2006	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

@		420MG	A076563	001	Sep 12, 2006	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

@	AGILA SPECLTS	5MG/ML	A075375	001	Sep 30, 1999	Feb	CAHN
---	---------------	--------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@	INTL MEDICATION	50MG/ML	A084094	001		Jun	DISC
---	-----------------	---------	---------	-----	--	-----	------

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPRO

@	AKORN	0.1%	A074382	001	Sep 29, 1995	Jun	DISC
---	-------	------	---------	-----	--------------	-----	------

DIPIVEFRIN HYDROCHLORIDE

@	FALCON PHARMS	0.1%	A073636	001	Jun 30, 1994	Jun	DISC
---	---------------	------	---------	-----	--------------	-----	------

PROPINE

@	ALLERGAN	0.1%	N018239	001		Jun	DISC
---	----------	------	---------	-----	--	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

@ GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991	Mar DISC
@	50MG	A089000	001	Feb 05, 1991	Mar DISC
@	75MG	A089001	001	Feb 05, 1991	Mar DISC
@ WATSON LABS	50MG	A087160	001	Jun 07, 1996	May DISC

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB	ROXANE	250MG	A202652	001	Feb 05, 2014	Jan NEWA
AB		500MG	A202652	002	Feb 05, 2014	Jan NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB	AUROBINDO PHARMA LTD	EQ 250MG VALPROIC ACID	A202419	001	Jun 02, 2014	May NEWA
AB		EQ 500MG VALPROIC ACID	A202419	002	Jun 02, 2014	May NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994	Aug CAHN
	@ WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993	May DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jul CTEC
		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jul CTEC
AP	+	160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012	Aug CRLD
AP	DR REDDYS LABS LTD	20MG/ML (20MG/ML)	A204193	001	Nov 05, 2014	Oct NEWA
AP		80MG/4ML (20MG/ML)	A204193	002	Nov 05, 2014	Oct NEWA
	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Mar NEWA
		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Mar NEWA
		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Mar NEWA
		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	JUBILANT GENERICS	5MG	A090768	001	May 31, 2011	Jul CAHN
AB		10MG	A090768	002	May 31, 2011	Jul CAHN
AB	MACLEODS PHARMS LTD	23MG	A202631	001	Jan 22, 2014	Jan NEWA
AB	SCIEGEN PHARMS INC	5MG	A203907	001	Oct 29, 2014	Oct NEWA
AB		10MG	A203907	002	Oct 29, 2014	Oct NEWA
AB	TWI PHARMS INC	23MG	A203104	001	Oct 29, 2014	Oct NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014	Sep NEWA
----	-----------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	AKORN INC	EQ 2% BASE; EQ 0.5% BASE	A203058	001	Sep 22, 2014	Sep NEWA
AT	WATSON LABS INC	EQ 2% BASE; EQ 0.5% BASE	A202054	001	Sep 03, 2014	Aug NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

@ WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992	May DISC
---------------	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	ACCORD HLTHCARE	EQ 1MG BASE	A202824	001	Jun 11, 2014	May NEWA
AB		EQ 2MG BASE	A202824	002	Jun 11, 2014	May NEWA
AB		EQ 4MG BASE	A202824	003	Jun 11, 2014	May NEWA

TABLET;ORAL
DOXAZOSIN MESYLATE

AB EQ 8MG BASE A202824 004 Jun 11, 2014 May NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION
DOXERCALCIFEROL

AP SANDOZ 4MCG/2ML (2MCG/ML) A091333 001 May 05, 2014 Apr NEWA
AP 4MCG/2ML (2MCG/ML) A200926 001 Feb 04, 2014 Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
DOXORUBICIN HYDROCHLORIDE

AP ACTAVIS INC 2MG/ML A203622 001 Jun 27, 2014 Jun NEWA
AP + EUROHLTH INTL 2MG/ML A062975 001 Mar 17, 1989 Aug CAHN
AP + 10MG/VIAL A062921 001 Mar 17, 1989 Aug CAHN
AP + 20MG/VIAL A062921 002 Mar 17, 1989 Aug CAHN
AP + 50MG/VIAL A062921 003 Mar 17, 1989 Aug CAHN
AP + 200MG/100ML A064097 001 Sep 13, 1994 Aug CAHN
AP PHARMACHEMIE BV 2MG/ML A063336 001 Feb 28, 1995 Feb CAHN
AP 10MG/VIAL A063097 001 May 21, 1990 Feb CAHN
AP 20MG/VIAL A063097 002 May 21, 1990 Feb CAHN
AP 50MG/VIAL A063097 003 May 21, 1990 Feb CAHN
AP 200MG/100ML A063336 004 Feb 28, 1995 Feb CAHN

DOXYCYCLINE

CAPSULE;ORAL
DOXYCYCLINE

AB LUPIN LTD EQ 50MG BASE A204234 001 Mar 05, 2014 Feb NEWA
AB EQ 75MG BASE A204234 002 Mar 05, 2014 Feb NEWA
AB EQ 100MG BASE A204234 003 Mar 05, 2014 Feb NEWA
@ WATSON LABS EQ 50MG BASE A065041 001 Apr 28, 2000 May DISC
@ EQ 100MG BASE A065041 002 Apr 28, 2000 May DISC
ORACEA
+ GALDERMA LABS LP 40MG N050805 001 May 26, 2006 Jul CTEC

DOXYCYCLINE HYCLATE

CAPSULE;ORAL
DOXYCYCLINE HYCLATE

+ HIKMA INTL PHARMS EQ 20MG BASE A065103 001 May 13, 2005 Sep CAHN
AB EQ 50MG BASE A062396 002 Nov 07, 1984 Sep CAHN
AB EQ 100MG BASE A062396 001 May 07, 1984 Sep CAHN
AB MYLAN EQ 50MG BASE A062337 001 Mar 29, 1982 Jul CMFD
AB EQ 100MG BASE A062337 002 Mar 29, 1982 Jul CMFD

INJECTABLE;INJECTION
DOXYCYCLINE

AP + EUROHLTH INTL EQ 100MG BASE/VIAL A062569 001 Mar 09, 1988 Aug CAHN
@ EQ 200MG BASE/VIAL A062569 002 Mar 09, 1988 Aug CAHN

TABLET;ORAL
ACTICLATE

>D> AQUA PHARMS LLC EQ 75MG BASE N205931 001 Jul 25, 2014 Jul NEWA
EQ 150MG BASE N205931 002 Jul 25, 2014 Nov CRLD
>A> + EQ 150MG BASE N205931 002 Jul 25, 2014 Nov CRLD
EQ 150MG BASE N205931 002 Jul 25, 2014 Jul NEWA

DOXYCYCLINE HYCLATE

AB + HIKMA INTL PHARMS EQ 100MG BASE A065095 001 Jul 02, 2003 Sep CAHN
AB + LANNETT EQ 20MG BASE A065277 001 Nov 10, 2005 Oct CRLD
AB MYLAN EQ 100MG BASE A062432 001 Feb 15, 1983 Jul CMFD

PERIOSTAT

@ GALDERMA LABS LP EQ 20MG BASE N050783 001 Feb 02, 2001 Oct DISC

TABLET, DELAYED RELEASE;ORAL
DORYX

AB MAYNE PHARMA EQ 150MG BASE N050795 003 Jun 20, 2008 Feb CRLD
+ EQ 200MG BASE N050795 005 Apr 11, 2013 Feb CRLD

DRONABINOL

CAPSULE;ORAL
DRONABINOL

AB AKORN INC 2.5MG A079217 001 Jun 20, 2014 Jun NEWA
AB 5MG A079217 002 Jun 20, 2014 Jun NEWA
AB 10MG A079217 003 Jun 20, 2014 Jun NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

NIKKI

AB	LUPIN LTD	3MG;0.02MG	A201661	001	May 27, 2014	May NEWA
----	-----------	------------	---------	-----	--------------	----------

TABLET; ORAL-28

YAELA

>A> AB	NOVAST LABS LTD	3MG;0.03MG	A202015	001	Nov 19, 2014	Nov NEWA
--------	-----------------	------------	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

BAYER HLTHCARE

3MG,N/A;0.02MG,N/A;0.451MG,0.451MG

N022532	001	Sep 24, 2010	Jul CRLD
---------	-----	--------------	----------

SAFYRAL

+ BAYER HLTHCARE

3MG,N/A;0.03MG,N/A;0.451MG,0.451MG

N022574	001	Dec 16, 2010	Jul CRLD
---------	-----	--------------	----------

DROXIDOPA

CAPSULE; ORAL

NORTHERA

CHELSEA THERAPS INC

100MG

N203202	001	Feb 18, 2014	Feb NEWA
---------	-----	--------------	----------

200MG

N203202	002	Feb 18, 2014	Feb NEWA
---------	-----	--------------	----------

+

300MG

N203202	003	Feb 18, 2014	Feb NEWA
---------	-----	--------------	----------

LUNDBECK NA LTD

100MG

N203202	001	Feb 18, 2014	Jun CAHN
---------	-----	--------------	----------

200MG

N203202	002	Feb 18, 2014	Jun CAHN
---------	-----	--------------	----------

+

300MG

N203202	003	Feb 18, 2014	Jun CAHN
---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

DULOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A202949	001	Jun 09, 2014	May NEWA
----	--------------------	--------------	---------	-----	--------------	----------

AB		EQ 30MG BASE	A202949	002	Jun 09, 2014	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB		EQ 60MG BASE	A202949	003	Jun 09, 2014	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB	APOTEX INC	EQ 20MG BASE	A202045	001	Jun 11, 2014	May NEWA
----	------------	--------------	---------	-----	--------------	----------

AB		EQ 30MG BASE	A202045	002	Jun 11, 2014	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB		EQ 60MG BASE	A202045	003	Jun 11, 2014	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB	BRECKENRIDGE PHARM	EQ 20MG BASE	A203088	001	Jun 11, 2014	May NEWA
----	--------------------	--------------	---------	-----	--------------	----------

AB		EQ 30MG BASE	A203088	002	Jun 11, 2014	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB		EQ 60MG BASE	A203088	003	Jun 11, 2014	May NEWA
----	--	--------------	---------	-----	--------------	----------

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb NEWA
----	---------------	-------------	---------	-----	--------------	----------

JALYN

AB	+ GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb CFTG
----	-------------------	-------------	---------	-----	--------------	----------

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL

ECOZA

+ VELDANA MEDICAL SA

1%

N205175	001	Oct 24, 2013	Feb CAHN
---------	-----	--------------	----------

CREAM; TOPICAL

SPECTAZOLE

@ MERZ PHARMS LLC

1%

N018751	001	Dec 23, 1982	Jan CAHN
---------	-----	--------------	----------

EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

+ DOW PHARM

10%

N203567	001	Jun 06, 2014	Jun NEWA
---------	-----	--------------	----------

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

+ GENZYME CORP

EQ 84MG BASE

N205494	001	Aug 19, 2014	Aug NEWA
---------	-----	--------------	----------

ELVITEGRAVIR

TABLET; ORAL

VITEKTA

GILEAD SCIENCES INC

85MG

N203093	001	Sep 24, 2014	Sep NEWA
---------	-----	--------------	----------

+

150MG

N203093	002	Sep 24, 2014	Sep NEWA
---------	-----	--------------	----------

EMPAGLIFLOZINTABLET; ORAL
JARDIANCE

BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Aug NEWA
+	25MG	N204629	002	Aug 01, 2014	Aug NEWA

ENALAPRIL MALEATETABLET; ORAL
ENALAPRIL MALEATE

@ WATSON LABS	2.5MG	A075501	001	Aug 22, 2000	May DISC
@	5MG	A075501	002	Aug 22, 2000	May DISC
@	10MG	A075501	003	Aug 22, 2000	May DISC
@	20MG	A075501	004	Aug 22, 2000	May DISC

ENOXAPARIN SODIUMINJECTABLE; SUBCUTANEOUS
ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	TEVA	30MG/0.3ML (100MG/ML)	A076726	001	Jun 23, 2014	Jun NEWA
AP		40MG/0.4ML (100MG/ML)	A076726	002	Jun 23, 2014	Jun NEWA
AP		60MG/0.6ML (100MG/ML)	A076726	003	Jun 23, 2014	Jun NEWA
AP		80MG/0.8ML (100MG/ML)	A076726	004	Jun 23, 2014	Jun NEWA
AP		100MG/ML (100MG/ML)	A076726	005	Jun 23, 2014	Jun NEWA
AP		120MG/0.8ML (150MG/ML)	A076726	006	Jun 23, 2014	Jun NEWA
AP		150MG/ML (150MG/ML)	A076726	007	Jun 23, 2014	Jun NEWA

ENTECAVIRTABLET; ORAL
BARACLUDE

AB	BRISTOL MYERS SQUIBB	0.5MG	N021797	001	Mar 29, 2005	Aug CFTG
AB	+	1MG	N021797	002	Mar 29, 2005	Aug CFTG
	ENTECAVIR					
AB	TEVA PHARMS USA	0.5MG	A202122	001	Aug 26, 2014	Aug NEWA
AB		1MG	A202122	002	Aug 26, 2014	Aug NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT	GAVIS PHARMS LLC	0.05%	A090951	001	Oct 31, 2011	Sep CAHN
AT	TESA PHARMS LLC	0.05%	A090951	001	Oct 31, 2011	Jul CAHN

EPINEPHRINEINJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	1MG/ML	N204200	001	Dec 07, 2012	Apr CAHN
---	----------------------	--------	---------	-----	--------------	----------

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	30MG/30ML (1MG/ML)	N204640	001	Dec 18, 2013	Apr CAHN
---	----------------------	--------------------	---------	-----	--------------	----------

EPINEPHRINE HYDROCHLORIDEINJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN
---	----------------------	---------------------------------	---------	-----	--------------	----------

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN
---	----------------------	------------------------------------	---------	-----	--------------	----------

SOLUTION; IV (INFUSION)

EPINEPHRINE

BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul NEWA
--------------------	---------------------------------	---------	-----	--------------	----------

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

AP	ACTAVIS ELIZABETH	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Aug CAHN
AP		50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008	Aug CAHN
AP		200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008	Aug CAHN
AP	ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Oct CAHN
AP		50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008	Oct CAHN
AP		200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008	Oct CAHN
>D> AP	EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009	Nov DISC
>A>	@	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009	Nov DISC
>D> AP		200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009	Nov DISC

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

>A>	@	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009	Nov	DISC
AP	EUROHLTH INTL	50MG/25ML (2MG/ML)	A065289	001	Jun 27, 2007	Aug	CAHN
AP		200MG/100ML (2MG/ML)	A065289	002	Jun 27, 2007	Aug	CAHN
	@ HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007	May	DISC
	@ MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Mar	DISC
	@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Mar	DISC

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

	@ HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006	Jun	DISC
--	-----------	-----------	---------	-----	--------------	-----	------

ERGOCALCIFEROL

CAPSULE; ORAL

ERGOCALCIFEROL

AA	STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Aug	CAHN
----	----------------	-----------	---------	-----	--------------	-----	------

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

	@ WATSON LABS	0.5MG	A087233	001		May	DISC
--	---------------	-------	---------	-----	--	-----	------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	May	NEWA
AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	May	NEWA
AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	May	NEWA
	TARCEVA						
AB	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	May	CFTG
AB		EQ 100MG BASE	N021743	002	Nov 18, 2004	May	CFTG
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	May	CFTG

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB	ARBOR PHARMS LLC	250MG	A062746	001	Dec 22, 1986	Sep	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

SWAB; TOPICAL

ERYTHROMYCIN

	@ FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	May	DISC
--	------------------	----	---------	-----	--------------	-----	------

TABLET; ORAL

ERYTHROMYCIN

	ARBOR PHARMS LLC	250MG	A061621	001		Sep	CAHN
+		500MG	A061621	002		Sep	CAHN

TABLET, COATED PARTICLES; ORAL

PCE

	ARBOR PHARMS LLC	333MG	N050611	001	Sep 09, 1986	Sep	CAHN
+		500MG	N050611	002	Aug 22, 1990	Sep	CAHN

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

	ARBOR PHARMS LLC	333MG	A062298	003	Mar 29, 1982	Sep	CRLD
+		500MG	A062298	002		Sep	CRLD

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	001		Sep	CAHN
----	------------------	-------------------	---------	-----	--	-----	------

ERYPED

AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Sep	CAHN
+		EQ 400MG BASE/5ML	N050207	002		Sep	CAHN

SUSPENSION; ORAL

E.E.S. 200

AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A061639	001		Sep	CAHN
----	------------------	-------------------	---------	-----	--	-----	------

E.E.S. 400

AB	+	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A061639	002		Sep	CAHN
----	---	------------------	-------------------	---------	-----	--	-----	------

PEDIAMYCIN

AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304	001		Sep	CAHN
----	------------------	-------------------	---------	-----	--	-----	------

PEDIAMYCIN 400

AB	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304	002		Sep	CAHN
----	------------------	-------------------	---------	-----	--	-----	------

TABLET;ORAL

E.E.S. 400

BX	+	@ ARBOR PHARMS LLC	EQ 400MG BASE	A061905	001		Sep CAHN
			EQ 400MG BASE	A061905	002	Aug 12, 1982	Sep CAHN
BX	+	ERYTHROMYCIN ETHYLSUCCINATE					
		ARBOR PHARMS LLC	EQ 400MG BASE	A061904	001		Sep CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

+	HOSPIRA	EQ 1GM BASE/VIAL	A062638	002	Oct 31, 1986	May CTEC
---	---------	------------------	---------	-----	--------------	----------

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

	@ ARBOR PHARMS LLC	EQ 125MG BASE	A060359	002		Sep CAHN
+		EQ 250MG BASE	A060359	001		Sep CAHN
	@	EQ 500MG BASE	A060359	003		Sep CAHN
	ERYTHROMYCIN STEARATE					
	@ ANI PHARMS INC	EQ 250MG BASE	A061461	001		Feb CAHN
	@	EQ 250MG BASE	A061591	001		Jan CAHN
	@	EQ 500MG BASE	A061461	002		Feb CAHN
	@	EQ 500MG BASE	A063179	001	May 15, 1990	Feb CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB	JUBILANT GENERICS	EQ 5MG BASE	A202280	001	Sep 12, 2012	Aug CAHN
AB		EQ 10MG BASE	A202280	002	Sep 12, 2012	Aug CAHN
AB		EQ 20MG BASE	A202280	003	Sep 12, 2012	Aug CAHN
AB	TEVA PHARMS USA	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb CAHN
AB		EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb CAHN
AB		EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP	EUROHLTH INTL	10MG/ML	A076323	001	Aug 10, 2004	Aug CAHN
----	---------------	---------	---------	-----	--------------	----------

ESTRADIOL

GEL;TOPICAL

ESTROGEL

@	ASCEND THERAPS US	0.06%	N021166	001	Feb 09, 2004	May CAHN
---	-------------------	-------	---------	-----	--------------	----------

GEL;TRANSDERMAL

DIVIGEL

	VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Apr CAHN
		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007	Apr CAHN
+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007	Apr CAHN

GEL, METERED;TRANSDERMAL

ESTROGEL

+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	May CAHN
---	-------------------	---------------------------	---------	-----	--------------	----------

SPRAY;TRANSDERMAL

EVAMIST

>A>	+	ELAN PHARMA INTL LTD	1.53MG/SPRAY	N022014	001	Jul 27, 2007	Nov CAHN
>D>	+	LUMARA HEALTH INC	1.53MG/SPRAY	N022014	001	Jul 27, 2007	Nov CAHN
	+		1.53MG/SPRAY	N022014	001	Jul 27, 2007	May CAHN

TABLET;ORAL

ESTRADIOL

>D>	@	AAI PHARMA INC	0.5MG	A040138	001	Jan 30, 1998	Nov CAHN
>D>	@		1MG	A040138	002	Jan 30, 1998	Nov CAHN
>D>	@		2MG	A040138	003	Jan 30, 1998	Nov CAHN
>A>	@	LANNETT HOLDINGS INC	0.5MG	A040138	001	Jan 30, 1998	Nov CAHN
>A>	@		1MG	A040138	002	Jan 30, 1998	Nov CAHN
>A>	@		2MG	A040138	003	Jan 30, 1998	Nov CAHN

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

+	PHARMACIA AND UPJOHN	5MG/ML	A085470	003		May CTEC
---	----------------------	--------	---------	-----	--	----------

ESTRADIOL CYPIONATE

@	WATSON LABS	5MG/ML	A085620	001		May DISC
---	-------------	--------	---------	-----	--	----------

ESTRADIOL VALERATEINJECTABLE; INJECTION
DELESTROGEN

>D>	AO	+	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Nov	CTEC
>A>		+		10MG/ML	N009402	002		Nov	CTEC
	AO	+		10MG/ML	N009402	002		Apr	CAHN
	AO	+		20MG/ML	N009402	004		Apr	CAHN
	AO	+		40MG/ML	N009402	003		Apr	CAHN

ESTRADIOL VALERATE

>D>	AO		SANDOZ	10MG/ML	A040628	001	Oct 04, 2007	Nov	DISC
>A>		@		10MG/ML	A040628	001	Oct 04, 2007	Nov	DISC
>D>	AO			20MG/ML	A040628	002	Oct 04, 2007	Nov	DISC
>A>		@		20MG/ML	A040628	002	Oct 04, 2007	Nov	DISC
>D>	AO			40MG/ML	A040628	003	Oct 04, 2007	Nov	DISC
>A>		@		40MG/ML	A040628	003	Oct 04, 2007	Nov	DISC

ESTRADIOL; NORETHINDRONE ACETATETABLET; ORAL
ACTIVEVILLA

AB			AMNEAL PHARMS LLC	0.5MG; 0.1MG	N020907	002	Dec 28, 2006	Jun	CAHN
AB		+		1MG; 0.5MG	N020907	001	Nov 18, 1998	Jun	CAHN

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

		+	BARR	1MG, 1MG; N/A, 0.09MG	A076812	001	Apr 29, 2005	Oct	CTEC
AB		+		1MG, 1MG; N/A, 0.09MG	A076812	001	Apr 29, 2005	Sep	CRLD
			PREFEST						
		@	TEVA WOMENS	1MG, 1MG; N/A, 0.09MG	N021040	001	Oct 22, 1999	Sep	DISC

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

@ WATSON LABS

OGEN 5

PHARMACIA AND UPJOHN

ORTHO-EST

@ SUN PHARM INDS INC

@

6MG

6MG

0.75MG

1.5MG

A081216 001 Sep 23, 1993 May DISC

A083220 004 May CTEC

A089567 001 Feb 27, 1991 Jun CAHN

A089582 001 Jul 17, 1991 Jun CAHN

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB			DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014	Mar	NEWA
AB				2MG	A091024	002	Apr 15, 2014	Mar	NEWA
AB				3MG	A091024	003	Apr 15, 2014	Mar	NEWA
AB			GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014	Mar	NEWA
AB				2MG	A091166	002	Apr 15, 2014	Mar	NEWA
AB				3MG	A091166	003	Apr 15, 2014	Mar	NEWA
AB			LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Mar	CMFD
AB				2MG	A091124	002	Sep 13, 2011	Mar	CMFD
AB				3MG	A091124	003	Sep 13, 2011	Mar	CMFD
AB			ORCHID HLTHCARE	1MG	A091113	001	Jun 10, 2014	May	NEWA
AB				2MG	A091113	002	Jun 10, 2014	May	NEWA
AB				3MG	A091113	003	Jun 10, 2014	May	NEWA
AB			ROXANE	1MG	A091153	001	Apr 15, 2014	Mar	NEWA
AB				2MG	A091153	002	Apr 15, 2014	Mar	NEWA
AB				3MG	A091153	003	Apr 15, 2014	Mar	NEWA
AB			TEVA	1MG	A091169	001	May 23, 2011	Jan	CMFD
AB				2MG	A091169	002	May 23, 2011	Jan	CMFD
AB				3MG	A091169	003	May 23, 2011	Jan	CMFD

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

@ HIKMA INTL PHARMS

@

100MG

400MG

A075095 001 Nov 30, 1999 Oct CAHN

A075095 002 Nov 30, 1999 Oct CAHN

ETHINYL ESTRADIOL; ETONOGESTRELRING;VAGINAL
NUVARING

+ ORGANON USA INC 0.015MG/24HR;0.12MG/24HR N021187 001 Oct 03, 2001 Apr CPOT

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET;ORAL
SETLAKIN

AB NOVAST LABS LTD 0.03MG;0.15MG A090716 001 Sep 15, 2014 Sep NEWA

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A> AB2 FAMY CARE LTD 0.02MG;0.1MG A202247 001 Dec 08, 2014 Nov NEWA

AB1 HAUPT PHARMA 0.02MG;0.1MG A201108 001 Feb 05, 2014 Jan NEWA

>A> AB 0.03MG;0.15MG A201095 001 Dec 08, 2014 Nov NEWA

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE;TRANSDERMAL
ORTHO EVRA

AB + JANSSEN PHARMS 0.035MG/24HR;0.15MG/24HR N021180 001 Nov 20, 2001 Mar CFTG

+ 0.035MG/24HR;0.15MG/24HR N021180 001 Nov 20, 2001 Mar CPOT

XULANE

AB MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A200910 001 Apr 16, 2014 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

NORETHIN 1/35E-21

@ WATSON LABS 0.035MG;1MG A071480 001 Apr 12, 1988 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON LABS 0.035MG;0.4MG A078379 001 Feb 23, 2010 May DISC

@ 0.035MG;1MG A070685 001 Jan 29, 1987 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

@ WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071043 001 Apr 01, 1988 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071041 001 Sep 24, 1991 May DISC

TABLET;ORAL-28

NORETHIN 1/35E-28

@ WATSON LABS 0.035MG;1MG A071481 001 Apr 12, 1988 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON LABS 0.035MG,0.035MG;0.5MG,0.75 MG,1MG A076393 001 Feb 04, 2010 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071042 001 Sep 24, 1991 May DISC

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB FAMY CARE LTD 0.025MG;0.8MG A203371 001 Apr 23, 2014 Apr NEWA

AB + WARNER CHILCOTT 0.025MG;0.8MG N022573 001 Dec 22, 2010 Apr CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

GILDESS 24 FE

>A> AB VINTAGE PHARMS 0.02MG;1MG A090293 001 Dec 01, 2014 Nov NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>A> AB BARR LABS INC 0.02MG;1MG A090938 001 Dec 01, 2014 Nov NEWA

AB FAMY CARE LTD 0.02MG;1MG A202742 001 Oct 30, 2014 Oct NEWA

TABLET;ORAL-21

GILDESS 1.5/30

AB VINTAGE PHARMS LLC 0.03MG;1.5MG A077075 002 Jul 24, 2012 Mar NEWA

GILDESS 1/20

AB VINTAGE PHARMS LLC 0.02MG;1MG A077077 002 Jul 24, 2012 Mar NEWA

LARIN 1.5/30

AB NOVAST LABS LTD 0.03MG;1.5MG A202996 001 Mar 20, 2014 Mar NEWA

LOESTRIN 21 1.5/30

AB WARNER CHILCOTT LLC 0.03MG;1.5MG N017875 001 Oct CMFD

@ 0.03MG;1.5MG N017875 001 May DISC

LOESTRIN 21 1/20

AB WARNER CHILCOTT LLC 0.02MG;1MG N017876 001 Oct CMFD

@ 0.02MG;1MG N017876 001 May DISC

TABLET;ORAL-28

LOESTRIN FE 1.5/30

AB + WARNER CHILCOTT LLC 0.03MG;1.5MG N017355 001 Oct CMFD

TABLET;ORAL-28									
LOESTRIN FE 1.5/30									
	@	0.03MG;1.5MG		N017355	001			May	DISC
LOESTRIN FE 1/20									
AB	WARNER CHILCOTT	0.02MG;1MG		N017354	001			Oct	CMFD
	@	0.02MG;1MG		N017354	001			May	DISC
MICROGESTIN FE 1.5/30									
AB	WATSON LABS	0.03MG;1.5MG		A075548	001	Feb 05, 2001		Oct	CRLD
AB	+	0.03MG;1.5MG		A075548	001	Feb 05, 2001		May	CRLD
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>									
TABLET;ORAL-28									
NORGESTIMATE AND ETHINYL ESTRADIOL									
	@ WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.2		A090479	001	Mar 09, 2011		May	DISC
		15MG,0.25MG							
	@	0.035MG,0.035MG,0.035MG;0.18MG,0.2		A076626	001	Aug 17, 2006		May	DISC
		15MG,0.25MG							
	@	0.035MG;0.25MG		A076627	001	Aug 17, 2006		May	DISC
<u>ETHINYL ESTRADIOL; NORGESTREL</u>									
TABLET;ORAL-21									
LOW-OGESTREL-21									
	@ WATSON LABS	0.03MG;0.3MG		A075288	001	Jul 28, 1999		May	DISC
TABLET;ORAL-28									
LOW-OGESTREL-28									
	@ WATSON LABS	0.03MG;0.3MG		A075288	002	Jul 28, 1999		May	DISC
<u>ETHIODIZED OIL</u>									
OIL;INTRALYMPHATIC, INTRAUTERINE									
ETHIODOL									
+	GUERBET	99%		N009190	001			Apr	CMFD
LIPIODOL									
+	GUERBET	99%		N009190	001			Apr	CTNA
<u>ETODOLAC</u>									
CAPSULE;ORAL									
ETODOLAC									
	@ ANI PHARMS INC	200MG		A074899	001	Jul 08, 1997		Feb	CAHN
	@	200MG		A075126	001	Sep 16, 1999		Jan	CAHN
	@	300MG		A074899	002	Jul 08, 1997		Feb	CAHN
AB		300MG		A075126	002	Sep 16, 1999		Jan	CAHN
TABLET, EXTENDED RELEASE;ORAL									
ETODOLAC									
AB	ZYDUS PHARMS USA INC	400MG		A091134	001	Jan 23, 2014		May	NEWA
AB		500MG		A091134	002	Jan 23, 2014		May	NEWA
AB		600MG		A091134	003	Jan 23, 2014		May	NEWA
<u>ETOMIDATE</u>									
INJECTABLE;INJECTION									
ETOMIDATE									
AP	AGILA SPECLTS	2MG/ML		A078289	001	Jan 02, 2009		Feb	CAHN
AP	EMCURE PHARMS LTD	2MG/ML		A204618	001	Aug 13, 2014		Aug	NEWA
AP	PAR STERILE PRODUCTS	2MG/ML		A091297	001	Jun 20, 2012		Jul	CAHN
AP	ZYDUS PHARMS USA INC	2MG/ML		A202360	001	Jul 18, 2014		Jul	NEWA
<u>ETOPOSIDE</u>									
CAPSULE;ORAL									
VEPESID									
	@ DAVA PHARMS INC	50MG		N019557	001	Dec 30, 1986		Sep	CAHN
	@	100MG		N019557	002	Dec 30, 1986		Sep	CAHN
INJECTABLE;INJECTION									
ETOPOSIDE									
AP	EUROHLTH INTL	20MG/ML		A074290	001	Jul 17, 1995		Aug	CAHN
	@ PHARMACHEMIE BV	20MG/ML		A074227	001	Feb 22, 1996		Feb	CAHN
	@ TEVA PHARMS USA	20MG/ML		A074284	001	Feb 10, 1994		May	DISC
<u>EXEMESTANE</u>									
TABLET;ORAL									
EXEMESTANE									
AB	ALVOGEN INC	25MG		A200898	001	Jul 28, 2014		Aug	CAHN
AB	EIRGEN PHARMA LTD	25MG		A200898	001	Jul 28, 2014		Jul	NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON

+	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Jun CAHN
	INJECTABLE;SUBCUTANEOUS					
	BYETTA					
+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar CAHN
+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar CAHN

FAMCICLOVIR

TABLET;ORAL
FAMCICLOVIR

AB	HETERO LABS LTD V	125MG	A202438	001	Sep 10, 2014	Sep NEWA
AB		250MG	A202438	002	Sep 10, 2014	Sep NEWA
AB		500MG	A202438	003	Sep 10, 2014	Sep NEWA

FAMOTIDINE

FOR SUSPENSION;ORAL
FAMOTIDINE

AB	HI-TECH PHARMA CO	40MG/5ML	A201995	001	May 30, 2014	May NEWA
	INJECTABLE;INJECTION					
	FAMOTIDINE PRESERVATIVE FREE					
AP	BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001	Feb CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

>D>	AB	WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012	Nov DISC
>A>		@	2.5MG	A091484	001	Aug 15, 2012	Nov DISC
>D>	AB		5MG	A091484	002	Aug 15, 2012	Nov DISC
>A>		@	5MG	A091484	002	Aug 15, 2012	Nov DISC
>D>	AB		10MG	A091484	003	Aug 15, 2012	Nov DISC
>A>		@	10MG	A091484	003	Aug 15, 2012	Nov DISC

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE

AB	RANBAXY LABS LTD	43MG	A201748	001	Oct 31, 2014	Oct NEWA
AB		130MG	A201748	002	Oct 31, 2014	Oct NEWA

TABLET;ORAL
FENOGLIDE

	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb CAHN
+		120MG	N022118	002	Aug 10, 2007	Feb CAHN
	TRIGLIDE					
	@ SKYEPHARMA AG	50MG	N021350	001	May 07, 2005	May DISC

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION
FENOLDOPAM MESYLATE

AP	EUROHLTH INTL	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Aug CAHN
----	---------------	-----------------	---------	-----	--------------	----------

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

@	NOVEN	100MCG/HR	A077775	004	Oct 16, 2009	Apr DISC
	FENTANYL-25					
@	NOVEN	25MCG/HR	A077775	001	Oct 16, 2009	Apr DISC
	FENTANYL-50					
@	NOVEN	50MCG/HR	A077775	002	Oct 16, 2009	Apr DISC
	FENTANYL-75					
@	NOVEN	75MCG/HR	A077775	003	Oct 16, 2009	Apr DISC

FENTANYL CITRATE

TABLET;BUCCAL
FENTANYL CITRATE

@	WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	May DISC
@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	May DISC
@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	May DISC
@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	May DISC
@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	May DISC

TABLET;BUCCAL, SUBLINGUAL
FENTANYL CITRATE

@ WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	Jun CDFR
@	EQ 0.2MG BASE	A079075	002	Jan 07, 2011	Jun CDFR
@	EQ 0.4MG BASE	A079075	003	Jan 07, 2011	Jun CDFR
@	EQ 0.6MG BASE	A079075	004	Jan 07, 2011	Jun CDFR
@	EQ 0.8MG BASE	A079075	005	Jan 07, 2011	Jun CDFR

FENTORA

CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Jun CTEC
	EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Jun CTEC
+	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Jun CTEC
	EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Jun CTEC
	EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Jun CTEC

TABLET;SUBLINGUAL
FENTANYL CITRATE

@ WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	May CDFR
@	EQ 0.2MG BASE	A079075	002	Jan 07, 2011	May CDFR
@	EQ 0.4MG BASE	A079075	003	Jan 07, 2011	May CDFR
@	EQ 0.6MG BASE	A079075	004	Jan 07, 2011	May CDFR
@	EQ 0.8MG BASE	A079075	005	Jan 07, 2011	May CDFR

FERRIC CITRATE

TABLET;ORAL
FERRIC CITRATE

+ KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Sep NEWA
-------------------	---------------	---------	-----	--------------	----------

FIDAXOMICIN

TABLET;ORAL
DIFICID

+ CUBIST PHARMS	200MG	N201699	001	May 27, 2011	Jul CAHN
-----------------	-------	---------	-----	--------------	----------

FINASTERIDE

TABLET;ORAL
FINASTERIDE

AB	ACTAVIS ELIZABETH	1MG	A078371	001	Nov 05, 2013	Aug CAHN
AB		5MG	A077914	001	Mar 28, 2007	Aug CAHN
AB	ACTAVIS TOTOWA	1MG	A078371	001	Nov 05, 2013	Oct CAHN
AB		5MG	A077914	001	Mar 28, 2007	Oct CAHN
>A> AB	CIPLA LTD	1MG	A077335	001	Nov 20, 2014	Nov NEWA

FLECAINIDE ACETATE

TABLET;ORAL
TAMBOCOR

@ CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jul CAHN
@	100MG	N018830	001	Oct 31, 1985	Jul CAHN
@	150MG	N018830	003	Jun 03, 1988	Jul CAHN
@	200MG	N018830	002	Oct 31, 1985	Jul CAHN

FLORBETABEN F-18

SOLUTION;INTRAVENOUS
NEURACEQ

+ PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Mar NEWA
-------------------	----------------------	---------	-----	--------------	----------

FLOXURIDINE

INJECTABLE;INJECTION
FLOXURIDINE

AP	+ EUROHLTH INTL	500MG/VIAL	A075387	001	Apr 16, 2000	Aug CAHN
----	-----------------	------------	---------	-----	--------------	----------

FLUCONAZOLE

INJECTABLE;INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Apr DISC
@	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Apr DISC

TABLET;ORAL
FLUCONAZOLE

>D> BX	DR REDDYS LABS INC	50MG	A076658	001	Jul 29, 2004	Nov CTEC
>A> AB		50MG	A076658	001	Jul 29, 2004	Nov CTEC
>D> BX		100MG	A076658	002	Jul 29, 2004	Nov CTEC
>A> AB		100MG	A076658	002	Jul 29, 2004	Nov CTEC
>D> BX		150MG	A076658	003	Jul 29, 2004	Nov CTEC
>A> AB		150MG	A076658	003	Jul 29, 2004	Nov CTEC
>D> BX		200MG	A076658	004	Jul 29, 2004	Nov CTEC

TABLET;ORAL
FLUCONAZOLE

>A> AB 200MG A076658 004 Jul 29, 2004 Nov CTEC

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

AP ACTAVIS ELIZABETH 50MG/VIAL A078610 001 Feb 11, 2009 Aug CAHN
AP ACTAVIS TOTOWA 50MG/VIAL A078610 001 Feb 11, 2009 Oct CAHN
AP MUSTAFA NEVZAT ILAC 50MG/2ML (25MG/ML) A090724 001 Sep 27, 2010 May CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP BRIGHAM WOMENS 20-300mCi/ML A203816 001 Oct 30, 2014 Oct NEWA
AP CHILDRENS HOSP MI 20-300mCi/ML A204385 001 Oct 29, 2014 Oct NEWA
AP ESSENTIAL ISOTOPES 20-300mCi/ML A203946 001 Feb 05, 2014 Jan NEWA
AP GLOBAL ISOTOPES LLC 20-300mCi/ML A204463 001 Oct 21, 2014 Oct NEWA
HOT SHOTS NM LLC 4-500mCi/ML A203937 001 Oct 30, 2014 Oct NEWA
AP LANTHEUS MEDICAL 20-200mCi/ML A203664 001 Feb 04, 2014 Jan NEWA
AP MA GENERAL HOSP 20-300mCi/ML A204333 001 Sep 25, 2014 Sep NEWA
AP SPDC 20-300mCi/ML A204525 001 Oct 29, 2014 Oct NEWA
AP TRUSTEES UNIV PA 20-200mCi/ML A203801 001 Oct 29, 2014 Oct NEWA
AP UCSF RODIOPHARM 20-300mCi/ML A203902 001 May 09, 2014 Apr NEWA
AP UIHC PET IMAGING 20-300mCi/ML A203990 001 Aug 06, 2014 Jul NEWA
@ WEILL MEDCL COLL 10-100mCi/ML N021768 001 Aug 05, 2004 Feb DISC
AP WUSM CYCLOTRON 20-300mCi/ML A203935 001 Feb 05, 2014 Jan NEWA

FLUDROCORTISONE ACETATE

TABLET;ORAL
FLUDROCORTISONE ACETATE

AB HIKMA PHARMS 0.1MG A091302 001 Jul 22, 2011 Jan CAHN

FLUNISOLIDE

AEROSOL, METERED;INHALATION
AEROSPAN HFA

+ MEDA PHARMS INC 0.078MG/INH N021247 001 Jan 27, 2006 Aug CPOT
+ EQ 78MG BASE/INH N021247 001 Jan 27, 2006 Mar CAHN

FLUOCINOLONE ACETONIDE

IMPLANT;INTRAVITREAL
ILUVIEN

+ ALIMERA SCIENCES INC 0.19MG N201923 001 Sep 26, 2014 Sep NEWA

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL
NEO-SYNALAR

+ MEDIMETRIKS PHARMS 0.025%;EQ 3.5MG BASE/GM A060700 001 Apr CMFD

FLUOCINONIDE

CREAM;TOPICAL
FLUOCINONIDE

AB FOUGERA PHARMS INC 0.1% A200735 001 Jul 14, 2014 Jun NEWA
AB GLENMARK GENERICS 0.1% A091282 001 Jul 14, 2014 Jun NEWA
AB TARO 0.1% A200734 001 Jul 14, 2014 Jun NEWA

SOLUTION;TOPICAL
FLUOCINONIDE

AT G AND W LABS INC 0.05% A071535 001 Dec 02, 1988 May CAHN
LIDEX
AT CNTY LINE PHARMS 0.05% N018849 001 Apr 06, 1984 Apr CMFD

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL
FLUOXETINE HYDROCHLORIDE

AB2 ANI PHARMS INC EQ 10MG BASE A076287 001 May 20, 2008 Jan CAHN
AB2 EQ 20MG BASE A076287 002 May 20, 2008 Jan CAHN

TABLET;ORAL
SARAFEM

AB1 WARNER CHILCOTT LLC EQ 10MG BASE N021860 001 May 19, 2006 Jan CFTG
AB1 EQ 15MG BASE N021860 002 May 19, 2006 Jan CFTG
AB1 + EQ 20MG BASE N021860 003 May 19, 2006 Jan CFTG

TABLET;ORAL							
SELFEMRA							
AB1	TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Jan	NEWA
AB1		EQ 15MG BASE	A200151	002	Feb 03, 2014	Jan	NEWA
AB1		EQ 20MG BASE	A200151	003	Feb 03, 2014	Jan	NEWA
<u>FLUPHENAZINE DECANOATE</u>							
INJECTABLE;INJECTION							
FLUPHENAZINE DECANOATE							
AO	EUROHLTH INTL	25MG/ML	A074531	001	Aug 30, 1996	Aug	CAHN
AO	PAR STERILE PRODUCTS	25MG/ML	A203732	001	Jul 03, 2014	Jun	NEWA
<u>FLUPHENAZINE HYDROCHLORIDE</u>							
ELIXIR;ORAL							
FLUPHENAZINE HYDROCHLORIDE							
	@ ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb	CAHN
<u>FLURANDRENOLIDE</u>							
TAPE;TOPICAL							
CORDRAN							
+	WATSON LABS INC	0.004MG/SQ CM	N016455	001		Sep	CAHN
<u>FLURAZEPAM HYDROCHLORIDE</u>							
CAPSULE;ORAL							
FLURAZEPAM HYDROCHLORIDE							
	MYLAN PHARMS INC	15MG	A070345	002	Nov 27, 1985	May	CTEC
+		30MG	A070345	001	Nov 27, 1985	May	CTEC
	@ WATSON LABS	15MG	A071205	001	Nov 25, 1986	May	DISC
	@	30MG	A071068	001	Nov 25, 1986	May	DISC
	@	30MG	A072369	001	Mar 30, 1989	May	DISC
<u>FLURBIPROFEN</u>							
TABLET;ORAL							
FLURBIPROFEN							
AB	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001	Jul	CAHN
AB		100MG	A075058	002	Apr 27, 2001	Jul	CAHN
<u>FLUTICASONE FUROATE</u>							
POWDER;INHALATION							
ARNUITY ELLIPTA							
	GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Aug	NEWA
+		0.2MG/INH	N205625	002	Aug 20, 2014	Aug	NEWA
<u>FLUVOXAMINE MALEATE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
FLUVOXAMINE MALEATE							
AB	TORRENT PHARMS LTD	100MG	A203240	001	Oct 31, 2014	Oct	NEWA
AB		150MG	A203240	002	Oct 31, 2014	Oct	NEWA
TABLET;ORAL							
FLUVOXAMINE MALEATE							
	@ SUN PHARM INDS INC	25MG	A075900	001	Feb 23, 2006	Jul	CAHN
	@	50MG	A075900	002	Feb 23, 2006	Jul	CAHN
	@	100MG	A075900	003	Feb 23, 2006	Jul	CAHN
<u>FOLIC ACID</u>							
TABLET;ORAL							
FOLIC ACID							
AA	CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan	NEWA
<u>FOLLITROPIN ALFA/BETA</u>							
INJECTABLE;SUBCUTANEOUS							
GONAL-F RFF REDI-JECT							
+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004	May	CTNA
+		450 IU/0.75ML	N021684	002	May 25, 2004	May	CTNA
+		900 IU/1.5ML	N021684	003	May 25, 2004	May	CTNA

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

@ MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009	Jun DISC
-----------------------	----------------------	---------	-----	--------------	----------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

AP	+	AGI	2.5MG/0.5ML	N021345	001	Dec 07, 2001	May CAHN
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	May CAHN
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	May CAHN
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	May CAHN
AP	+	MYLAN IRELAND LTD	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Oct CAHN
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Oct CAHN
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Oct CAHN
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Oct CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ WATSON LABS	10MG	A077531	001	Aug 31, 2006	May DISC
@	20MG	A077531	002	Aug 31, 2006	May DISC
@	40MG	A077531	003	Aug 31, 2006	May DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		EMCURE PHARMS INDIA	10MG; 12.5MG	A079025	001	Sep 17, 2010	Feb CAIN
AB	+		20MG; 12.5MG	A079025	002	Sep 17, 2010	Feb CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	+	EMCURE PHARMS INDIA	20MG; 12.5MG	A079025	002	Sep 17, 2010	Jan CRLD
----	---	---------------------	--------------	---------	-----	--------------	----------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

AP		PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb CMFD
		FOSPHENYTOIN SODIUM					
AP		AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb CAHN
AP		AMNEAL PHARMS CO	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	Jun CAHN

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

AB	+	ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Aug CFTG
		FROVATRIPTAN SUCCINATE					
AB		MYLAN PHARMS INC	EQ 2.5MG BASE	A202931	001	Aug 28, 2014	Aug NEWA

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP		CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan NEWA
AP		EMCURE PHARMS LTD	10MG/ML	A203428	001	Aug 26, 2014	Aug NEWA

TABLET; ORAL

FUROSEMIDE

AB		CARACO	20MG	A091258	001	Apr 01, 2014	Mar NEWA
AB			40MG	A091258	002	Apr 01, 2014	Mar NEWA
AB			80MG	A091258	003	Apr 01, 2014	Mar NEWA
AB		SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	Jul CAHN
AB			40MG	A091258	002	Apr 01, 2014	Jul CAHN
AB			80MG	A091258	003	Apr 01, 2014	Jul CAHN
		@ WATSON LABS	20MG	A070412	001	Feb 26, 1986	May DISC
		@	20MG	A070449	001	Nov 22, 1985	May DISC
		@	20MG	A071379	001	Jan 02, 1987	May DISC
		@	40MG	A070450	001	Nov 22, 1985	May DISC
		@	80MG	A070528	001	Jan 07, 1986	May DISC
		@	80MG	A071594	001	Feb 09, 1988	May DISC

GABAPENTIN

CAPSULE; ORAL							
GABAPENTIN							
	@ WATSON LABS	100MG	A075485	003	May 11, 2007	May	DISC
	@	300MG	A075485	002	May 11, 2007	May	DISC
	@	400MG	A075485	001	May 11, 2007	May	DISC
TABLET; ORAL							
GABAPENTIN							
AB	ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb	CAHN
AB		800MG	A203244	001	Jul 12, 2013	Feb	CAHN

GALANTAMINE HYDROBROMIDE

TABLET; ORAL							
GALANTAMINE HYDROBROMIDE							
	@ YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May	CAHN
	@	EQ 8MG BASE	A077604	002	Feb 06, 2009	May	CAHN
	@	EQ 12MG BASE	A077604	003	Feb 06, 2009	May	CAHN

GANCICLOVIR SODIUM

INJECTABLE; INJECTION							
GANCICLOVIR SODIUM							
	@ EUROHLTH INTL	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Aug	CAHN

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC							
GATIFLOXACIN							
AT	HI-TECH PHARMA CO	0.5%	A203189	001	Sep 03, 2014	Aug	NEWA
	ZYMAR						
+	ALLERGAN	0.3%	N021493	001	Mar 28, 2003	Sep	CTEC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION							
GEMCITABINE HYDROCHLORIDE							
AP	ACTAVIS ELIZABETH	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Aug	CAHN
AP		EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Aug	CAHN
AP	ACTAVIS TOTOWA	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Oct	CAHN
AP		EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Oct	CAHN

GEMFIBROZIL

TABLET; ORAL							
GEMFIBROZIL							
AB	SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Jun	CAHN
	@ WATSON LABS	600MG	A074442	001	Apr 28, 1995	May	DISC

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS							
COPAXONE							
+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan	NEWA

GLIMEPIRIDE

TABLET; ORAL							
GLIMEPIRIDE							
	@ WATSON LABS	1MG	A077280	001	Feb 03, 2006	May	DISC
	@	2MG	A077280	002	Feb 03, 2006	May	DISC
	@	4MG	A077280	003	Feb 03, 2006	May	DISC

GLIPIZIDE

TABLET; ORAL							
GLIPIZIDE							
AB	SUN PHARM INDS INC	5MG	A077820	001	Jul 11, 2006	Jul	CAHN
AB		10MG	A077820	002	Jul 11, 2006	Jul	CAHN
	@ WATSON LABS	5MG	A074370	001	Nov 22, 1994	May	DISC
	@	10MG	A074370	002	Nov 22, 1994	May	DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL							
GLIPIZIDE AND METFORMIN HYDROCHLORIDE							
AB	SUN PHARM INDS INC	2.5MG; 250MG	A077620	001	Jan 11, 2008	Jul	CAHN
AB		2.5MG; 500MG	A077620	002	Jan 11, 2008	Jul	CAHN
AB		5MG; 500MG	A077620	003	Jan 11, 2008	Jul	CAHN

GLYBURIDE

TABLET;ORAL

GLYBURIDE

@	ACTAVIS ELIZABETH	1.5MG	A075947	001	Nov 14, 2002	Aug CAHN
@		3MG	A075947	002	Nov 14, 2002	Aug CAHN
@		6MG	A075947	003	Nov 14, 2002	Aug CAHN

GLYCOPYRROLATE

TABLET;ORAL

GLYCOPYRROLATE

AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan NEWA
AA		2MG	A091182	002	Feb 03, 2014	Jan NEWA
AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb CAHN
AA		2MG	A090020	002	Oct 19, 2011	Feb CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP	BANNER PHARMACAPS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Aug CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Sep CAHN
	@ SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Jun CAHN
AP	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078835	001	Jun 30, 2008	Jun CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078835	002	Jun 30, 2008	Jun CAHN
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BANNER PHARMACAPS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Aug CAHN
	SOLUTION;ORAL					
	GRANISOL					
	@ PEDIATRAX	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jul DISC
+		EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jul CTNA

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

	@ VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Oct DISC
	GRISEOFULVIN					
AB	+ ACTAVIS MID ATLANTIC	125MG/5ML	A065394	001	Jul 06, 2007	Oct CRLD

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

GRIS-PEG

AB	VALEANT PHARMS INC	125MG	N050475	001		Sep CAHN
AB	+	250MG	N050475	002		Sep CAHN

>A> GUAIFENESIN; HYDROCODONE BITARTRATE

>A> SOLUTION;ORAL

>A> OBREDON

>A>	+	SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001	Nov 14, 2014	Nov NEWA
-----	---	------------------	---------------------	---------	-----	--------------	----------

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

	ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan CAHN
	@	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar CAHN
+		EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan CAHN
	@	EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar CAHN

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

AB	TARO	0.05%	A076994	001	Dec 16, 2004	Apr CMFD
----	------	-------	---------	-----	--------------	----------

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO	AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb CMFD
AO		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb CMFD
AO	EUROHLTH INTL	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Aug CAHN
AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Aug CAHN

HALOPERIDOL LACTATEINJECTABLE; INJECTION
HALOPERIDOL

AP	EUROHLTH INTL	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Aug CAHN
----	---------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUMINJECTABLE; INJECTION
HEPARIN SODIUM

	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011	Mar NEWA
	+	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar CRLD
	+	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar CRLD
	+		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar CRLD
	+		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar CRLD
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A202957	001	Jun 12, 2014	Jun NEWA
AP			5,000 UNITS/ML	A202733	001	Jun 12, 2014	Jun NEWA
AP			5,000 UNITS/ML	A202957	002	Jun 12, 2014	Jun NEWA
AP			10,000 UNITS/ML	A203198	001	Jun 12, 2014	Jun NEWA
AP			20,000 UNITS/ML	A203198	002	Jun 12, 2014	Jun NEWA
		HEPARIN SODIUM IN PLASTIC CONTAINER					
AP	+	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	013	Dec 05, 1985	Jun CTEC
	+		1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar CTEC
AP	+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Jun CTEC
	+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar CTEC
AP	+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Jun CTEC
	+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar CTEC
		HEPARIN SODIUM PRESERVATIVE FREE					
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar NEWA
	+	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987	Mar CTEC
	+	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar CRLD
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Jun NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

@	ACTAVIS ELIZABETH	1.5MG; 5MG	A040295	001	Dec 01, 2000	Aug CAHN
---	-------------------	------------	---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	@	ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984	Aug CAHN
	@		50MG	A088649	001	Oct 18, 1984	Aug CAHN
AA		CADILA PHARMS LTD	25MG	A203845	001	Sep 18, 2014	Sep NEWA
AA			50MG	A203845	002	Sep 18, 2014	Sep NEWA
AA			100MG	A203845	003	Sep 18, 2014	Sep NEWA
AA		STRIDES PHARMA	25MG	A200770	001	May 03, 2013	Aug CAHN
AA			50MG	A200770	002	May 03, 2013	Aug CAHN
AA			100MG	A200770	003	May 03, 2013	Aug CAHN
	@	WATSON LABS	25MG	A084504	001		May DISC
	@		50MG	A084503	001		May DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

+	ARBOR PHARMS LLC	37.5MG; 20MG	N020727	001	Jun 23, 2005	Sep CAHN
---	------------------	--------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		CARACO	12.5MG	A090651	001	Apr 07, 2014	Mar NEWA
	@	HIKMA INTL PHARMS	12.5MG	A077885	001	Nov 26, 2007	Sep CAHN
AB		SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014	Jul CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB		SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014	Jul NEWA
AB			50MG	A203018	002	Jul 23, 2014	Jul NEWA
AB		SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008	Jul CAHN
AB			25MG	A040810	001	Mar 27, 2007	Jul CAHN
AB			50MG	A040810	002	Mar 27, 2007	Jul CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;150MG	A203072	001	May 09, 2014	Apr NEWA
AB		12.5MG;300MG	A203072	002	May 09, 2014	Apr NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	HIKMA INTL PHARMS	12.5MG;10MG	A076265	001	Jul 08, 2002	Sep CAHN
AB		12.5MG;20MG	A076265	002	Jul 08, 2002	Sep CAHN
AB		25MG;20MG	A076265	003	Jul 08, 2002	Sep CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

	@ WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011	May DISC
	@	12.5MG;100MG	A200180	002	Jan 12, 2011	May DISC
	@	25MG;100MG	A200180	003	Jan 12, 2011	May DISC

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG;250MG	A070265	002	Jan 23, 1986	Mar CMS1
--	-------	------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	COVIS PHARMA SARL	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun CAHN
		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun CAHN
+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Apr CAHN
AB		12.5MG;15MG	A202150	002	Mar 07, 2014	Apr CAHN
AB		25MG;15MG	A202150	003	Mar 07, 2014	Apr CAHN
AB	INDICUS PHARMA	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Feb NEWA
AB		12.5MG;15MG	A202150	002	Mar 07, 2014	Feb NEWA
AB		25MG;15MG	A202150	003	Mar 07, 2014	Feb NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;40MG	A070947	002	Mar 04, 1987	Mar CMS1
----	-------	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

	@ WATSON LABS	25MG;25MG	A087398	001		May DISC
--	---------------	-----------	---------	-----	--	----------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB	BOEHRINGER INGELHEIM	12.5MG;40MG	N021162	001	Nov 17, 2000	Feb CFTG
AB		12.5MG;80MG	N021162	002	Nov 17, 2000	Feb CFTG
AB	+	25MG;80MG	N021162	003	Apr 19, 2004	Feb CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;40MG	A203010	001	Feb 25, 2014	Feb NEWA
AB		12.5MG;80MG	A203010	002	Feb 25, 2014	Feb NEWA
AB		25MG;80MG	A203010	003	Feb 25, 2014	Feb NEWA
AB	LUPIN LTD	12.5MG;40MG	A091351	001	Aug 07, 2014	Jul NEWA
AB		12.5MG;80MG	A091351	002	Aug 07, 2014	Jul NEWA
AB		25MG;80MG	A091351	003	Aug 07, 2014	Jul NEWA
AB	MYLAN PHARMS INC	12.5MG;40MG	A091648	001	Feb 25, 2014	Feb NEWA
AB		12.5MG;80MG	A091648	002	Feb 25, 2014	Feb NEWA
AB		25MG;80MG	A091648	003	Feb 25, 2014	Feb NEWA
AB	TORRENT PHARMS LTD	12.5MG;40MG	A201192	001	Feb 25, 2014	Feb NEWA
AB		12.5MG;80MG	A201192	002	Feb 25, 2014	Feb NEWA
AB		25MG;80MG	A201192	003	Feb 25, 2014	Feb NEWA

HYDROCODONE BITARTRATE

>A>	TABLET, EXTENDED RELEASE;ORAL							
>A>	HYSINGLA							
>A>	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Nov	NEWA	
>A>		30MG	N206627	002	Nov 20, 2014	Nov	NEWA	
>A>		40MG	N206627	003	Nov 20, 2014	Nov	NEWA	
>A>		60MG	N206627	004	Nov 20, 2014	Nov	NEWA	
>A>		80MG	N206627	005	Nov 20, 2014	Nov	NEWA	
>A>		100MG	N206627	006	Nov 20, 2014	Nov	NEWA	
>A>		120MG	N206627	007	Nov 20, 2014	Nov	NEWA	

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

	SOLUTION;ORAL							
	HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
AA	PADDOCK LLC	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014	Apr	NEWA	
AA	TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014	Oct	NEWA	
	REZIRA							
AA	+ CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Apr	CFTG	

HYDROCORTISONE

	CREAM;TOPICAL							
	HYDROCORTISONE							
	@ TARO	1%	A086155	001		Mar	DISC	
	LOTION;TOPICAL							
	ALA-CORT							
	@ CROWN LABS	1%	A083201	001		Mar	DISC	
	NUTRACORT							
	@ DOW PHARM	1%	A080443	003		Mar	DISC	
	TABLET;ORAL							
	HYDROCORTISONE							
	@ HIKMA INTL PHARMS	20MG	A083365	001		Sep	CAHN	

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

	AEROSOL, METERED;TOPICAL							
	HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%							
	@ VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988	Feb	CAHN	

HYDROCORTISONE BUTYRATE

	CREAM;TOPICAL							
	HYDROCORTISONE BUTYRATE							
AB2	GLENMARK GENERICS	0.1%	A202145	001	Sep 27, 2013	Aug	CTEC	
AB1	TARO PHARM INDS	0.1%	A076654	001	Aug 03, 2005	Aug	CTEC	
	LOCOID							
AB1	+ PRECISION DERMAT	0.1%	N018514	001	Mar 31, 1982	Aug	CTEC	
	LOCOID LIPOCREAM							
AB2	+ PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Aug	CTEC	

HYDROMORPHONE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL							
	EXALGO							
AB	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010	Apr	CFTG	
AB		12MG	N021217	002	Mar 01, 2010	Apr	CFTG	
AB		16MG	N021217	003	Mar 01, 2010	Apr	CFTG	
	HYDROMORPHONE HYDROCHLORIDE							
AB	ACTAVIS LABS FL INC	8MG	A202144	001	May 12, 2014	Apr	NEWA	
AB		12MG	A202144	002	May 12, 2014	Apr	NEWA	
AB		16MG	A202144	003	May 12, 2014	Apr	NEWA	

HYDROXYCHLOROQUINE SULFATE

	TABLET;ORAL							
	HYDROXYCHLOROQUINE SULFATE							
	@ WATSON LABS	200MG	A040133	001	Nov 30, 1995	May	DISC	

HYDROXYPROGESTERONE CAPROATE

	SOLUTION;INTRAMUSCULAR							
	MAKENA							
	+ LUMARA HEALTH INC	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	May	CAHN	

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986	Aug CAHN
	@	25MG	A089072	001	Jul 22, 1986	Aug CAHN
	@	50MG	A089073	001	Jul 22, 1986	Aug CAHN
AB	EMCURE PHARMS USA	10MG	A204279	001	Aug 20, 2014	Aug NEWA
AB		25MG	A204279	002	Aug 20, 2014	Aug NEWA
AB		50MG	A204279	003	Aug 20, 2014	Aug NEWA
AB	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Jun CAHN
AB		25MG	A040899	002	Jun 10, 2008	Jun CAHN
AB		50MG	A040899	003	Jun 10, 2008	Jun CAHN
	@ WATSON LABS	10MG	A081149	001	Mar 18, 1994	May DISC
	@	25MG	A081150	001	Mar 18, 1994	May DISC
	@	50MG	A081151	001	Mar 18, 1994	May DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	EMCURE PHARMS USA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Jun CPOT
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jun CPOT
	@ WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991	May DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

AP	+ ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG
	IBANDRONATE SODIUM					
AP	AGILA SPECLTS	EQ 3MG BASE/3ML	A202671	001	Sep 02, 2014	Aug NEWA
AP	EMCURE PHARMS LTD	EQ 3MG BASE/3ML	A203987	001	Sep 02, 2014	Aug NEWA
AP	SAGENT PHARMS	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	Aug NEWA
AP	SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	@ WATSON LABS	400MG	A070436	001	Aug 21, 1985	May DISC
	@	600MG	A070437	001	Aug 21, 1985	May DISC

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP	EUROHLTH INTL	1MG/ML	A065275	001	Dec 14, 2006	Aug CAHN
AP		1MG/ML	A065288	001	May 15, 2007	Aug CAHN
>D> AP	SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Nov DISC
>A>	@	1MG/ML	A091293	001	Mar 29, 2011	Nov DISC

IDELALISIB

TABLET; ORAL

ZYDELIG

	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Jul NEWA
+		150MG	N205858	002	Jul 23, 2014	Jul NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP	EUROHLTH INTL	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Aug CAHN
AP		3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Aug CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	STRIDES ARCOLAB LTD	5%	A202002	001	Jun 24, 2014	Jun NEWA
AB	STRIDES PHARMA	5%	A202002	001	Jun 24, 2014	Aug CAHN

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

+	EUROHLTH INTL	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Aug CAHN
---	---------------	----------------	---------	-----	--------------	----------

INDAPAMIDETABLET; ORAL
INDAPAMIDE

@ AMERIGEN PHARMS LTD	1.25MG	A075201	001	Dec 04, 1998	Jul CAHN
@	2.5MG	A075201	002	Dec 04, 1998	Jul CAHN
@ WATSON LABS	1.25MG	A074585	001	Sep 26, 1996	May DISC
@	2.5MG	A074585	002	Sep 26, 1996	May DISC

INDOMETHACINCAPSULE; ORAL
INDOCIN

@ IROKO PHARMS LLC	25MG	N016059	001		May CAHN
@	50MG	N016059	002		May CAHN

INDOMETHACIN

@	CYCLE PHARMS LTD	25MG	A070353	001	Jun 18, 1985	Sep CAHN
@		50MG	A070354	001	Jun 18, 1985	Sep CAHN
AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Jun CAHN
AB		50MG	A091401	002	Mar 28, 2013	Jun CAHN

TIVORBEX

IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014	Feb NEWA
+	40MG	N204768	002	Feb 24, 2014	Feb NEWA

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

AB	MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014	Mar NEWA
----	------------------	------	---------	-----	--------------	----------

SUSPENSION; ORAL
INDOMETHACIN

@	CYCLE PHARMS LTD	25MG/5ML	A071412	001	Mar 18, 1987	Sep CAHN
---	------------------	----------	---------	-----	--------------	----------

INDOMETHACIN SODIUMINJECTABLE; INJECTION
INDOMETHACIN SODIUM

AP	EUROHLTH INTL	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Aug CAHN
----	---------------	------------------	---------	-----	--------------	----------

INSULIN ASPART RECOMBINANTINJECTABLE; SUBCUTANEOUS
NOVOLOG FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb NEWA
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANTINJECTABLE; SUBCUTANEOUS
LEVEMIR FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb NEWA
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMANPOWDER; INHALATION
AFREZZA

>D>	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Nov CAHN
		4 UNITS/INH	N022472	001	Jun 27, 2014	Jun NEWA
>D>	+	8 UNITS/INH	N022472	002	Jun 27, 2014	Nov CAHN
	+	8 UNITS/INH	N022472	002	Jun 27, 2014	Jun NEWA
>A>	SANOFI AVENTIS	4 UNITS/INH	N022472	001	Jun 27, 2014	Nov CAHN
>A>	+	8 UNITS/INH	N022472	002	Jun 27, 2014	Nov CAHN

IPRATROPIUM BROMIDESOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN	+	MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Mar CAHN
----	---	--------------	-------	---------	-----	--------------	----------

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

AB	MYLAN SPECLT	0.021MG/SPRAY	A075552	001	Mar 31, 2003	May CAHN
AB		0.042MG/SPRAY	A075553	001	Mar 31, 2003	May CAHN

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP	ACTAVIS ELIZABETH	40MG/2ML (20MG/ML)	A078589	001	Feb 27, 2008	Aug CAHN
AP		100MG/5ML (20MG/ML)	A078589	002	Feb 27, 2008	Aug CAHN
AP	ACTAVIS TOTOWA	40MG/2ML (20MG/ML)	A078589	001	Feb 27, 2008	Oct CAHN
AP		100MG/5ML (20MG/ML)	A078589	002	Feb 27, 2008	Oct CAHN
AP	MUSTAFA NEVZAT ILAC	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May CAHN
AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May CAHN

ISOFLURANELIQUID; INHALATION
ISOFLURANE

AN	PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995	Feb CAHN
----	-------------	-------	---------	-----	--------------	----------

ISONIAZIDTABLET; ORAL
ISONIAZID

	@ HIKMA INTL PHARMS	100MG	A080212	001		Sep CAHN
	@	300MG	A087425	001		Sep CAHN
AA	THEPHARMANETWORK LLC	100MG	A202610	001	Oct 29, 2014	Oct NEWA
AA		300MG	A202610	002	Oct 29, 2014	Oct NEWA

ISONIAZID; RIFAMPINCAPSULE; ORAL
RIFAMPIN AND ISONIAZID

	@ HIKMA INTL PHARMS	150MG; 300MG	A065221	001	Jul 29, 2005	Sep CAHN
--	---------------------	--------------	---------	-----	--------------	----------

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+ AUXILIUM PHARMS LLC 40MG

N019790	001	Sep 02, 1988	Apr CAHN
---------	-----	--------------	----------

TABLET; ORAL

ISOSORBIDE DINITRATE

AB	HIKMA INTL PHARMS	5MG	A086067	001	Oct 29, 1987	Jul CAHN
AB		10MG	A086066	001	Oct 29, 1987	Jul CAHN
AB		20MG	A088088	001	Nov 02, 1987	Jul CAHN
AB		30MG	A040591	001	Jan 10, 2007	Jul CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ HIKMA INTL PHARMS	2.5MG
@	5MG

A086054	001	Oct 29, 1987	Jul CAHN
A086055	001	Nov 02, 1987	Jul CAHN

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE DINITRATE

AB	+ SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Jul CAHN
----	----------------------	------	---------	-----	--------------	----------

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

AB	ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998	Jan CAHN
----	----------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

@ ACTAVIS ELIZABETH	30MG
@	60MG

A075306	001	Dec 31, 1998	May DISC
A075306	002	Dec 31, 1998	May DISC

ISOSULFAN BLUEINJECTABLE; INJECTION
ISOSULFAN BLUE+ MYLAN INSTITUTIONAL 1%
LYMPHAZURIN

A090874	001	Jul 20, 2010	Sep CRLD
---------	-----	--------------	----------

@ COVIDIEN 1%

N018310	001		Sep DISC
---------	-----	--	----------

ISRADIPINECAPSULE; ORAL
ISRADIPINE

AB	MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	May CMFD
	@	2.5MG	A077169	001	Apr 24, 2006	Feb DISC
AB		5MG	A077169	002	Apr 24, 2006	May CMFD
	@	5MG	A077169	002	Apr 24, 2006	Feb DISC
AB	WATSON LABS	2.5MG	A077317	001	Jan 05, 2006	May CTEC
		2.5MG	A077317	001	Jan 05, 2006	Feb CTEC
AB	+	5MG	A077317	002	Jan 05, 2006	May CTEC
	+	5MG	A077317	002	Jan 05, 2006	Feb CTEC

IVERMECTINTABLET; ORAL
IVERMECTIN

AB	EDENBRIDGE PHARMS	3MG	A204154	001	Oct 24, 2014	Oct NEWA
----	-------------------	-----	---------	-----	--------------	----------

STROMEKTOL

AB	+ MERCK SHARP DOHME	3MG	N050742	002	Oct 08, 1998	Oct CFTG
----	---------------------	-----	---------	-----	--------------	----------

KETAMINE HYDROCHLORIDEINJECTABLE; INJECTION
KETALAR

AP	+	PAR STERILE PRODUCTS	EQ 10MG BASE/ML	N016812	001		Apr	CAHN
AP	+		EQ 50MG BASE/ML	N016812	002		Apr	CAHN
AP	+		EQ 100MG BASE/ML	N016812	003		Apr	CAHN

KETAMINE HYDROCHLORIDE

AP		EUROHLTH INTL	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Aug	CAHN
AP			EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Aug	CAHN

KETOCONAZOLEAEROSOL, FOAM; TOPICAL
EXTINA

AT	+	DELCOR ASSET CORP	2%	N021738	001	Jun 12, 2007	Jun	CAHN
----	---	-------------------	----	---------	-----	--------------	-----	------

TABLET; ORAL

KETOCONAZOLE

		@ APOTEX	200MG	A075912	001	Jan 10, 2002	Oct	DISC
		@ MUTUAL PHARMA	200MG	A075314	001	Jun 15, 1999	Oct	DISC
		@ PLIVA	200MG	A075362	001	Jun 15, 1999	Oct	DISC
AB	+	TEVA	200MG	A075273	001	Jun 15, 1999	Oct	CRLD
		NIZORAL						
		@ JANSSEN PHARMS	200MG	N018533	001		Oct	DISC
AB	+		200MG	N018533	001		Mar	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP		AGILA SPECLTS	15MG/ML	A201155	001	Aug 04, 2014	Jul	NEWA
AP			30MG/ML	A201155	002	Aug 04, 2014	Jul	NEWA
		@ HIKMA MAPLE	15MG/ML	A075299	001	Nov 03, 1999	Jun	DISC
		@	15MG/ML	A075772	001	Jul 21, 2004	Jun	DISC
		@	30MG/ML	A075299	002	Nov 03, 1999	Jun	DISC
		@	30MG/ML	A075772	002	Jul 21, 2004	Jun	DISC
AP	+	HOSPIRA	15MG/ML	A074802	001	Jun 05, 1997	Jul	CRLD
AP	+		30MG/ML	A074802	002	Jun 05, 1997	Jul	CRLD
		@ SANDOZ	15MG/ML	A076271	001	Oct 06, 2004	Jul	DISC
		@ SUN PHARMA GLOBAL	15MG/ML	A078737	001	Oct 06, 2008	Jul	DISC
		@	30MG/ML	A078737	002	Oct 06, 2008	Jul	DISC
		@ WOCKHARDT	30MG/ML	A077943	001	Mar 27, 2007	Jun	DISC

SOLUTION/DROPS; OPHTHALMIC

ACUVAIL

AT	+	ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Jan	CFTG
		KETOROLAC TROMETHAMINE						
		@ AKORN	0.45%	A203376	001	Feb 10, 2014	Feb	DISC
AT			0.45%	A203376	001	Feb 10, 2014	Jan	NEWA

TABLET; ORAL

KETOROLAC TROMETHAMINE

		@ CYCLE PHARMS LTD	10MG	A074790	001	Jun 26, 1997	Sep	CAHN
--	--	--------------------	------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

	+	OMEROS	EQ 2.88MG BASE/ML; EQ 10.16MG BASE/ML	N205388	001	May 30, 2014	Jun	CPOT
	+		EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	May	NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP		EUROHLTH INTL	5MG/ML	A075303	001	May 28, 1999	Aug	CAHN
----	--	---------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

TRANDATE

>A>	AB	CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Nov	CAHN
>A>	AB		200MG	N018716	002	Aug 01, 1984	Nov	CAHN
>A>	AB		300MG	N018716	003	Aug 01, 1984	Nov	CAHN
>A>		@	400MG	N018716	004	Aug 01, 1984	Nov	CAHN
>D>	AB	PROMETHEUS LABS	100MG	N018716	001	May 24, 1985	Nov	CAHN
	AB		100MG	N018716	001	May 24, 1985	Oct	CMFD
>D>	AB		200MG	N018716	002	Aug 01, 1984	Nov	CAHN
	AB		200MG	N018716	002	Aug 01, 1984	Oct	CMFD

TABLET;ORAL
TRANDATE

>D>	AB	300MG	N018716	003	Aug 01, 1984	Nov CAHN
	AB	300MG	N018716	003	Aug 01, 1984	Oct CMFD
>D>	@	400MG	N018716	004	Aug 01, 1984	Nov CAHN

LAMIVUDINE

SOLUTION;ORAL
EPIVIR

AA	+	VIIV HLTHCARE	10MG/ML	N020596	001	Nov 17, 1995	Oct CFTG
		LAMIVUDINE					
AA		SILARX PHARMS INC	10MG/ML	A203564	001	Oct 31, 2014	Oct NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE

AB		HETERO LABS LTD V	150MG;300MG	A203259	001	Feb 03, 2014	Jan NEWA
AB		MYLAN PHARMS INC	150MG;300MG	A204005	001	Aug 28, 2014	Aug NEWA

LAMOTRIGINE

TABLET;ORAL
LAMOTRIGINE

	@	ACTAVIS ELIZABETH	25MG	A078669	001	Apr 08, 2011	Aug CAHN
	@		100MG	A078669	002	Apr 08, 2011	Aug CAHN
	@		150MG	A078669	003	Apr 08, 2011	Aug CAHN
	@		200MG	A078669	004	Apr 08, 2011	Aug CAHN
	@	ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Oct CAHN
	@		25MG	A078669	001	Apr 08, 2011	May DISC
	@		100MG	A078669	002	Apr 08, 2011	Oct CAHN
	@		100MG	A078669	002	Apr 08, 2011	May DISC
	@		150MG	A078669	003	Apr 08, 2011	Oct CAHN
	@		150MG	A078669	003	Apr 08, 2011	May DISC
	@		200MG	A078669	004	Apr 08, 2011	Oct CAHN
	@		200MG	A078669	004	Apr 08, 2011	May DISC
	@	PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009	Jul DISC
BX			25MG	A078310	001	Feb 04, 2009	Jul CAHN
	@		100MG	A078310	002	Feb 04, 2009	Jul DISC
BX			100MG	A078310	002	Feb 04, 2009	Jul CAHN
	@		150MG	A078310	003	Feb 04, 2009	Jul DISC
BX			150MG	A078310	003	Feb 04, 2009	Jul CAHN
	@		200MG	A078310	004	Feb 04, 2009	Jul DISC
BX			200MG	A078310	004	Feb 04, 2009	Jul CAHN

TABLET, CHEWABLE;ORAL
LAMOTRIGINE

AB		ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	May NEWA
AB			25MG	A201168	002	Jun 12, 2014	May NEWA
AB		JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jul CAHN
AB			25MG	A200220	002	Feb 28, 2011	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB		IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Jul CAHN
AB			50MG	A200828	002	Jul 15, 2013	Jul CAHN
AB			100MG	A200828	003	Jul 15, 2013	Jul CAHN
AB			200MG	A200828	004	Jul 15, 2013	Jul CAHN

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL
LANSOPRAZOLE

	@	ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Jan CAHN
	@		30MG	A078730	002	Oct 15, 2010	Jan CAHN

LANTHANUM CARBONATE

POWDER;ORAL
FOSRENOL

+		SHIRE DEV LLC	EQ 1GM BASE	N204734	002	Sep 24, 2014	Sep NEWA
			EQ 750MG BASE	N204734	001	Sep 24, 2014	Sep NEWA

LEDIPASVIR; SOFOSBUVIR

TABLET; ORAL

HARVONI

+	GILEAD SCIENCES INC	90MG; 400MG	N205834	001	Oct 10, 2014	Sep NEWA
---	---------------------	-------------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

>D>	AB	SANDOZ	10MG	A077087	001	Sep 13, 2005	Nov DISC
>A>		@	10MG	A077087	001	Sep 13, 2005	Nov DISC
>D>	AB		20MG	A077087	002	Sep 13, 2005	Nov DISC
>A>		@	20MG	A077087	002	Sep 13, 2005	Nov DISC

LETROZOLE

TABLET; ORAL

LETROZOLE

	@	ACTAVIS ELIZABETH	2.5MG	A090292	001	Jul 13, 2011	Aug CAHN
	@	ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	Oct CAHN
	@		2.5MG	A090292	001	Jul 13, 2011	May DISC
	@	IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011	Oct DISC
AB		LANNETT HOLDINGS INC	2.5MG	A202048	001	Oct 29, 2014	Oct NEWA

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	+	EUROHLTH INTL	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Aug CAHN
AP	+		EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Aug CAHN
		LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	+	EUROHLTH INTL	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Aug CAHN
AP	+		EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Aug CAHN
AP	+		EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Aug CAHN

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+	ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995	May NEWA
---	----------------------	--------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		MYLAN SPECLT	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	May CAHN
AN			EQ 0.021% BASE	A077800	002	Mar 15, 2013	May CAHN
AN			EQ 0.042% BASE	A077800	003	Mar 15, 2013	May CAHN
AN		TEVA PARENTERAL	EQ 0.25% BASE	A200875	001	Sep 11, 2014	Sep NEWA
AN		WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Jun CMFD
	@		EQ 0.0103% BASE	A077756	003	Apr 09, 2008	May DISC
AN			EQ 0.021% BASE	A077756	001	Apr 09, 2008	Jun CMFD
	@		EQ 0.021% BASE	A077756	001	Apr 09, 2008	May DISC
AN			EQ 0.042% BASE	A077756	002	Apr 09, 2008	Jun CMFD
	@		EQ 0.042% BASE	A077756	002	Apr 09, 2008	May DISC
		XOPENEX					
AN	+	OAK PHARMS INC	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Oct CAHN
AN	+		EQ 0.021% BASE	N020837	001	Mar 25, 1999	Oct CAHN
AN	+		EQ 0.042% BASE	N020837	002	Mar 25, 1999	Oct CAHN
AN	+		EQ 0.25% BASE	N020837	004	Jul 18, 2003	Oct CAHN

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

	@	SANDOZ	1GM	A077324	004	Jan 15, 2009	Jun DISC
	@		250MG	A077324	001	Jan 15, 2009	Jun DISC
	@		500MG	A077324	002	Jan 15, 2009	Jun DISC
	@		750MG	A077324	003	Jan 15, 2009	Jun DISC
AB		VINTAGE PHARMS	250MG	A077319	001	Mar 20, 2009	Feb CAHN
AB			500MG	A077319	002	Mar 20, 2009	Feb CAHN
AB			750MG	A077319	003	Mar 20, 2009	Feb CAHN
	@	WATSON LABS INC	1GM	A078797	001	Jan 15, 2009	May DISC
	@		250MG	A078797	002	Jan 15, 2009	Oct DISC
	@		500MG	A078797	003	Jan 15, 2009	Oct DISC
	@		750MG	A078797	004	Jan 15, 2009	Oct DISC

TABLET, EXTENDED RELEASE;ORAL							
LEVETIRACETAM							
AB	VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Feb	CAHN
AB		750MG	A201464	002	May 25, 2012	Feb	CAHN
<u>LEVOCARNITINE</u>							
INJECTABLE;INJECTION							
LEVOCARNITINE							
AP	EUROHLTH INTL	200MG/ML	A075567	001	Mar 29, 2001	Aug	CAHN
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>							
SOLUTION;ORAL							
LEVOCETIRIZINE DIHYDROCHLORIDE							
AA	APOTEX INC	2.5MG/5ML	A202915	001	Aug 21, 2014	Aug	NEWA
AA	L PERRIGO CO	2.5MG/5ML	A091263	001	Nov 07, 2011	Jan	CAHN
TABLET;ORAL							
LEVOCETIRIZINE DIHYDROCHLORIDE							
	@ SANDOZ	5MG	A090486	001	Mar 26, 2013	May	DISC
AB	SCIEGEN PHARMS INC	5MG	A203646	001	Sep 09, 2014	Aug	NEWA
<u>LEVOFLOXACIN</u>							
SOLUTION/DROPS;OPHTHALMIC							
IQUIX							
	@ SANTEN	1.5%	N021571	001	Mar 01, 2004	Jun	DISC
LEVOFLOXACIN							
AT	WATSON LABS INC	0.5%	A076826	001	Feb 10, 2011	May	CAHN
TABLET;ORAL							
LEVOFLOXACIN							
	@ WATSON LABS INC	250MG	A201484	001	Nov 22, 2013	Oct	DISC
	@	500MG	A201484	002	Nov 22, 2013	Oct	DISC
	@	750MG	A201484	003	Nov 22, 2013	Oct	DISC
<u>LEVONORGESTREL</u>							
TABLET;ORAL							
LEVONORGESTREL							
	@ LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Sep	DISC
	@ WATSON LABS	0.75MG	A078666	001	Jun 24, 2009	Aug	DISC
<u>LEVORPHANOL TARTRATE</u>							
TABLET;ORAL							
LEVORPHANOL TARTRATE							
+	ROXANE	2MG	A074278	001	Mar 31, 2000	Feb	CRLD
<u>LIDOCAINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
LIDOCAINE HYDROCHLORIDE							
AP	AGILA SPECLTS	2%	A202242	001	Apr 11, 2014	Mar	NEWA
LIDOPEN							
	@ MERIDIAN MEDCL TECHN	10%	N017549	001		Mar	DISC
XYLOCAINE PRESERVATIVE FREE							
	@ FRESENIUS KABI USA	10%	N016801	003		Jun	DISC
+		10%	N016801	003		Mar	CTEC
JELLY;TOPICAL							
ANESTACON							
	@ BANNER PHARMACAPS	2%	A080429	001		Jun	CAHN
	@ DSM PHARMS INC	2%	A080429	001		Jan	CAHN
GLYDO							
AT	SAGENT PHARMS	2%	A201094	001	Apr 28, 2014	Apr	NEWA
LIDOCAINE HYDROCHLORIDE							
AT	WATSON LABS INC	2%	A040837	001	Mar 23, 2011	May	CAHN
SOLUTION;TOPICAL							
LIDOCAINE HYDROCHLORIDE							
AT	IGI LABS INC	4%	A204494	001	Mar 12, 2014	Feb	NEWA
SYSTEM;INTRADERMAL							
ZINGO							
	POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Mar	CMFD

LIDOCAINE; PRILOCAINECREAM; TOPICAL
EMLA

AB	+	WATSON LABS INC	2.5%; 2.5%	N019941	001	Dec 30, 1992	May CAHN
----	---	-----------------	------------	---------	-----	--------------	----------

LIOTHYRONINE SODIUMINJECTABLE; INJECTION
TRIOSTAT

AP	+	PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Apr CAHN
----	---	----------------------	-------------------	---------	-----	--------------	----------

LISDEXAMFETAMINE DIMESYLATECAPSULE; ORAL
VYVANSE

SHIRE DEVELOPMENT

10MG

N021977	007	Oct 30, 2014	Oct NEWA
---------	-----	--------------	----------

LISINOPRILTABLET; ORAL
LISINOPRIL

AB		HIKMA INTL PHARMS	2.5MG
AB			5MG
AB			10MG
AB			20MG
AB			30MG
AB			40MG

A076063	001	Jul 01, 2002	Jul CAHN
A076063	002	Jul 01, 2002	Jul CAHN
A076063	003	Jul 01, 2002	Jul CAHN
A076063	004	Jul 01, 2002	Jul CAHN
A076063	006	Jun 27, 2003	Jul CAHN
A076063	005	Jul 01, 2002	Jul CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB		HIKMA INTL PHARMS	150MG
AB			300MG

A076243	002	Feb 24, 2003	Sep CAHN
A076243	001	Jun 27, 2002	Sep CAHN

TABLET; ORAL

LITHIUM CARBONATE

@ HIKMA INTL PHARMS

300MG

A078715	001	Dec 28, 2010	Sep CAHN
---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB		HIKMA INTL PHARMS	450MG
AB	+	ANI PHARMS INC	300MG

A076490	001	Jun 17, 2003	Sep CAHN
N018027	001		Jun CAHN

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

CORDEN PHARMA

10MG

N017588	001		Aug CTNA
---------	-----	--	----------

40MG

N017588	002		Aug CTNA
---------	-----	--	----------

+

100MG

N017588	003		Aug CTNA
---------	-----	--	----------

LORAZEPAMINJECTABLE; INJECTION
ATIVAN

AP	+	HIKMA MAPLE	2MG/ML
AP	+		4MG/ML

N018140	001		Jun CAHN
N018140	002		Jun CAHN

TABLET; ORAL

LORAZEPAM

@ WATSON LABS

1MG

A071118	001	Jul 24, 1986	May DISC
---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

@ WATSON LABS

25MG

A091129	001	Oct 06, 2010	Oct DISC
---------	-----	--------------	----------

@

50MG

A091129	002	Oct 06, 2010	Oct DISC
---------	-----	--------------	----------

@

100MG

A091129	003	Oct 06, 2010	Oct DISC
---------	-----	--------------	----------

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB INC

0.5%

N202872	001	Sep 28, 2012	Feb CAHN
---------	-----	--------------	----------

LUBIPROSTONECAPSULE;ORAL
AMITIZA

SUCAMPO PHARMA LLC

8MCG

N021908 002 Apr 29, 2008

Aug CAHN

+

24MCG

N021908 001 Jan 31, 2006

Aug CAHN

LULICONAZOLECREAM;TOPICAL
LUZU

+ MEDICIS

1%

N204153 001 Nov 14, 2013

Jan CRLD

MAFENIDE ACETATEFOR SOLUTION;TOPICAL
MAFENIDE ACETATE

AT

PAR FORM

5%

A201511 001 Feb 12, 2013

Aug CTEC

SULFAMYLON

AT

+ MYLAN INSTITUTIONAL

5%

N019832 003 Jun 05, 1998

Aug CTEC

MAGNESIUM SULFATEINJECTABLE;INJECTION
MAGNESIUM SULFATE

AP

+ HOSPIRA

500MG/ML

A075151 001 Apr 25, 2000

Jun CRLD

MALATHIONLOTION;TOPICAL
MALATHION

@ MYLAN PHARMS INC

0.5%

A078743 001 Mar 06, 2009

Mar DISC

MANNITOLPOWDER;INHALATION
ARIDOL KIT

@ PHARMAXIS LTD

N/A, 5MG, 10MG, 20MG, 40MG

N022368 001 Oct 05, 2010

Sep DISC

MEBENDAZOLETABLET, CHEWABLE;ORAL
MEBENDAZOLE

+ AMEDRA PHARMS LLC

100MG

A073580 001 Jan 04, 1995

Jun CAHN

MECHLORETHAMINE HYDROCHLORIDEGEL;TOPICAL
VALCHLOR

+ ACTELION PHARMS LTD

EQ 0.016% BASE

N202317 001 Aug 23, 2013

Jun CPOT

MECLIZINE HYDROCHLORIDETABLET;ORAL
ANTIVERT

@ CITRON PHARMA LLC

12.5MG

N010721 006

Oct DISC

@

25MG

N010721 004

Oct DISC

@

50MG

N010721 001 Jan 20, 1982

Oct DISC

MECLIZINE HYDROCHLORIDE

@ AMNEAL PHARMS

50MG

A201451 003 Feb 23, 2011

Oct DISC

@ MYLAN PHARMS INC

50MG

A202640 003 Sep 17, 2012

Oct DISC

@ PAR PHARM

50MG

A089674 001 Mar 31, 1988

Oct DISC

@ WATSON LABS

25MG

A085740 001

May DISC

MEDROXYPROGESTERONE ACETATE

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

@ USL PHARMA

10MG

A088484 001 Jul 26, 1984

Mar DISC

MEFENAMIC ACIDCAPSULE;ORAL
MEFENAMIC ACID

AB

VINTAGE PHARMS LLC

250MG

A091608 001 Jun 02, 2014

May NEWA

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+	PAR PHARM	125MG/ML	N021778	001	Jul 05, 2005	Aug CFTG
AB		TWI PHARMS INC	125MG/ML	A203139	001	Aug 27, 2014	Aug NEWA

MELOXICAM

TABLET;ORAL

MELOXICAM

AB		STRIDES PHARMA	7.5MG	A077928	001	May 13, 2009	Aug CAHN
AB			15MG	A077928	002	May 13, 2009	Aug CAHN
AB		SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006	Jul CAHN
AB			15MG	A077937	002	Jul 19, 2006	Jul CAHN
	@	YABAO PHARM	7.5MG	A077933	001	Jul 19, 2006	May CAHN
	@		15MG	A077933	002	Jul 19, 2006	May CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

AP		EUROHLTH INTL	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Aug CAHN
----	--	---------------	-------------------	---------	-----	--------------	----------

MEMANTINE HYDROCHLORIDE

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

	@	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jul DISC
AB			5MG	A090048	001	Apr 14, 2010	Jun CMFD
	@		10MG	A090048	002	Apr 14, 2010	Jul DISC
AB			10MG	A090048	002	Apr 14, 2010	Jun CMFD
		NAMENDA					
AB		FOREST LABS	5MG	N021487	001	Oct 16, 2003	Sep CMFD
	@		5MG	N021487	001	Oct 16, 2003	Aug DISC
			5MG	N021487	001	Oct 16, 2003	Jul CTEC
AB			5MG	N021487	001	Oct 16, 2003	Jun CTEC
AB	+		10MG	N021487	002	Oct 16, 2003	Sep CMFD
	@		10MG	N021487	002	Oct 16, 2003	Aug DISC
	+		10MG	N021487	002	Oct 16, 2003	Jul CTEC
AB	+		10MG	N021487	002	Oct 16, 2003	Jun CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

@ WATSON LABS 50MG/ML

A073444 001 Mar 17, 1992 May DISC

@ 100MG/ML

A073445 001 Mar 17, 1992 May DISC

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

@ INTL MEDICATION 10MG/ML

A081309 001 Aug 30, 1993 Mar DISC

@ WATSON LABS 10MG/ML

A073443 001 Mar 17, 1992 May DISC

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

AA		SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002	Jul CAHN
AA			100MG	A040446	002	Aug 08, 2002	Jul CAHN
	@	WATSON LABS	50MG	A040186	001	Jun 30, 1997	May DISC
	@		100MG	A040186	002	Jun 30, 1997	May DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPIVACAINE HYDROCHLORIDE

@ WATSON LABS 1%

A088769 001 Nov 20, 1984 May DISC

@ 2%

A088770 001 Nov 20, 1984 May DISC

MERCAPTOPURINE

SUSPENSION;ORAL

PURIXAN

+ NOVA LABS LTD 20MG/ML

N205919 001 Apr 28, 2014 Apr NEWA

TABLET;ORAL

MERCAPTOPURINE

>D>	AB		ROXANE	50MG	A040528	001	Feb 13, 2004	Nov CRLD
>A>	AB	+		50MG	A040528	001	Feb 13, 2004	Nov CRLD
>D>			PURINETHOL					
>D>	AB	+	TEVA	50MG	N009053	002		Nov DISC
>A>		@		50MG	N009053	002		Nov DISC

MESALAMINESUPPOSITORY; RECTAL
CANASA

+	FOREST LABS INC	1GM	N021252	002	Nov 05, 2004	Apr CAHN
@		500MG	N021252	001	Jan 05, 2001	Apr CAHN

MESNAINJECTABLE; INTRAVENOUS
MESNA

AP	AGILA SPECLTS	100MG/ML	A203364	001	Jul 18, 2014	Jul NEWA
AP	EUROHLTH INTL	100MG/ML	A075739	001	Jan 09, 2004	Aug CAHN

METAPROTERENOL SULFATESOLUTION; INHALATION
METAPROTERENOL SULFATE

AN	+	MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	May CAHN
AN	+		0.6%	A070804	001	Aug 17, 1987	May CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	ATLAS PHARMS LLC	1GM	A076033	003	Jan 24, 2002	May CAHN
AB		500MG	A076033	001	Jan 24, 2002	May CAHN
AB		850MG	A076033	002	Jan 24, 2002	May CAHN
AB	SUN PHARM INDS INC	1GM	A075967	003	Jan 29, 2002	Jul CAHN
AB		500MG	A075967	001	Jan 29, 2002	Jul CAHN
AB		850MG	A075967	002	Jan 29, 2002	Jul CAHN
	@ WATSON LABS	1GM	A075979	003	Jan 24, 2002	May DISC
	@	500MG	A075979	001	Jan 24, 2002	May DISC
	@	850MG	A075979	002	Jan 24, 2002	May DISC
AB	ZYDUS HLTHCARE	1GM	A203686	003	Aug 28, 2014	Aug NEWA
AB		500MG	A203686	001	Aug 28, 2014	Aug NEWA
AB		850MG	A203686	002	Aug 28, 2014	Aug NEWA

TABLET, EXTENDED RELEASE; ORAL
GLUMETZA

+	SALIX PHARMS INC	1GM	N021748	002	Jun 03, 2005	Feb CTEC
		500MG	N021748	001	Jun 03, 2005	Feb CTEC
+	SANTARUS INC	1GM	N021748	002	Jun 03, 2005	Mar CAHN
		500MG	N021748	001	Jun 03, 2005	Mar CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	TEVA PHARMS USA	500MG;EQ 15MG BASE	A091155	001	Mar 10, 2014	Feb NEWA
AB		850MG;EQ 15MG BASE	A091155	002	Mar 10, 2014	Feb NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

AB	SB PHARMCO	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	Apr CFTG
AB	+	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	Apr CFTG
AB		500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	Apr CFTG
AB		500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	Apr CFTG

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

AB	TEVA	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	Apr NEWA
AB		1GM;EQ 2MG BASE	A077337	003	May 07, 2014	Apr NEWA
AB		500MG;EQ 2MG BASE	A077337	001	May 07, 2014	Apr NEWA
AB		500MG;EQ 4MG BASE	A077337	002	May 07, 2014	Apr NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Apr CAHN
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr CAHN
		500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Apr CAHN

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB	ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan CAHN
AB		50MG	A040001	002	Jun 30, 1993	Jan CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	SUN PHARM INDS INC	5MG	A040870	001	Sep 25, 2007	Jul CAHN
AB		10MG	A040870	002	Sep 25, 2007	Jul CAHN
AB	VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb CAHN
AB		10MG	A202068	002	Mar 07, 2012	Feb CAHN

METHOCARBAMOL

INJECTABLE; INJECTION

ROBAXIN

>D>	+ HIKMA MAPLE	100MG/ML	N011790	001		Nov CFTG
-----	---------------	----------	---------	-----	--	----------

SOLUTION; IM-IV

>A>	METHOCARBAMOL					
-----	---------------	--	--	--	--	--

>A>	AP	MYLAN INSTITUTIONAL	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Nov NEWA
		ROBAXIN					

>A>	AP	+ HIKMA MAPLE	1GM/10ML (100MG/ML)	N011790	001		Nov CFTG
-----	----	---------------	---------------------	---------	-----	--	----------

TABLET; ORAL

METHOCARBAMOL

AA	HIKMA INTL PHARMS	500MG	A085159	001		Jul CAHN
AA		750MG	A085123	001		Jul CAHN
	@ WATSON LABS	500MG	A085180	001		May DISC
	@	750MG	A085192	001		May DISC

ROBAXIN

AA	+ AUXILIUM PHARMS LLC	500MG	N011011	004		Apr CAHN
	ROBAXIN-750					

AA	+ AUXILIUM PHARMS LLC	750MG	N011011	006		Apr CAHN
----	-----------------------	-------	---------	-----	--	----------

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

	+ PAR STERILE PRODUCTS	2.5GM/VIAL	N011559	002		Apr CAHN
	@	5GM/VIAL	N011559	003		Apr CAHN
	+	200MG/VIAL	N011559	004	Dec 21, 2012	Apr CAHN
	+	500MG/VIAL	N011559	001		Apr CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

>A>	ANTARES PHARMA INC	7.5MG/0.4ML	N204824	005	Nov 07, 2014	Nov NEWA
	RASUVO					

	MEDAC PHARMA INC	7.5MG/0.15ML	N205776	001	Jul 10, 2014	Jul NEWA
		10MG/0.20ML	N205776	002	Jul 10, 2014	Jul NEWA
		12.5MG/0.25ML	N205776	003	Jul 10, 2014	Jul NEWA
		15MG/0.30ML	N205776	004	Jul 10, 2014	Jul NEWA
		17.5MG/0.35ML	N205776	005	Jul 10, 2014	Jul NEWA
		20MG/0.4ML	N205776	006	Jul 10, 2014	Jul NEWA
		22.5MG/0.45ML	N205776	007	Jul 10, 2014	Jul NEWA
		25MG/0.5ML	N205776	008	Jul 10, 2014	Jul NEWA
		27.5MG/0.55ML	N205776	009	Jul 10, 2014	Jul NEWA
		30MG/0.6ML	N205776	010	Jul 10, 2014	Jul NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

AP	+ EUROHLTH INTL	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Aug CAHN
	+	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Aug CAHN

METHOTREXATE SODIUM PRESERVATIVE FREE

	+ EUROHLTH INTL	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Aug CAHN
AP	+	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Aug CAHN
AP	+	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Aug CAHN

METHOXSALENCAPSULE; ORAL
METHOXSALEN

AB	STRIDES ARCOLAB LTD	10MG	A202687	001	Jun 05, 2014	May NEWA
AB	STRIDES PHARMA	10MG	A202687	001	Jun 05, 2014	Aug CAHN
OXSORALEN-ULTRA						
AB	+ DOW PHARM	10MG	N019600	001	Oct 30, 1986	May CTEC

METHSCOPOLAMINE BROMIDETABLET; ORAL
METHSCOPOLAMINE BROMIDE

AA	VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb CAHN
AA		5MG	A040624	002	Dec 28, 2006	Feb CAHN

METHYLDOPATABLET; ORAL
METHYLDOPA

AB	MYLAN	250MG	A070076	002	Apr 18, 1985	Apr CMS1
----	-------	-------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATEINJECTABLE; INJECTION
METHERGINE

AP	+ EDISON THERAPS LLC	0.2MG/ML	N006035	004		Feb CAHN
----	----------------------	----------	---------	-----	--	----------

TABLET; ORAL
METHERGINE

AB	+ EDISON THERAPS LLC	0.2MG	N006035	003		Feb CAHN
----	----------------------	-------	---------	-----	--	----------

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB1	BARR LABS INC	10MG	A079031	004	Oct 15, 2014	Oct NEWA
	RITALIN LA					
AB1	NOVARTIS	10MG	N021284	004	Apr 10, 2004	Oct CTEC
		60MG	N021284	005	Oct 27, 2014	Oct NEWA

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	SUN PHARM INDS INC	5MG/5ML	A201466	001	Nov 12, 2013	Sep CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Sep CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb NEWA
AB		10MG	A091159	002	Mar 12, 2014	Feb NEWA
AB		20MG	A091159	003	Mar 12, 2014	Feb NEWA
AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Jun CAHN
AB		10MG	A090710	002	Mar 15, 2012	Jun CAHN
AB		20MG	A090710	003	Mar 15, 2012	Jun CAHN
AB	VINTAGE PHARMS	5MG	A202892	001	Sep 23, 2014	Sep NEWA
AB		10MG	A202892	002	Sep 23, 2014	Sep NEWA
AB		20MG	A202892	003	Sep 23, 2014	Sep NEWA

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

	JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Oct CTEC
		27MG	N021121	004	Apr 01, 2002	Oct CTEC
		36MG	N021121	002	Aug 01, 2000	Oct CTEC
+		54MG	N021121	003	Dec 08, 2000	Oct CTEC

METHYLPHENIDATE HYDROCHLORIDE

BX	KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013	Oct CTEC
BX		27MG	A091695	002	Jul 09, 2013	Oct CTEC
BX		36MG	A091695	003	Sep 23, 2013	Oct CTEC
BX		54MG	A091695	004	Sep 23, 2013	Oct CTEC
BX	MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012	Oct CTEC
BX		36MG	A202608	002	Dec 28, 2012	Oct CTEC
BX		54MG	A202608	003	Dec 28, 2012	Oct CTEC
	@ WATSON LABS	20MG	A040410	001	Feb 09, 2001	May DISC

METOCLOPRAMIDE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

AB	NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014	Aug NEWA
		EQ 10MG BASE	A202191	002	Aug 15, 2014	Aug NEWA
	METOSOLV ODT					
AB	+ SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Aug CFTG

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

AB	REDDYS	EQ 100MG TARTRATE	A078889	001	Aug 15, 2012	Aug CPOT
AB		EQ 200MG TARTRATE	A078889	002	Aug 15, 2012	Aug CPOT

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

AP	GLAND PHARMA LTD	1MG/ML	A204205	001	Aug 27, 2014	Aug NEWA
	TABLET;ORAL					
	METOPROLOL TARTRATE					
AB	RUBICON RES PVT LTD	25MG	A200981	001	Oct 28, 2014	Oct NEWA
AB		50MG	A200981	002	Oct 28, 2014	Oct NEWA
AB		100MG	A200981	003	Oct 28, 2014	Oct NEWA
AB	SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004	Jul CAHN
AB		50MG	A074644	001	Dec 10, 1996	Jul CAHN
AB		100MG	A074644	002	Dec 10, 1996	Jul CAHN

METRONIDAZOLE

GEL;VAGINAL
METRONIDAZOLE

	VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Mar NEWA
	+ WATSON LABS INC	1.3%	N205223	001	Mar 24, 2014	Sep CRLD
		1.3%	N205223	001	Mar 24, 2014	Jun CAHN
	TABLET;ORAL					
	METRONIDAZOLE					
AB	UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan NEWA
AB		500MG	A203458	002	Jan 22, 2014	Jan NEWA
	@ VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	Apr CAHN
	@	500MG	A070039	001	Jan 29, 1985	Apr CAHN
	@ WATSON LABS	250MG	N018764	001	Sep 17, 1982	May DISC
	@	500MG	N018764	002	Dec 20, 1982	May DISC
AB	WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar CAHN

MICONAZOLE

TABLET;BUCCAL
ORAVIG

	+ BIOALLIANCE PHARMA	50MG	N022404	001	Apr 16, 2010	Apr CAHN
--	----------------------	------	---------	-----	--------------	----------

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL
MONISTAT 3

AB	+ MEDTECH PRODUCTS	200MG	N018888	001	Aug 15, 1984	Oct CAHN
----	--------------------	-------	---------	-----	--------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL
VUSION

	+ DELCOR ASSET	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jun CAHN
--	----------------	------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

AP	BEDFORD LABS	EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr CAHN
	MIDAZOLAM HYDROCHLORIDE	PRESERVATIVE FREE				
AP	BD RX	EQ 1MG BASE/ML	A203460	001	Aug 22, 2014	Aug NEWA
AP		EQ 5MG BASE/ML	A203460	002	Aug 22, 2014	Aug NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

AP	HOSPIRA INC	EQ 1MG BASE/ML	A203280	001	Sep 03, 2014	Aug NEWA
----	-------------	----------------	---------	-----	--------------	----------

MILTEFOSINE

CAPSULE;ORAL
IMPAVIDO

+	KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014	Sep CRLD
		50MG	N204684	001	Mar 19, 2014	Sep CAHN
	PALADIN THERAP	50MG	N204684	001	Mar 19, 2014	Mar NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL
DYNACIN

	@ CNTY LINE PHARMS	EQ 50MG BASE	A063066	001	Aug 14, 1990	Aug CAHN
AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	Jul CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jul CAHN
AB	MEDICIS	EQ 75MG BASE	A063067	002	Sep 15, 1999	May CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	May CAHN
	MINOCYCLINE HYDROCHLORIDE					
AB	SUN PHARM INDS INC	EQ 50MG BASE	A090867	001	May 13, 2013	Jul CAHN
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Jul CAHN
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 80MG BASE	A203443	002	Aug 22, 2014	Aug NEWA
AB		EQ 105MG BASE	A203443	003	Aug 22, 2014	Aug NEWA
AB	RANBAXY LABS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Sep NEWA
AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Sep NEWA
AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Sep NEWA
AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Sep NEWA
AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Sep NEWA
	SOLODYN					
AB	+ MEDICIS	EQ 80MG BASE	N050808	007	Aug 27, 2010	Aug CTEC
AB		EQ 105MG BASE	N050808	006	Aug 27, 2010	Aug CTEC

MIRTAZAPINE

TABLET;ORAL
MIRTAZAPINE

	@ ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003	Aug CAHN
	@	30MG	A076241	002	Jun 25, 2003	Aug CAHN
	@	45MG	A076241	003	Jun 25, 2003	Aug CAHN
AB	SUN PHARM INDS INC	7.5MG	A076541	004	Apr 22, 2004	Jul CAHN
AB		15MG	A076541	001	Apr 22, 2004	Jul CAHN
AB		30MG	A076541	002	Apr 22, 2004	Jul CAHN
AB		45MG	A076541	003	Apr 22, 2004	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

	@ ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005	Jun CAHN
	@	30MG	A076689	002	Aug 31, 2005	Jun CAHN
	@	45MG	A076689	003	Aug 31, 2005	Jun CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION
MITOXANTRONE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Aug CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Aug CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Aug CAHN

MIVACURIUM CHLORIDE

INJECTABLE;INJECTION
MIVACURIUM CHLORIDE

	@ AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	Feb CAHN
--	-----------------	----------------	---------	-----	--------------	----------

MODAFINIL

TABLET; ORAL
MODAFINIL

AB	APOTEX INC	100MG	A077667	001	Feb 03, 2014	Jan NEWA
AB		200MG	A077667	002	Feb 03, 2014	Jan NEWA

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION
ASMANEX HFA

	MERCK SHARP DOHME	0.10MG/INH	N205641	001	Apr 25, 2014	Apr NEWA
+		0.20MG/INH	N205641	002	Apr 25, 2014	Apr NEWA

POWDER; INHALATION

ASMANEX TWISTHALER

	MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008	Mar CAHN
+		0.22MG/INH	N021067	001	Mar 30, 2005	Mar CAHN

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX

+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	May CAHN
---	-------------------	----------------------	---------	-----	--------------	----------

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

AB	HETERO LABS LTD V	EQ 10MG BASE	A202843	001	Sep 10, 2014	Sep NEWA
AB	MACLEODS PHARMS LTD	EQ 10MG BASE	A203366	001	Sep 11, 2014	Sep NEWA
AB	UNIMARK REMEDIES LTD	EQ 10MG BASE	A202859	001	Oct 30, 2014	Oct NEWA

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	UNIMARK REMEDIES LTD	EQ 4MG BASE	A203037	001	Oct 30, 2014	Oct NEWA
AB		EQ 5MG BASE	A203037	002	Oct 30, 2014	Oct NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

AB2	KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Mar CAHN
AB2		45MG	N021260	005	Dec 18, 2008	Mar CAHN
AB2		60MG	N021260	002	Mar 20, 2002	Mar CAHN
AB2		75MG	N021260	006	Dec 18, 2008	Mar CAHN
AB2		90MG	N021260	003	Mar 20, 2002	Mar CAHN
AB2	+	120MG	N021260	004	Mar 20, 2002	Mar CAHN

INJECTABLE; INJECTION

MORPHINE SULFATE

@	WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991	May DISC
@		0.5MG/ML	A073375	001	Sep 30, 1991	May DISC
@		1MG/ML	A073374	001	Sep 30, 1991	May DISC
@		1MG/ML	A073376	001	Sep 30, 1991	May DISC

SOLUTION; ORAL

MORPHINE SULFATE

AA	CARACO	10MG/5ML	A201011	001	Feb 05, 2014	Jan NEWA
AA		20MG/5ML	A201011	002	Feb 05, 2014	Jan NEWA
AA	SUN PHARM INDS INC	10MG/5ML	A201011	001	Feb 05, 2014	Sep CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Sep CAHN

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

	ALPHARMA PHARMS	20MG; 0.8MG	N022321	001	Aug 13, 2009	Mar CAHN
		30MG; 1.2MG	N022321	002	Aug 13, 2009	Mar CAHN
		50MG; 2MG	N022321	003	Aug 13, 2009	Mar CAHN
+		60MG; 2.4MG	N022321	004	Aug 13, 2009	Mar CAHN
		80MG; 3.2MG	N022321	005	Aug 13, 2009	Mar CAHN
		100MG; 4MG	N022321	006	Aug 13, 2009	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	Aug NEWA	
	VIGAMOX						
AT	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Aug CFTG

TABLET;ORAL

AVELOX

AB	+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb CFTG
		MOXIFLOXACIN HYDROCHLORIDE					
AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb NEWA
AB		DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb NEWA
AB		TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb NEWA
AB		TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar NEWA

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

AB		STRIDES PHARMA	250MG	A090055	001	Jun 10, 2010	Aug CAHN
----	--	----------------	-------	---------	-----	--------------	----------

SUSPENSION;ORAL

CELLCEPT

>D>	+	ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998	Nov CFTG
>A>	AB	+	200MG/ML	N050759	001	Oct 01, 1998	Nov CFTG
>A>		MYCOPHENOLATE MOFETIL					
>A>	AB	ALKEM LABS LTD	200MG/ML	A203005	001	Nov 14, 2014	Nov NEWA

TABLET;ORAL

MYCOPHENOLATE MOFETIL

AB		STRIDES PHARMA	500MG	A090456	001	Jun 10, 2010	Aug CAHN
----	--	----------------	-------	---------	-----	--------------	----------

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

AB		APOTEX INC	360MG	A091558	002	Aug 19, 2014	Aug NEWA
AB		TEVA PHARMS USA	180MG	A202720	001	Oct 30, 2014	Oct NEWA
AB			360MG	A202720	002	Oct 30, 2014	Oct NEWA

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP		AGILA SPECLTS	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Mar NEWA
AP			EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Mar NEWA
AP		ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011	Jan CPOT
AP			EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011	Jan CPOT
AP		ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Feb CAHN
AP			EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Feb CAHN
AP			EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Feb CAHN

NALOXEGOL OXALATE

TABLET;ORAL

MOVANTIK

		ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Sep NEWA
	+		EQ 25MG BASE	N204760	002	Sep 16, 2014	Sep NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014	Feb NEWA
		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
		EVZIO					
	+	KALEO INC	0.4MG/0.4ML	N205787	001	Apr 03, 2014	Apr NEWA

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARGINIQ

	@	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014	Jul DISC
	@		10MG;20MG	N205777	002	Jul 23, 2014	Jul DISC
	@		20MG;40MG	N205777	003	Jul 23, 2014	Jul DISC

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALBALON

	@	ALLERGAN	0.1%	A080248	001		Jun DISC
		NAPHAZOLINE HYDROCHLORIDE					
	+	AKORN INC	0.1%	A083590	001		Jun CRLD

NAPROXEN

TABLET; ORAL

NAPROXEN

	@ DAVA PHARMS INC	250MG	A074410	001	Apr 28, 1995	Feb DISC
	@	375MG	A074410	002	Apr 28, 1995	Feb DISC
	@	500MG	A074410	003	Apr 28, 1995	Feb DISC
AB	HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	Sep CAHN
AB		375MG	A076494	002	Jan 14, 2004	Sep CAHN
AB		500MG	A076494	003	Jan 14, 2004	Sep CAHN
	@ WATSON LABS	250MG	A074457	001	May 31, 1995	May DISC
	@	375MG	A074457	002	May 31, 1995	May DISC
	@	500MG	A074457	003	May 31, 1995	May DISC

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

	@ WATSON LABS	EQ 250MG BASE	A074455	001	May 31, 1995	May DISC
	@	EQ 500MG BASE	A074455	002	May 31, 1995	May DISC
	TABLET, EXTENDED RELEASE; ORAL					
	NAPRELAN					
AB	ALMATICA PHARMA INC	EQ 375MG BASE	N020353	001	Jan 05, 1996	Aug CTEC
AB		EQ 500MG BASE	N020353	002	Jan 05, 1996	Aug CTEC
	NAPROXEN SODIUM					
AB	ACTAVIS LABS FL INC	EQ 375MG BASE	A075416	002	Apr 23, 2003	Aug CMFD
AB		EQ 500MG BASE	A075416	001	Aug 27, 2002	Aug CMFD

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

>A>	+	PERNIX IRELAND LTD	500MG; EQ 85MG BASE	N021926	001	Apr 15, 2008	Nov CAHN
>D>	+	SMITHKLINE BEECHAM	500MG; EQ 85MG BASE	N021926	001	Apr 15, 2008	Nov CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan CAIN
AB		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan CAIN
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan CAIN

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

AKYNZEO

	+	HELSINN HLTHCARE	300MG; EQ 0.5MG BASE	N205718	001	Oct 10, 2014	Sep NEWA
--	---	------------------	----------------------	---------	-----	--------------	----------

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

AB	STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan CAHN
AB	STRIDES PHARMA	200MG	A078195	001	May 22, 2012	Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar NEWA
AB	MYLAN PHARMS INC	400MG	A205651	001	Oct 27, 2014	Oct NEWA
AB	SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar NEWA
	VIRAMUNE XR					
AB	+ BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar CFTG

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB	LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar NEWA
AB		500MG	A090860	001	Mar 20, 2014	Mar NEWA
AB		750MG	A090892	001	Mar 20, 2014	Mar NEWA
AB	SUN PHARMA GLOBAL	1GM	A200484	002	Apr 23, 2014	Apr NEWA
AB		500MG	A200484	001	Apr 23, 2014	Apr NEWA
AB		750MG	A201273	001	Apr 23, 2014	Apr NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL							
CARDENE							
AB	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	Apr	CAHN
AB	+	30MG	N019488	002	Dec 21, 1988	Apr	CAHN
NICARDIPINE HYDROCHLORIDE							
AB	ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan	CAHN
AB		20MG	A074540	001	Oct 28, 1996	Jan	CAHN
AB		30MG	A074439	002	Dec 10, 1996	Jan	CAHN
AB		30MG	A074540	002	Oct 28, 1996	Jan	CAHN
	@ WATSON LABS	20MG	A074670	001	Oct 28, 1996	May	DISC
	@	30MG	A074670	002	Oct 28, 1996	May	DISC
CAPSULE, EXTENDED RELEASE; ORAL							
CARDENE SR							
+	CHIESI USA INC	30MG	N020005	001	Feb 21, 1992	Apr	CAHN
	@	45MG	N020005	002	Feb 21, 1992	Apr	CAHN
+		60MG	N020005	003	Feb 21, 1992	Apr	CAHN
INJECTABLE; INJECTION							
CARDENE							
AP	+	CHIESI USA INC 25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Apr	CAHN
NICARDIPINE HYDROCHLORIDE							
AP	LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan	CAHN
INJECTABLE; INTRAVENOUS							
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER							
+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CAHN
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER							
+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CAHN
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER							
+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008	Apr	CAHN
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER							
+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Apr	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL							
NIFEDIPINE							
AB2	TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar	NEWA
AB2		60MG	A203126	002	Apr 03, 2014	Mar	NEWA
AB2		90MG	A203126	003	Apr 03, 2014	Mar	NEWA

NIMODIPINE

CAPSULE; ORAL							
NIMODIPINE							
AB	THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar	NEWA
SOLUTION; ORAL							
NYMALIZE							
+	ARBOR PHARMS LLC	60MG/20ML	N203340	001	May 10, 2013	Sep	CAHN

NINTEDANIB

CAPSULE; ORAL							
OFEV							
	BOEHRINGER INGELHEIM	100MG	N205832	001	Oct 15, 2014	Oct	NEWA
+		150MG	N205832	002	Oct 15, 2014	Oct	NEWA

NITROFURANTOIN

SUSPENSION; ORAL							
NITROFURANTOIN							
AB	NOVEL LABS INC	25MG/5ML	A201693	001	Sep 08, 2014	Aug	NEWA
AB	SUN PHARM INDS INC	25MG/5ML	A201355	001	Aug 14, 2013	Sep	CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL							
MINITRAN							
AB1	VALEANT PHARM NORTH	0.1MG/HR	A089771	001	Aug 30, 1996	Aug	CAHN
AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Aug	CAHN
NITROGLYCERIN							
	@ KREMERS URBAN PHARMS	0.2MG/HR	A075115	001	Aug 10, 2004	May	DISC
	@	0.4MG/HR	A075115	002	Aug 10, 2004	May	DISC
OINTMENT; INTRA-ANAL							
RECTIV							
+	FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011	Apr	CAHN

NIZATIDINE

CAPSULE;ORAL							
NIZATIDINE							
	@ ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan	CAHN
AB		150MG	A075668	001	Sep 12, 2002	Jan	CAHN
	@	300MG	A075461	002	Jul 08, 2002	Jan	CAHN
AB		300MG	A075668	002	Sep 12, 2002	Jan	CAHN

NORFLOXACIN

TABLET;ORAL							
NOROXIN							
	@ MERCK	400MG	N019384	002	Oct 31, 1986	Jul	DISC

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION;ORAL							
NORTRIPTYLINE HYDROCHLORIDE							
AA	+ PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	Apr	CRLD

NYSTATIN

CREAM;TOPICAL							
MYCOSTATIN							
	@ DELCOR ASSET CORP	100,000 UNITS/GM	A060575	001		Jul	CAHN
NYSTATIN							
	@ G AND W LABS INC	100,000 UNITS/GM	A061966	001		Oct	CAHN
OINTMENT;TOPICAL							
MYCOSTATIN							
	@ DELCOR ASSET CORP	100,000 UNITS/GM	A060571	001		Jul	CAHN
POWDER;TOPICAL							
MYCOSTATIN							
	@ DELCOR ASSET CORP	100,000 UNITS/GM	A060578	001		Jul	CAHN
SUSPENSION;ORAL							
MYCOSTATIN							
	@ DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001		Jul	CAHN
TABLET;ORAL							
MYCOSTATIN							
	@ DELCOR ASSET CORP	500,000 UNITS	A060574	001		Jul	CAHN
TABLET;VAGINAL							
MYCOSTATIN							
	@ DELCOR ASSET CORP	100,000 UNITS	A060577	001		Jul	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL							
MYCOLOG-II							
	@ DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	A060576	002	May 01, 1985	Sep	CAHN
	@	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985	Sep	CAHN
OINTMENT;TOPICAL							
MYCOLOG-II							
	@ DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Sep	CAHN

OCTREOTIDE ACETATE

INJECTABLE;INJECTION							
OCTREOTIDE ACETATE							
AP	+ EUROHLTH INTL	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005	Aug	CAHN
AP	+	EQ 1MG BASE/ML	A076330	002	Apr 08, 2005	Aug	CAHN
OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
AP	+ EUROHLTH INTL	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005	Aug	CAHN
AP	+	EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005	Aug	CAHN
AP	+	EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005	Aug	CAHN

OFLOXACIN

TABLET;ORAL							
OFLOXACIN							
AB	CADILA PHARMS LTD	200MG	A091656	001	Sep 18, 2014	Sep	NEWA
AB		300MG	A091656	002	Sep 18, 2014	Sep	NEWA
AB		400MG	A091656	003	Sep 18, 2014	Sep	NEWA

OLANZAPINE

TABLET; ORAL
OLANZAPINE

AB	MACLEODS PHARMS LTD	2.5MG	A202862	001	Aug 15, 2014	Aug	NEWA
AB		5MG	A202862	002	Aug 15, 2014	Aug	NEWA
AB		7.5MG	A202862	003	Aug 15, 2014	Aug	NEWA
AB		10MG	A202862	004	Aug 15, 2014	Aug	NEWA
AB		15MG	A202862	005	Aug 15, 2014	Aug	NEWA
AB		20MG	A202862	006	Aug 15, 2014	Aug	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB	AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014	Apr	NEWA
AB		10MG	A203708	002	May 15, 2014	Apr	NEWA
AB		15MG	A203708	003	May 15, 2014	Apr	NEWA
AB		20MG	A203708	004	May 15, 2014	Apr	NEWA
AB	JUBILANT GENERICS	5MG	A200221	001	Sep 12, 2012	Jul	CAHN
AB		10MG	A200221	002	Sep 12, 2012	Jul	CAHN
AB		15MG	A200221	003	Sep 12, 2012	Jul	CAHN
AB		20MG	A200221	004	Sep 12, 2012	Jul	CAHN
AB	MYLAN PHARMS INC	5MG	A202285	001	May 12, 2014	Apr	NEWA
AB		10MG	A202285	002	May 12, 2014	Apr	NEWA
AB		15MG	A202285	003	May 12, 2014	Apr	NEWA
AB		20MG	A202285	004	May 12, 2014	Apr	NEWA

OLODATEROL HYDROCHLORIDE

SPRAY, METERED; INHALATION
STRIVERDI RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014	Sep	CPOT
+		EQ 2.5MG BASE/INH	N203108	001	Jul 31, 2014	Jul	NEWA

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED; NASAL
OLOPATADINE HYDROCHLORIDE

AB	APOTEX INC	0.665MG/SPRAY	A091572	001	Oct 08, 2014	Sep	NEWA
AB	PATANASE						
AB	+ ALCON PHARMS LTD	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Sep	CFTG

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL
LOVAZA

AB	+ SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar	CFTG
	OMEGA-3-ACID ETHYL ESTERS						
AB	APOTEX INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Sep	NEWA
AB	TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar	NEWA

OMTRYG

+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Apr	NEWA
---	-------	--	---------	-----	--------------	-----	------

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE; ORAL
EPANOVA

+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	May	NEWA
---	--------------------	--	---------	-----	--------------	-----	------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB	GLENMARK GENERICS	10MG	A091672	001	Oct 31, 2014	Oct	NEWA
AB		20MG	A091672	002	Oct 31, 2014	Oct	NEWA
AB		40MG	A091672	003	Oct 31, 2014	Oct	NEWA

OMEPRAZOLE; SODIUM BICARBONATECAPSULE; ORAL
ZEGERID

AB	SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb CAHN
AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Feb CAHN
	FOR SUSPENSION; ORAL					
	OMEPRAZOLE AND SODIUM BICARBONATE					
	@ PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jun DISC
	@	40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jun DISC
	ZEGERID					
	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jun CTEC
	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN

ONDANSETRONFILM; ORAL
ZUPLENZ

	GALENA BIOPHARMA INC	4MG	N022524	001	Jul 02, 2010	Aug CAHN
	+	8MG	N022524	002	Jul 02, 2010	Aug CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

	@ LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Jan DISC
AP	QILU PHARM CO LTD	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Aug NEWA
	TABLET; ORAL					
	ONDANSETRON HYDROCHLORIDE					
AB	IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan NEWA
AB		EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan NEWA

ORITAVANCIN DIPHOSPHATEPOWDER; IV (INFUSION)
ORBACTIV

	+	MEDICINES CO	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Aug NEWA
--	---	--------------	--------------------	---------	-----	--------------	----------

ORPHENADRINE CITRATEINJECTABLE; INJECTION
ORPHENADRINE CITRATE

AP	EUROHLTH INTL	30MG/ML	A040463	001	Mar 04, 2003	Aug CAHN
	@ WATSON LABS	30MG/ML	A087062	001		May DISC

OXACILLIN SODIUMINJECTABLE; INJECTION
OXACILLIN SODIUM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Aug NEWA
AP		EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Aug NEWA
	@ ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995	Feb CAHN
	@	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995	Feb CAHN
	@	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995	Feb CAHN
	@	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995	Feb CAHN
	@	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995	Feb CAHN
	POWDER; INTRAVENOUS					
	OXACILLIN SODIUM					
AP	+ SANDOZ	EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986	Sep CRLD
AP		EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986	Sep CDFR
AP	+	EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986	Sep CRLD
AP		EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986	Sep CDFR

OXALIPLATININJECTABLE; IV (INFUSION)
OXALIPLATIN

AP	ACTAVIS ELIZABETH	50MG/VIAL	A078803	001	Aug 08, 2012	Aug CAHN
AP		100MG/VIAL	A078803	002	Aug 08, 2012	Aug CAHN
AP	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Oct CAHN
AP		100MG/VIAL	A078803	002	Aug 08, 2012	Oct CAHN
AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Jun NEWA
AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Jun NEWA
AP	SUN PHARMA GLOBAL	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Mar NEWA
AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Mar NEWA

OXANDROLONETABLET; ORAL
OXANDRIN

AB	CREALTA PHARMS LLC	2.5MG	N013718	001		Jan	CAHN
AB	+	10MG	N013718	002	Nov 05, 2001	Jan	CAHN

OXAPROZINTABLET; ORAL
OXAPROZIN

AB	SUN PHARM INDS INC	600MG	A075844	001	Jan 03, 2002	Jul	CAHN
	@ WATSON LABS	600MG	A075848	001	Feb 09, 2001	May	DISC

OXAZEPAMCAPSULE; ORAL
OXAZEPAM

@	IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987	Apr	DISC
@		15MG	A070944	001	Aug 03, 1987	Apr	DISC
@		30MG	A070945	001	Aug 03, 1987	Apr	DISC
@	WATSON LABS	10MG	A072952	001	Sep 28, 1990	May	DISC
@		15MG	A072953	001	Sep 28, 1990	May	DISC
@		30MG	A072954	001	Sep 28, 1990	May	DISC

OXCARBAZEPINETABLET; ORAL
OXCARBAZEPINE

@	ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jan	CAHN
@		300MG	A078005	002	Dec 11, 2007	Jan	CAHN
@		600MG	A078005	003	Dec 11, 2007	Jan	CAHN

OXYBUTYNINFILM, EXTENDED RELEASE; TRANSDERMAL
OXYBUTYNIN

AB	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014	Feb	NEWA
AB	+	WATSON LABS (UTAH)	N021351	002	Feb 26, 2003	Feb	CFTG

OXYCODONE HYDROCHLORIDECAPSULE; ORAL
OXYCODONE HYDROCHLORIDE

AB	LANNETT HOLDINGS INC	5MG	A203823	001	Aug 01, 2014	Jul	NEWA
----	----------------------	-----	---------	-----	--------------	-----	------

SOLUTION; ORAL
OXYCODONE HYDROCHLORIDE

AA	COASTAL PHARMS	100MG/5ML	A204092	001	Jun 05, 2014	May	NEWA
AA	LANNETT HOLDINGS INC	100MG/5ML	A204085	001	Sep 09, 2014	Aug	NEWA
AA	LEHIGH VALLEY	5MG/5ML	N200535	002	Aug 22, 2013	Jun	NEWA

TABLET; ORAL
OXECTA

	ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	May	CAHN
		7.5MG	N202080	002	Jun 17, 2011	May	CAHN

OXYCODONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	15MG	A076636	001	Feb 06, 2004	Jul	CAHN
AB		30MG	A076636	002	Feb 06, 2004	Jul	CAHN
AB	AMNEAL PHARMS	5MG	A203638	001	Jun 03, 2014	May	NEWA
AB		10MG	A203638	002	Jun 03, 2014	May	NEWA
AB		15MG	A203638	003	Jun 03, 2014	May	NEWA
AB		20MG	A203638	004	Jun 03, 2014	May	NEWA
AB		30MG	A203638	005	Jun 03, 2014	May	NEWA

OXYMORPHONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
OXYMORPHONE HYDROCHLORIDE

AB	MALLINCKRODT INC	5MG	A202946	001	Jun 27, 2014	Jun	NEWA
AB		7.5MG	A202946	002	Jun 27, 2014	Jun	NEWA
AB		10MG	A202946	003	Jun 27, 2014	Jun	NEWA
AB		15MG	A202946	004	Jun 27, 2014	Jun	NEWA
AB		20MG	A202946	005	Jun 27, 2014	Jun	NEWA
AB		30MG	A202946	006	Jun 27, 2014	Jun	NEWA
AB		40MG	A202946	007	Jun 27, 2014	Jun	NEWA
AB	PAR PHARM	5MG	A200792	001	Oct 24, 2014	Oct	NEWA
AB		7.5MG	A200792	002	Oct 24, 2014	Oct	NEWA
AB		10MG	A200792	003	Oct 24, 2014	Oct	NEWA

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

AB		15MG	A200792	004	Oct 24, 2014	Oct NEWA
AB		20MG	A200792	005	Oct 24, 2014	Oct NEWA
AB		30MG	A200792	006	Oct 24, 2014	Oct NEWA
AB		40MG	A200792	007	Oct 24, 2014	Oct NEWA

OXYTOCIN

INJECTABLE;INJECTION
OXYTOCIN

AP	+	HIKMA MAPLE	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		May CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	May CAHN
AP		SAGENT PHARMS	10USP UNITS/ML (10USP UNITS/ML)	A091676	001	Oct 29, 2014	Oct NEWA
AP			100USP UNITS/10ML (10USP UNITS/ML)	A091676	002	Oct 29, 2014	Oct NEWA

PITOCIN

AP	+	PAR STERILE PRODUCTS	10USP UNITS/ML (10USP UNITS/ML)	N018261	001		Apr CAHN
AP			100USP UNITS/10ML (10USP UNITS/ML)	N018261	002	Jul 27, 2007	Apr CAHN
			500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012	Apr CAHN

SOLUTION;NASAL
SYNTOCINON

	@	RETROPHIN INC	40USP UNITS/ML	N012285	001		Feb CAHN
--	---	---------------	----------------	---------	-----	--	----------

PACLITAXEL

INJECTABLE;INJECTION
PACLITAXEL

AP		ACTAVIS ELIZABETH	6MG/ML	A090130	001	Dec 09, 2009	Aug CAHN
AP		ACTAVIS TOTOWA	6MG/ML	A090130	001	Dec 09, 2009	Oct CAHN
AP		EUROHLTH INTL	6MG/ML	A075190	001	Jan 28, 2002	Aug CAHN
	@	MYLAN	6MG/ML	A075278	001	Jan 25, 2002	Jun DISC

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP		EUROHLTH INTL	30MG/VIAL	A075290	001	Apr 30, 2001	Aug CAHN
AP	+		30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Aug CAHN
AP			90MG/VIAL	A075290	003	Apr 30, 2001	Aug CAHN
AP	+		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Aug CAHN
	@	MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009	Jan DISC
	@		90MG/VIAL	A078300	002	Mar 10, 2009	Jan DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL
PANCREAZE

		JANSSEN PHARMS	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523	005	Mar 07, 2014	Jun NEWA
--	--	----------------	---	---------	-----	--------------	----------

ULTRESA

		FOREST LABS INC	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	May CAHN
			41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	May CAHN
+			46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	May CAHN

ZENPEP

		APTALIS PHARMA US	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Mar NEWA
		FOREST LABS INC	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Apr CAHN
			16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011	Apr CAHN
			55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210	002	Aug 27, 2009	Apr CAHN
			82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210	003	Aug 27, 2009	Apr CAHN
			27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009	Apr CAHN
			109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009	Apr CAHN
+			136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011	Apr CAHN

TABLET;ORAL

VIOKACE

		FOREST LABS INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Apr CAHN
+			78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Apr CAHN

TABLET;ORAL

VIOKACE

	FOREST RES INST INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar CAHN
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS ELIZABETH	EQ 20MG BASE	A090797	001	Feb 07, 2011	Aug CAHN
AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Aug CAHN
AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Oct CAHN
AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Oct CAHN
AB	HETERO LABS LTD V	EQ 20MG BASE	A202882	001	Sep 10, 2014	Aug NEWA
AB		EQ 40MG BASE	A202882	002	Sep 10, 2014	Aug NEWA
AB	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jul CAHN
AB		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jul CAHN
>A>	ORCHID HLTHCARE	EQ 20MG BASE	A202052	001	Dec 02, 2014	Nov NEWA
>A>		EQ 40MG BASE	A202052	002	Dec 02, 2014	Nov NEWA
AB	PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014	Apr NEWA

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	ANCHEN PHARMS	1MCG	A202124	001	Jun 24, 2014	Jun NEWA
AB		2MCG	A202124	002	Jun 24, 2014	Jun NEWA
AB		4MCG	A202124	003	Jun 24, 2014	Jun NEWA
AB	BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar NEWA
AB		2MCG	A202539	002	Mar 27, 2014	Mar NEWA
AB		4MCG	A202539	003	Mar 27, 2014	Mar NEWA
AB	DR REDDYS LABS LTD	1MCG	A091412	001	Jun 24, 2014	Jun NEWA
AB		2MCG	A091412	002	Jun 24, 2014	Jun NEWA
AB		4MCG	A091412	003	Jun 24, 2014	Jun NEWA
AB	RISING PHARMS INC	1MCG	A202124	001	Jun 24, 2014	Sep CAHN
AB		2MCG	A202124	002	Jun 24, 2014	Sep CAHN
AB		4MCG	A202124	003	Jun 24, 2014	Sep CAHN
>D>	INJECTABLE;INJECTION					
>D>	PARICALCITOL					
>D>	HOSPIRA INC	0.002MG/ML	N201657	001	Oct 21, 2014	Nov CDFR
		0.002MG/ML	N201657	001	Oct 21, 2014	Oct NEWA
>D>		0.005MG/ML	N201657	002	Oct 21, 2014	Nov CDFR
		0.005MG/ML	N201657	002	Oct 21, 2014	Oct NEWA
>D>		0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	Nov CDFR
		0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	Oct NEWA
>D>	SANDOZ CANADA INC	0.002MG/ML	A091108	001	Jul 27, 2011	Nov CDFR
>D>		0.005MG/ML	A091108	002	Jul 27, 2011	Nov CDFR
>D>	ZEMPLAR					
>D>	+ ABBVIE	0.002MG/ML	N020819	002	Feb 01, 2000	Nov CDFR
>D>	+	0.005MG/ML	N020819	001	Apr 17, 1998	Nov CDFR

SOLUTION;INTRAVENOUS

PARICALCITOL

>A>	HIKMA PHARMS	0.002MG/ML (0.002MG/ML)	N205917	001	Nov 18, 2014	Nov NEWA
>A>		0.005MG/ML (0.005MG/ML)	N205917	002	Nov 18, 2014	Nov NEWA
>A>		0.01MG/2ML (0.005MG/ML)	N205917	003	Nov 18, 2014	Nov NEWA
>A>	HOSPIRA INC	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014	Nov CDFR
>A>		0.005MG/ML (0.005MG/ML)	N201657	002	Oct 21, 2014	Nov CDFR
>A>		0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	Nov CDFR
>A>	SANDOZ CANADA INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Nov CDFR
>A>		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Nov CDFR
>A>		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Nov NEWA
>A>	ZEMPLAR					
>A>	+ ABBVIE	0.002MG/ML (0.002MG/ML)	N020819	002	Feb 01, 2000	Nov CDFR
>A>	+	0.005MG/ML (0.005MG/ML)	N020819	001	Apr 17, 1998	Nov CDFR
>A>	+	0.01MG/2ML (0.005MG/ML)	N020819	003	Feb 01, 2000	Nov NEWA

PAROMOMYCIN SULFATE

CAPSULE;ORAL

PAROMOMYCIN SULFATE

AA	+ SUN PHARM INDS INC	EQ 250MG BASE	A064171	001	Jun 30, 1997	Jul CAHN
----	----------------------	---------------	---------	-----	--------------	----------

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION; ORAL

PAXIL

AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN
----	---	---------------------	------------------	---------	-----	--------------	----------

TABLET; ORAL

PAROXETINE

AB		PRINSTON INC	EQ 10MG BASE	A203854	001	Oct 31, 2014	Oct NEWA
AB			EQ 20MG BASE	A203854	002	Oct 31, 2014	Oct NEWA
AB			EQ 30MG BASE	A203854	003	Oct 31, 2014	Oct NEWA
AB			EQ 40MG BASE	A203854	004	Oct 31, 2014	Oct NEWA

PAROXETINE HYDROCHLORIDE

AB		SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007	Jul CAHN
AB			EQ 20MG BASE	A078194	002	Jun 29, 2007	Jul CAHN
AB			EQ 30MG BASE	A078194	003	Jun 29, 2007	Jul CAHN
AB			EQ 40MG BASE	A078194	004	Jun 29, 2007	Jul CAHN

PAXIL

AB		APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan CAHN
AB			EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan CAHN
AB			EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan CAHN
AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan CAHN
	@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

PAXIL CR

AB		APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB			EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+	PHARMACIA AND UPJOHN	25MG/VIAL	N021106	004	Jul 31, 2014	Jul NEWA
+		30MG/VIAL	N021106	005	Jul 31, 2014	Jul NEWA

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC

ALAMAST

@	SANTEN	0.1%	N021079	001	Sep 24, 1999	Jun DISC
---	--------	------	---------	-----	--------------	----------

PEMOLINE

TABLET; ORAL

PEMOLINE

@	ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000	Aug CAHN
@		37.5MG	A075595	002	Feb 28, 2000	Aug CAHN
@		75MG	A075595	003	Feb 28, 2000	Aug CAHN

TABLET, CHEWABLE; ORAL

PEMOLINE

@	ACTAVIS ELIZABETH	37.5MG	A075678	001	Jul 26, 2000	Aug CAHN
---	-------------------	--------	---------	-----	--------------	----------

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Apr CAHN
@		20MG	N018976	004	Jan 05, 1989	Sep DISC
+		20MG	N018976	004	Jan 05, 1989	Apr CAHN

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

AP		ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
AP			20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN

PENTAMIDINE ISETHIONATEINJECTABLE;INJECTION
PENTAM

+	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	May CTEC
	PENTAMIDINE ISETHIONATE					
@	WATSON LABS	300MG/VIAL	A074303	001	Aug 17, 1995	May DISC

PENTOSTATININJECTABLE;INJECTION
PENTOSTATIN

AP	EUROHLTH INTL	10MG/VIAL	A077841	001	Aug 07, 2007	Aug CAHN
AP	MYLAN INSTITUTIONAL	10MG/VIAL	A203554	001	Sep 19, 2014	Sep NEWA

PENTOXIFYLLINETABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	VALEANT BERMUDA	400MG	A075028	001	Jul 20, 1998	Sep CAHN
	@ WATSON LABS	400MG	A075107	001	Sep 04, 1998	May DISC
	TRENTAL					
	@ SANOFI AVENTIS US	400MG	N018631	001	Aug 30, 1984	Jun DISC

PERINDOPRIL ERBUMINETABLET;ORAL
ACEON

AB	SYMPLMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993	Jul CAHN
AB		4MG	N020184	002	Dec 30, 1993	Jul CAHN
AB	+	8MG	N020184	003	Dec 30, 1993	Jul CAHN
	PERINDOPRIL ERBUMINE					
AB	ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Jan CAHN
AB		4MG	A078138	002	Nov 10, 2009	Jan CAHN
AB		8MG	A078138	003	Nov 10, 2009	Jan CAHN

PERPHENAZINETABLET;ORAL
PERPHENAZINE

@	ANI PHARMS INC	8MG	A089456	001	Sep 10, 1987	Apr CAHN
@	TEVA PHARMS USA	4MG	A089708	001	Sep 10, 1987	Apr CAHN
@		16MG	A089457	001	Sep 10, 1987	Apr CAHN

PHENDIMETRAZINE TARTRATETABLET;ORAL
PHENDIMETRAZINE TARTRATE

AA	ELITE LABS INC	35MG	A040762	001	Jan 28, 2008	Apr CAHN
----	----------------	------	---------	-----	--------------	----------

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE;ORAL
DIBENZYLINE

>A>	AB	+	COVIS PHARMA SARL	10MG	N008708	001	Nov CAHN
>D>	AB	+	WELLSPRING PHARM	10MG	N008708	001	Nov CAHN

PHENTERMINE HYDROCHLORIDECAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Feb NEWA	
AA		30MG	A202858	002	Feb 14, 2014	Feb NEWA	
AA		30MG	A204414	001	May 05, 2014	Apr NEWA	
AA		37.5MG	A202846	001	Feb 05, 2014	Jan NEWA	
>A>	AA	KEN LIFESCIENCE	15MG	A205019	001	Dec 05, 2014	Nov NEWA
>A>	AA		30MG	A205019	002	Dec 05, 2014	Nov NEWA
AA		37.5MG	A205017	001	Sep 25, 2014	Sep NEWA	

TABLET;ORAL
PHENTERMINE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	37.5MG	A203068	001	Aug 06, 2014	Jul NEWA
AA	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Jan NEWA
AA	KEN LIFESCIENCE	37.5MG	A205008	001	Sep 25, 2014	Sep NEWA
AA	MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997	May CMFD
AA	SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007	Jul CAHN

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE

AP	EUROHLTH INTL	5MG/VIAL	A040235	001	Mar 11, 1998	Aug CAHN
----	---------------	----------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)
VAZCULEP

	ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun NEWA
		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun NEWA
+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun NEWA

PHENYTOIN

TABLET, CHEWABLE; ORAL
PHENYTOIN

>A>	AB	COREPHARMA	50MG	A040884	001	Nov 28, 2014	Nov NEWA
	AB	TARO	50MG	A200565	001	Apr 17, 2014	Apr NEWA

PHENYTOIN SODIUM

CAPSULE; ORAL
EXTENDED PHENYTOIN SODIUM

	@ ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003	Apr CAHN
	@	100MG EXTENDED	A089441	001	Dec 18, 1986	Jan CAHN
	PROMPT PHENYTOIN SODIUM					
	@ ANI PHARMS INC	100MG PROMPT	A080259	001		Jan CAHN

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb CMFD
AB		10MG	A074063	002	Jan 27, 1994	Feb CMFD
AB	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb CTEC
AB	+	10MG	A074019	002	Sep 03, 1992	Feb CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE

AB	LUPIN LTD	EQ 15MG BASE	A204133	001	Apr 07, 2014	Mar NEWA
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Mar NEWA
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Mar NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION
PIPERACILLIN

+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb CAHN
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb CAHN
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb CAHN
+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP	AGILA SPECLTS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Aug NEWA
AP		EQ 3MG BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Aug NEWA
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Aug NEWA
AP	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb CAHN
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb CAHN
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb CAHN
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb CAHN

INJECTABLE; IV (INFUSION)
PIPERACILLIN AND TAZOBACTAM

	SANDOZ	EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014	Oct NEWA
--	--------	---------------------------------------	---------	-----	--------------	----------

PIRBUTEROL ACETATEAEROSOL, METERED; INHALATION
MAXAIR

@ VALEANT PHARM NORTH EQ 0.2MG BASE/INH N019009 001 Dec 30, 1986 Jul CAHN

PIRFENIDONECAPSULE; ORAL
ESBRIET

+ INTERMUNE INC 267MG N022535 001 Oct 15, 2014 Oct NEWA

PIROXICAMCAPSULE; ORAL
PIROXICAM

@ CYCLE PHARMS LTD	10MG	A073651	001	Feb 26, 1993	Sep	CAHN
@	20MG	A073651	002	Feb 26, 1993	Sep	CAHN
@ WATSON LABS	10MG	A074287	001	May 16, 1996	May	DISC
@	10MG	A074460	001	Sep 29, 1995	May	DISC
@	20MG	A074287	002	May 16, 1996	May	DISC
@	20MG	A074460	002	Sep 29, 1995	May	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSFOR SUSPENSION; ORAL
CO-LAV

@ VINTAGE PHARMS 240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT A073428 001 Jan 28, 1992 Feb CAHN

GO-EVAC

@ VINTAGE PHARMS 236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT A073433 001 Apr 28, 1992 Feb CAHN

POLYMYXIN B SULFATEINJECTABLE; INJECTION
POLYMYXIN B SULFATE

AP + EUROHLTH INTL EQ 500,000 U BASE/VIAL A060716 001 Aug CAHN

PORACTANT ALFASUSPENSION; INTRATRACHEAL
CUROSURF

+ CHIESI USA INC 80MG/ML N020744 001 Nov 18, 1999 Apr CAHN

PORFIMER SODIUMINJECTABLE; INJECTION
PHOTOFRIN

>A>	CONCORDIA LABS INC	75MG/VIAL	N020451	001	Dec 27, 1995	Nov	CAHN
>D>	PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995	Nov	CAHN

POSACONAZOLESOLUTION; IV (INFUSION)
NOXAFIL

+ MERCK SHARP DOHME 300MG/16.7ML (18MG/ML) N205596 001 Mar 13, 2014 Mar NEWA

POTASSIUM CHLORIDEINJECTABLE; INJECTION
POTASSIUM CHLORIDE

@ INTL MEDICATION 2MEQ/ML A083163 001 Mar DISC

TABLET, EXTENDED RELEASE; ORAL
K-TAB

>A>	BC	ABBVIE	8MEQ	N018279	002	Aug 01, 1988	Nov	CMFD
>D>	BC		20MEQ	N018279	003	Nov 25, 2013	Nov	CRLD
>A>	BC	+	20MEQ	N018279	003	Nov 25, 2013	Nov	CRLD
		KLOR-CON						
AB2		UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Aug	CTEC
AB2		+	10MEQ	N019123	002	Apr 17, 1986	Aug	CTEC
		KLOR-CON M10						
AB1		UPSHER SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Aug	CTEC
		KLOR-CON M20						
AB1		+	20MEQ	A074726	001	Nov 20, 1998	Aug	CTEC
		POTASSIUM CHLORIDE						
>D>		@ ABBVIE	8MEQ	N018279	002	Aug 01, 1988	Nov	CMFD
AB1		ACTAVIS LABS FL INC	10MEQ	A075604	001	Apr 10, 2002	Aug	CTEC
AB1			20MEQ	A075604	002	Apr 10, 2002	Aug	CTEC

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB1	EURAND	20MEQ	A076368	001	Aug 18, 2004	Aug CTEC
AB2	MYLAN PHARMS INC	8.0MEQ	A204662	001	Aug 21, 2014	Aug NEWA
AB2		10.0MEQ	A204662	002	Aug 21, 2014	Aug NEWA

POTASSIUM CITRATE

FOR SOLUTION;ORAL
POTASSIUM CITRATE

@ UT SW MEDCTR	10MEQ/PACKET	N019647	002	Oct 13, 1988	Jul CAHN
@	20MEQ/PACKET	N019647	001	Oct 13, 1988	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

AB	ZYDUS PHARMS USA INC	5MEQ	A203546	001	Aug 06, 2014	Jul NEWA
AB		10MEQ	A203546	002	Aug 06, 2014	Jul NEWA
AB		15MEQ	A203546	003	Aug 06, 2014	Jul NEWA
UROCIT-K						
AB	+ MISSION PHARMA	15MEQ	N019071	003	Dec 30, 2009	Jul CTEC

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	SCIEGEN PHARMS INC	0.125MG	A203855	001	Oct 28, 2014	Oct NEWA
AB		0.25MG	A203855	002	Oct 28, 2014	Oct NEWA
AB		0.5MG	A203855	003	Oct 28, 2014	Oct NEWA
AB		0.75MG	A203855	004	Oct 28, 2014	Oct NEWA
AB		1MG	A203855	005	Oct 28, 2014	Oct NEWA
AB		1.5MG	A203855	006	Oct 28, 2014	Oct NEWA
AB	STRIDES ARCOLAB LTD	0.125MG	A202702	001	Jun 03, 2014	May NEWA
AB		0.25MG	A202702	002	Jun 03, 2014	May NEWA
AB		0.5MG	A202702	003	Jun 03, 2014	May NEWA
AB		0.75MG	A202702	004	Jun 03, 2014	May NEWA
AB		1MG	A202702	005	Jun 03, 2014	May NEWA
AB		1.5MG	A202702	006	Jun 03, 2014	May NEWA
AB	STRIDES PHARMA	0.125MG	A202702	001	Jun 03, 2014	Aug CAHN
AB		0.25MG	A202702	002	Jun 03, 2014	Aug CAHN
AB		0.5MG	A202702	003	Jun 03, 2014	Aug CAHN
AB		0.75MG	A202702	004	Jun 03, 2014	Aug CAHN
AB		1MG	A202702	005	Jun 03, 2014	Aug CAHN
AB		1.5MG	A202702	006	Jun 03, 2014	Aug CAHN
	@ WATSON LABS	0.125MG	A078551	001	Oct 08, 2010	Oct DISC
	@	0.25MG	A078551	002	Oct 08, 2010	Oct DISC
	@	0.5MG	A078551	003	Oct 08, 2010	Oct DISC
	@	1MG	A078551	004	Oct 08, 2010	Oct DISC
	@	1.5MG	A078551	005	Oct 08, 2010	Oct DISC

TABLET, DELAYED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>A> AB	SANDOZ	0.375MG	A202353	001	Dec 04, 2014	Nov NEWA
>A> AB		0.75MG	A202353	002	Dec 04, 2014	Nov NEWA
>A> AB		1.5MG	A202353	003	Dec 04, 2014	Nov NEWA
>A> AB		3MG	A202353	004	Dec 04, 2014	Nov NEWA
>A> AB		4.5MG	A202353	005	Dec 04, 2014	Nov NEWA

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

AB	+ BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Jan CFTG
AB		0.75MG	N022421	002	Feb 19, 2010	Jan CFTG
AB		1.5MG	N022421	003	Feb 19, 2010	Jan CFTG
AB		2.25MG	N022421	006	Jun 17, 2011	Jan CFTG
AB		3MG	N022421	004	Feb 19, 2010	Jan CFTG
AB		3.75MG	N022421	007	Jun 17, 2011	Jan CFTG
AB		4.5MG	N022421	005	Feb 19, 2010	Jan CFTG

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan NEWA
AB		0.75MG	A202206	002	Feb 06, 2014	Jan NEWA
AB		1.5MG	A202206	003	Feb 06, 2014	Jan NEWA
AB		2.25MG	A202206	004	Feb 06, 2014	Jan NEWA
AB		3MG	A202206	005	Feb 06, 2014	Jan NEWA
AB		3.75MG	A202206	006	Feb 06, 2014	Jan NEWA
AB		4.5MG	A202206	007	Feb 06, 2014	Jan NEWA

PRAMLINTIDE ACETATEINJECTABLE;SUBCUTANEOUS
SYMMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb CAHN
+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb CAHN
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb CAHN

PRAVASTATIN SODIUMTABLET;ORAL
PRAVACHOL

	@ BRISTOL MYERS SQUIBB	10MG	N019898	002	Oct 31, 1991	Oct DISC
	PRAVASTATIN SODIUM					
AB	SANDOZ	10MG	A076397	003	Oct 23, 2006	Apr CMFD
AB		20MG	A076397	002	Oct 23, 2006	Apr CMFD
AB		40MG	A076397	001	Oct 23, 2006	Apr CMFD
AB		80MG	A077491	001	Feb 11, 2008	Aug CMFD

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

>A>	@ MEDICIS PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Nov CAHN
>D>	@ WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Nov CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	+	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10% VASOCIDIN	A074449	001	Dec 29, 1995	Feb CRLD
	@	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb DISC

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE

AB	+	SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan CFTG
		PRIMAQUINE PHOSPHATE					
AB		ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan NEWA
AB		BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

+	HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jul CTEC
+		500MG/ML	A089070	001	Feb 12, 1986	Jul CTEC
@	INTL MEDICATION	100MG/ML	A088636	001	Jul 31, 1984	Jul DISC
@		500MG/ML	A088637	001	Jul 31, 1984	Jul DISC

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

@ ANI PHARMS INC

@

@

@

@

@

1GM

250MG

500MG

500MG

750MG

A040111	001	Dec 13, 1996	Jan CAHN
A088958	001	Dec 02, 1985	Jan CAHN
A088959	001	Dec 02, 1985	Jan CAHN
A088974	001	Jul 22, 1985	Mar CAHN
A089438	001	Mar 23, 1987	Jan CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	+	HIKMA MAPLE	25MG/ML	A083312	001		Oct CRLD
AP	+		50MG/ML	A083312	002		Oct CRLD
	@	HOSPIRA	25MG/ML	A040372	001	Jun 08, 2000	Oct DISC
	@	LUITPOLD	25MG/ML	A040515	001	Mar 19, 2003	Sep DISC
	@	TEVA PHARMS USA	25MG/ML	A040454	001	Aug 22, 2002	Oct DISC
	@		50MG/ML	A040454	002	Aug 22, 2002	Oct DISC
	@	WOCKHARDT	25MG/ML	A040785	001	Sep 26, 2008	Oct DISC
	@		50MG/ML	A040785	002	Sep 26, 2008	Oct DISC

SUPPOSITORY;RECTAL

PHENERGAN

@ DELCOR ASSET CORP

50MG

N011689	001		Apr CAHN
---------	-----	--	----------

SYRUP;ORAL							
PROMETHAZINE HYDROCHLORIDE							
AA	SUN PHARM INDS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Sep	CAHN
TABLET;ORAL							
PHENERGAN							
	@ DELCOR ASSET CORP	12.5MG	N007935	002		Jul	CAHN
	@	12.5MG	N007935	002		Apr	CAHN
	@	25MG	N007935	003		Jul	CAHN
	@	25MG	N007935	003		Apr	CAHN
	@	50MG	N007935	004		Jul	CAHN
	@	50MG	N007935	004		Apr	CAHN
	@ SHIONOGI INC	12.5MG	N007935	002		May	CAHN
	@	25MG	N007935	003		May	CAHN
	@	50MG	N007935	004		May	CAHN
PROMETHAZINE HYDROCHLORIDE							
AB	SANDOZ	25MG	A084176	003		Apr	CMS1
AB	SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008	Jun	CAHN
AB		25MG	A040863	002	Dec 30, 2008	Jun	CAHN
AB		50MG	A040863	003	Dec 30, 2008	Jun	CAHN
<u>PROPAFENONE HYDROCHLORIDE</u>							
TABLET;ORAL							
PROPAFENONE HYDROCHLORIDE							
AB	ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan	CAHN
AB		225MG	A076550	002	Apr 23, 2004	Jan	CAHN
AB		300MG	A076550	003	Apr 23, 2004	Jan	CAHN
<u>PROPARACAINE HYDROCHLORIDE</u>							
SOLUTION/DROPS;OPHTHALMIC							
ALCAINE							
AT	+ ALCON	0.5%	A080027	001		Jun	CRLD
	OPHTHAINE						
	@ APOTHECON	0.5%	N008883	001		Jun	DISC
	OPHTHETIC						
	@ ALLERGAN	0.5%	N012583	001		Jun	DISC
<u>PROPOFOL</u>							
INJECTABLE;INJECTION							
PROPOFOL							
	@ EUROHLTH INTL	10MG/ML	A074848	001	Apr 19, 2005	Aug	CAHN
<u>PROPOXYPHENE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
PROPOXYPHENE HYDROCHLORIDE							
	@ MUTUAL PHARM	65MG	A083186	001		Aug	DISC
<u>PROPRANOLOL HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
PROPRANOLOL HYDROCHLORIDE							
AB	NORTEC DEV ASSOC	60MG	A078065	001	Jan 26, 2007	Sep	CAHN
AB		80MG	A078065	002	Jan 26, 2007	Sep	CAHN
AB		120MG	A078065	003	Jan 26, 2007	Sep	CAHN
AB		160MG	A078065	004	Jan 26, 2007	Sep	CAHN
SOLUTION;ORAL							
HEMANGEOL							
	+ PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014	Mar	NEWA
TABLET;ORAL							
INDERAL							
	@ WYETH PHARMS INC	40MG	N016418	002		Jan	DISC
	@	60MG	N016418	009	Oct 18, 1982	Jan	DISC
PROPRANOLOL HYDROCHLORIDE							
	@ ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988	Jan	CAHN
<u>PROPYLTHIOURACIL</u>							
TABLET;ORAL							
PROPYLTHIOURACIL							
	@ ANI PHARMS INC	50MG	A080215	001		Jan	CAHN

PYRIDOSTIGMINE BROMIDESYRUP;ORAL
MESTINON

+ VALEANT PHARM NORTH 60MG/5ML

N015193 001

Aug CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB ALEMBIC PHARMS LTD EQ 25MG BASE
 AB EQ 50MG BASE
 AB EQ 100MG BASE
 AB EQ 200MG BASE
 AB EQ 300MG BASE
 AB EQ 400MG BASE
 AB JUBILANT GENERICS EQ 25MG BASE

A203390 001 Oct 28, 2014 Oct NEWA
 A203390 002 Oct 28, 2014 Oct NEWA
 A203390 003 Oct 28, 2014 Oct NEWA
 A203390 004 Oct 28, 2014 Oct NEWA
 A203390 005 Oct 28, 2014 Oct NEWA
 A203390 006 Oct 28, 2014 Oct NEWA
 A203150 001 Nov 26, 2013 Jul CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ ACTAVIS ELIZABETH EQ 5MG BASE
 @ EQ 10MG BASE
 @ EQ 20MG BASE
 @ EQ 40MG BASE

A076459 001 Dec 22, 2004 Aug CAHN
 A076459 002 Dec 22, 2004 Aug CAHN
 A076459 003 Dec 22, 2004 Aug CAHN
 A076459 004 Dec 22, 2004 Aug CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@ WATSON LABS 324MG

A087810 001 Sep 29, 1982 May DISC

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB + LILLY 60MG
 RALOXIFENE HYDROCHLORIDE
 AB INVAGEN PHARMS 60MG
 AB TEVA PHARMS USA 60MG

N020815 001 Dec 09, 1997 Feb CFTG
 A090842 001 Sep 24, 2014 Sep NEWA
 A078193 001 Mar 04, 2014 Feb NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB ACCORD HLTHCARE INC 1.25MG
 AB 2.5MG
 AB 5MG
 AB 10MG

A202392 001 Apr 15, 2014 Mar NEWA
 A202392 002 Apr 15, 2014 Mar NEWA
 A202392 003 Apr 15, 2014 Mar NEWA
 A202392 004 Apr 15, 2014 Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP EUROHLTH INTL EQ 25MG BASE/ML
 AP EQ 25MG BASE/ML
 ZANTAC
 AP + COVIS INJECTABLES EQ 25MG BASE/ML
 ZANTAC IN PLASTIC CONTAINER
 @ COVIS INJECTABLES EQ 1MG BASE/ML
 @ EQ 50MG BASE/100ML

A074777 001 Mar 02, 2005 Aug CAHN
 A077458 001 Feb 16, 2006 Aug CAHN
 N019090 001 Oct 19, 1984 Apr CAHN
 N019593 002 Sep 27, 1991 Apr CAHN
 N019593 001 Dec 17, 1986 Apr CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ WOCKHARDT EQ 150MG BASE
 @ EQ 300MG BASE

A078701 001 Nov 12, 2009 Oct DISC
 A078701 002 Dec 11, 2009 Oct DISC

TABLET, EFFERVESCENT;ORAL

ZANTAC 25

@ GLAXO GRP LTD EQ 25MG BASE

N020251 003 Apr 01, 2004 Feb DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@ WATSON LABS INC EQ 0.5MG BASE
 @ EQ 1MG BASE

A201823 001 Jul 01, 2013 May DISC
 A201823 002 Jul 01, 2013 May DISC

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB	ACTAVIS ELIZABETH	0.5MG	A090008	001	Jan 22, 2014	Aug CAHN
AB		1MG	A090008	002	Jan 22, 2014	Aug CAHN
AB		2MG	A090008	003	Jan 22, 2014	Aug CAHN
AB	ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Oct CAHN
AB		0.5MG	A090008	001	Jan 22, 2014	Jan NEWA
AB		1MG	A090008	002	Jan 22, 2014	Oct CAHN
AB		1MG	A090008	002	Jan 22, 2014	Jan NEWA
AB		2MG	A090008	003	Jan 22, 2014	Oct CAHN
AB		2MG	A090008	003	Jan 22, 2014	Jan NEWA
AB	AUROBINDO PHARMA LTD	0.5MG	A203820	001	Jan 22, 2014	Jan NEWA
AB		1MG	A203820	002	Jan 22, 2014	Jan NEWA
AB		2MG	A203820	003	Jan 22, 2014	Jan NEWA
AB	MYLAN PHARMS INC	1MG	A090252	002	Jan 22, 2014	Jan NEWA
AB		2MG	A090252	003	Jan 22, 2014	Jan NEWA
AB	PADDOCK LLC	1MG	A201189	002	Jan 22, 2014	Jan NEWA
AB		2MG	A201189	003	Jan 22, 2014	Jan NEWA
AB	SANDOZ	1MG	A078555	002	Jan 22, 2014	Jan NEWA
AB		2MG	A078555	003	Jan 22, 2014	Jan NEWA
AB	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Jul CAHN
AB		2MG	A077571	003	Jul 11, 2013	Jul CAHN

RESERPINE

TABLET; ORAL

RESERPINE

>A>	@ CYCLE PHARMS LTD	0.1MG	N009859	001		Nov CAHN
>A>	@	0.25MG	N009859	002		Nov CAHN
>D>	@ ROXANE	0.1MG	N009859	001		Nov CAHN
>D>	@	0.25MG	N009859	002		Nov CAHN

RIBAVIRIN

TABLET; ORAL

RIBAVIRIN

AB	SANDOZ	200MG	A202546	001	Aug 12, 2014	Aug NEWA
AB		400MG	A202546	002	Aug 12, 2014	Aug NEWA
AB		500MG	A202546	003	Aug 12, 2014	Aug NEWA
AB		600MG	A202546	004	Aug 12, 2014	Aug NEWA
AB	ZYDUS PHARMS USA	500MG	A077094	004	Apr 18, 2008	Aug CTEC

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN

AB	+ PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992	Feb CFTG
AB	RIFABUTIN					
AB	LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Feb NEWA

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP	EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014	Aug NEWA
AP	FRESENIUS KABI USA	600MG/VIAL	A091181	001	Aug 21, 2014	Aug NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	100MG	A076375	001	Jan 14, 2003	Aug CAHN
---	-------------------	-------	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	+ WARNER CHILCOTT LLC	150MG	N020835	005	Apr 22, 2008	May CTEC
AB	RISEDRONATE SODIUM					
AB	APOTEX INC	75MG	A090877	002	Jun 10, 2014	May NEWA
AB		150MG	A090877	003	Jun 10, 2014	May NEWA
AB	MYLAN PHARMS INC	75MG	A200477	004	Jun 10, 2014	May NEWA
AB		150MG	A200477	005	Jun 10, 2014	May NEWA
AB	SUN PHARMA GLOBAL	75MG	A090886	004	Jun 10, 2014	May NEWA
AB		150MG	A090886	005	Jun 10, 2014	May NEWA
AB	TEVA PHARMS USA	150MG	A079215	001	Jun 13, 2014	Jun NEWA

RISPERIDONE

SOLUTION;ORAL						
RISPERIDONE						
AA	ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Jan CAHN
TABLET;ORAL						
RISPERIDONE						
AB	CARACO	0.25MG	A078036	001	Mar 10, 2014	Feb NEWA
AB		0.5MG	A078036	002	Mar 10, 2014	Feb NEWA
AB		1MG	A078036	003	Mar 10, 2014	Feb NEWA
AB		2MG	A078036	004	Mar 10, 2014	Feb NEWA
AB		3MG	A078036	005	Mar 10, 2014	Feb NEWA
AB		4MG	A078036	006	Mar 10, 2014	Feb NEWA
AB	SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014	Jul CAHN
AB		0.5MG	A078036	002	Mar 10, 2014	Jul CAHN
AB		1MG	A078036	003	Mar 10, 2014	Jul CAHN
AB		2MG	A078036	004	Mar 10, 2014	Jul CAHN
AB		3MG	A078036	005	Mar 10, 2014	Jul CAHN
AB		4MG	A078036	006	Mar 10, 2014	Jul CAHN
	@ WATSON LABS	0.25MG	A077860	001	Dec 05, 2008	Oct DISC
	@	0.5MG	A077860	002	Dec 05, 2008	Oct DISC
	@	1MG	A077860	003	Dec 05, 2008	Oct DISC
	@	2MG	A077860	004	Dec 05, 2008	Oct DISC
	@	3MG	A077860	005	Dec 05, 2008	Oct DISC
	@	4MG	A077860	006	Dec 05, 2008	Oct DISC
	@ WEST WARD PHARMS	0.25MG	A078740	001	May 29, 2009	Sep DISC
	@	0.5MG	A078740	002	May 29, 2009	Sep DISC
	@	1MG	A078740	003	May 29, 2009	Sep DISC
	@	2MG	A078740	004	May 29, 2009	Sep DISC
	@	3MG	A078740	005	May 29, 2009	Sep DISC
	@	4MG	A078740	006	May 29, 2009	Sep DISC
TABLET, ORALLY DISINTEGRATING;ORAL						
RISPERIDONE						
AB	JUBILANT GENERICS	0.5MG	A090839	001	Nov 04, 2011	Jul CAHN
AB		1MG	A090839	002	Nov 04, 2011	Jul CAHN
AB		2MG	A090839	003	Nov 04, 2011	Jul CAHN
AB		3MG	A090839	004	Nov 04, 2011	Jul CAHN
AB		4MG	A090839	005	Nov 04, 2011	Jul CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL						
RIVASTIGMINE TARTRATE						
AB	MACLEODS PHARMS LTD	EQ 1.5MG BASE	A203148	001	Aug 22, 2014	Aug NEWA
AB		EQ 3MG BASE	A203148	002	Aug 22, 2014	Aug NEWA
AB		EQ 4.5MG BASE	A203148	003	Aug 22, 2014	Aug NEWA
AB		EQ 6MG BASE	A203148	004	Aug 22, 2014	Aug NEWA
SOLUTION;ORAL						
EXELON						
	@ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Jun DISC

RIZATRIPTAN BENZOATE

TABLET;ORAL						
RIZATRIPTAN BENZOATE						
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan NEWA
AB		EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan NEWA
TABLET, ORALLY DISINTEGRATING;ORAL						
RIZATRIPTAN BENZOATE						
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203146	001	Sep 19, 2014	Sep NEWA
AB		EQ 10MG BASE	A203146	002	Sep 19, 2014	Sep NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION						
ROCURONIUM BROMIDE						
AP	+ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008	Sep CRLD
AP	+ ZEMURON	100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008	Sep CRLD
	@ ORGANON USA INC	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Sep DISC
	@	100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Sep DISC

ROPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
NAROPIN

AP	FRESENIUS KABI USA	2MG/ML	N020533	001	Sep 24, 1996	Sep CTEC
AP		5MG/ML	N020533	003	Sep 24, 1996	Jul CFTG
AP		7.5MG/ML	N020533	004	Sep 24, 1996	Sep CTEC
AP	+	10MG/ML	N020533	005	Sep 24, 1996	Jul CFTG

ROPIVACAINE HYDROCHLORIDE

AP	HOSPIRA	2MG/ML	A090194	001	Sep 23, 2014	Sep NEWA
AP		5MG/ML	A090194	002	Sep 23, 2014	Sep NEWA
AP		7.5MG/ML	A090194	003	Sep 23, 2014	Sep NEWA
AP		10MG/ML	A090194	004	Sep 23, 2014	Sep NEWA
AP	NAVINTA LLC	5MG/ML	A078601	002	Jul 17, 2014	Jul NEWA
AP		10MG/ML	A078601	003	Jul 17, 2014	Jul NEWA
AP	SAGENT STRIDES	2MG/ML	A090318	001	Sep 23, 2014	Sep NEWA
AP		5MG/ML	A090318	002	Sep 23, 2014	Sep NEWA
AP		7.5MG/ML	A090318	003	Sep 23, 2014	Sep NEWA
AP		10MG/ML	A090318	004	Sep 23, 2014	Sep NEWA

SALMETEROL XINAFOATEPOWDER; INHALATION
SEREVENT

+	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997	Sep CAHN
---	-----------------	--------------------	---------	-----	--------------	----------

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

	ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	May CAHN
+		EQ 5MG BASE	N022350	002	Jul 31, 2009	May CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

>D>	@ AAIPHARMA LLC	5MG	A075145	001	Sep 15, 2003	Nov CAHN
>A>	@ LANNETT HOLDINGS INC	5MG	A075145	001	Sep 15, 2003	Nov CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

@	G AND W LABS INC	2.5%	A086209	001		Aug CAHN
---	------------------	------	---------	-----	--	----------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202825	001	Nov 07, 2014	Oct NEWA
AB		EQ 50MG BASE	A202825	002	Nov 07, 2014	Oct NEWA
AB		EQ 100MG BASE	A202825	003	Nov 07, 2014	Oct NEWA
	@ WATSON LABS	EQ 25MG BASE	A077663	001	Feb 06, 2007	Oct DISC
	@	EQ 50MG BASE	A077663	002	Feb 06, 2007	Oct DISC
	@	EQ 100MG BASE	A077663	003	Feb 06, 2007	Oct DISC

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

>A>	AB	HETERO LABS LTD V	EQ 20MG BASE	A203623	001	Nov 26, 2014	Nov NEWA
-----	----	-------------------	--------------	---------	-----	--------------	----------

SIMEPREVIR SODIUM

CAPSULE; ORAL

OLYSIO

+	JANSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013	Jun CAHN
+	JANSSEN RES AND DEV	EQ 150MG BASE	N205123	001	Nov 22, 2013	Feb CAIN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>A>	AB	ACCORD HLTHCARE	5MG	A078155	005	Apr 05, 2013	Nov NEWA
-----	----	-----------------	-----	---------	-----	--------------	----------

SIROLIMUSTABLET; ORAL
RAPAMUNE

AB	PF PRISM CV	1MG	N021110	001	Aug 25, 2000	Oct CFTG
AB	+	2MG	N021110	002	Aug 22, 2002	Oct CFTG
	SIROLIMUS					
AB	DR REDDYS LABS LTD	1MG	A201578	001	Oct 27, 2014	Oct NEWA
AB		2MG	A201578	002	Oct 27, 2014	Oct NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; IV (INFUSION)
AMMONUL

+	MEDICIS	10%; 10% (5GM/50ML; 5GM/50ML)	N020645	001	Feb 17, 2005	Jul CAHN
---	---------	-------------------------------	---------	-----	--------------	----------

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

@	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Jun DISC
@		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Jun DISC
@		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Jun DISC
@		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Jun DISC
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
@	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Jun DISC

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP	ESSENTIAL ISOTOPES	10-200mCi/ML	A204541	001	Oct 29, 2014	Oct NEWA
AP	GLOBAL ISOTOPES LLC	10-200mCi/ML	A204464	001	Oct 21, 2014	Oct NEWA
>A>	AP	NCM USA BRONX LLC	A204513	001	Nov 28, 2014	Nov NEWA
AP	SHERTECH LABS LLC	10-200mCi/ML	A204315	001	Sep 22, 2014	Sep NEWA
>A>	THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014	Nov NEWA
AP	UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014	Mar NEWA

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

>A>	JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005	Nov CPOT
>D>		9-100mCi	N021305	006	May 19, 2005	Nov CPOT

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	EPIC PHARMA LLC	453.6GM/BOT	A202333	001	Mar 19, 2014	Mar NEWA
>A>	NUVO PHARM INC	15GM/BOT	A204071	002	Nov 28, 2014	Nov NEWA
>A>	AA	454GM/BOT	A204071	001	Nov 28, 2014	Nov NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB	TEVA PHARMS USA	5MG	A091464	001	Apr 02, 2014	Mar NEWA
AB		10MG	A091464	002	Apr 02, 2014	Mar NEWA
	VESICARE					
AB	ASTELLAS	5MG	N021518	001	Nov 19, 2004	Mar CFTG
AB	+	10MG	N021518	002	Nov 19, 2004	Mar CFTG

SOMATROPIN RECOMBINANTINJECTABLE; INJECTION
ACCRETROPIN

@	EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Feb CAHN
---	----------	-----------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

SOLUTION; ORAL

SOTYLIZE

+	ARBOR PHARMS LLC	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014	Oct NEWA
+		5MG/ML	N205108	001	Oct 22, 2014	Oct NEWA

SUVOREXANTTABLET; ORAL
BELSOMRA

MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014	Aug NEWA
	10MG	N204569	002	Aug 13, 2014	Aug NEWA
	15MG	N204569	003	Aug 13, 2014	Aug NEWA
+	20MG	N204569	004	Aug 13, 2014	Aug NEWA

TACROLIMUSCAPSULE; ORAL
TACROLIMUS

AB	STRIDES ARCOLAB LTD	EQ 0.5MG BASE	A090687	001	Jul 22, 2014	Jul NEWA
AB		EQ 1MG BASE	A090687	002	Jul 22, 2014	Jul NEWA
AB		EQ 5MG BASE	A090687	003	Jul 22, 2014	Jul NEWA
AB	STRIDES PHARMA	EQ 0.5MG BASE	A090687	001	Jul 22, 2014	Aug CAHN
AB		EQ 1MG BASE	A090687	002	Jul 22, 2014	Aug CAHN
AB		EQ 5MG BASE	A090687	003	Jul 22, 2014	Aug CAHN
	@ WATSON LABS	EQ 5MG BASE	A090402	001	Jul 01, 2010	May DISC

OINTMENT; TOPICAL
PROTOPIC

AB	+	ASTELLAS	0.03%	N050777	001	Dec 08, 2000	Aug CFTG
AB	+		0.1%	N050777	002	Dec 08, 2000	Aug CFTG
		TACROLIMUS					
AB		FOUGERA PHARMS INC	0.03%	A200744	001	Sep 09, 2014	Aug NEWA
AB			0.1%	A200744	002	Sep 09, 2014	Aug NEWA

TAFLOPROSTSOLUTION/DROPS; OPHTHALMIC
ZIOPTAN

+	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Apr CAHN
---	----------------	---------	---------	-----	--------------	----------

TASIMELTEONCAPSULE; ORAL
HETLIOZ

+	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	Jan NEWA
---	------------------	------	---------	-----	--------------	----------

TAVABOROLESOLUTION; TOPICAL
KERYDIN

+	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Jul NEWA
---	-------------------	----	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INJECTION, ORAL
TECHNELITE

@	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001		May DISC
	ULTRA-TECHNEKOW FM					
@	MALLINCKRODT	0.25-3 CI/GENERATOR	N017243	002		May DISC

SOLUTION; INTRAVENOUS
TECHNELITE

+	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	May NEWA
@		0.0083-2.7 CI/GENERATOR	N017771	001		May CDFR
	ULTRA-TECHNEKOW FM					
+	MALLINCKRODT	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	May NEWA
@		0.25-3 CI/GENERATOR	N017243	002		May CDFR

SOLUTION; INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR

+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	May NEWA
@		830-16600mCi/GENERATOR	N017693	001		May CDFR

TEDIZOLID PHOSPHATEPOWDER; IV (INFUSION)
SIVEXTRO

+	CUBIST PHARMS INC	200MG/VIAL	N205436	001	Jun 20, 2014	Jun NEWA
---	-------------------	------------	---------	-----	--------------	----------

TABLET; ORAL
SIVEXTRO

+	CUBIST PHARMS INC	200MG	N205435	001	Jun 20, 2014	Jun NEWA
---	-------------------	-------	---------	-----	--------------	----------

TELAVANCIN HYDROCHLORIDEPOWDER; IV (INFUSION)
VIBATIVTHERAVANCE BIOPHARMA EQ 250MG BASE/VIAL
+ EQ 750MG BASE/VIALN022110 001 Sep 11, 2009 Jun CAHN
N022110 002 Sep 11, 2009 Jun CAHNTELMISARTAN

TABLET; ORAL

TELMISARTAN

AB ALEMBIC PHARMS LTD 20MG
 AB 40MG
 AB 80MG
 AB GLENMARK GENERICS 20MG
 AB 40MG
 AB 80MG
 AB MYLAN PHARMS INC 20MG
 AB 40MG
 AB 80MG
 AB SANDOZ 20MG
 AB 40MG
 AB 80MG
 AB TORRENT PHARMS LTD 20MG
 AB 40MG
 AB 80MG
 AB ZYDUS PHARMS USA INC 20MG
 AB 40MG
 AB 80MG

A202130 001 Jul 07, 2014 Jun NEWA
 A202130 002 Jul 07, 2014 Jun NEWA
 A202130 003 Jul 07, 2014 Jun NEWA
 A090032 001 Jul 07, 2014 Jun NEWA
 A090032 002 Jul 07, 2014 Jun NEWA
 A090032 003 Jul 07, 2014 Jun NEWA
 A202397 001 Jul 07, 2014 Jun NEWA
 A202397 002 Jul 07, 2014 Jun NEWA
 A202397 003 Jul 07, 2014 Jun NEWA
 A203867 001 Nov 03, 2014 Oct NEWA
 A203867 002 Nov 03, 2014 Oct NEWA
 A203867 003 Nov 03, 2014 Oct NEWA
 A203171 001 Jul 07, 2014 Jun NEWA
 A203171 002 Jul 07, 2014 Jun NEWA
 A203171 003 Jul 07, 2014 Jun NEWA
 A203325 001 Aug 26, 2014 Aug NEWA
 A203325 002 Aug 26, 2014 Aug NEWA
 A203325 003 Aug 26, 2014 Aug NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

@ WATSON LABS 15MG
@ 30MGA071446 001 May 21, 1993 May DISC
A071447 001 May 21, 1993 May DISCTEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB SUN PHARMA GLOBAL 5MG
 AB 20MG
 AB 100MG
 AB 140MG
 AB 180MG
 AB 250MG

A201742 001 Feb 12, 2014 Feb NEWA
 A201742 002 Feb 12, 2014 Feb NEWA
 A201742 003 Feb 12, 2014 Feb NEWA
 A201742 004 Feb 12, 2014 Feb NEWA
 A201742 005 Feb 12, 2014 Feb NEWA
 A201742 006 Feb 12, 2014 Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB + SANDOZ EQ 2MG BASE

A074823 002 Mar 30, 1998 Apr CRLD

TABLET; ORAL

HYTRIN

@ ABBOTT EQ 1MG BASE
@ EQ 2MG BASE
@ EQ 5MG BASE
@ EQ 10MG BASE

N019057 001 Aug 07, 1987 Apr DISC
 N019057 002 Aug 07, 1987 Apr DISC
 N019057 003 Aug 07, 1987 Apr DISC
 N019057 004 Aug 07, 1987 Apr DISC

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

+ THERATECHNOLOGIES EQ 1MG BASE/VIAL
@ EQ 1MG BASE/VIAL
@ EQ 2MG BASE/VIAL
+ EQ 2MG BASE/VIAL

N022505 001 Nov 10, 2010 Aug CMFD
 N022505 001 Nov 10, 2010 May CAHN
 N022505 002 Nov 29, 2011 Aug DISC
 N022505 002 Nov 29, 2011 May CAHN

TESTOSTERONEFILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

>A> + ACTAVIS LABS UT INC 2MG/24HR
 >A> @ 2.5MG/24HR
 >A> + 4MG/24HR
 >A> @ 5MG/24HR
 >D> + WATSON LABS 2MG/24HR

N020489 003 Oct 20, 2011 Nov CAHN
 N020489 001 Sep 29, 1995 Nov CAHN
 N020489 004 Oct 20, 2011 Nov CAHN
 N020489 002 May 02, 1997 Nov CAHN
 N020489 003 Oct 20, 2011 Nov CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL									
ANDRODERM									
>D>	@	2.5MG/24HR	N020489	001	Sep 29, 1995	Nov	CAHN		
>D>	+	4MG/24HR	N020489	004	Oct 20, 2011	Nov	CAHN		
>D>	@	5MG/24HR	N020489	002	May 02, 1997	Nov	CAHN		
GEL;TRANSDERMAL									
ANDROGEL									
AB	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jul	CTEC		
AB	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jul	CTEC		
TESTOSTERONE									
AB	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jul	CTEC		
AB		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jul	CTEC		
BX	TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jul	CTEC		
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jul	CTEC		
VOGELXO									
	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun	NEWA		
GEL, METERED;NASAL									
NATESTO									
	@ TRIMEL BIOPHARMA SRL	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	DISC		
	+	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	May	NEWA		
GEL, METERED;TRANSDERMAL									
ANDROGEL									
AB	+	ABBVIE	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Jul	CTEC	
TESTOSTERONE									
AB	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013	Jul	CTEC		
VOGELXO									
>D>	UPSHER SMITH	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Nov	CTEC		
>A>	BX	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Nov	CTEC		
		12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun	NEWA		
TABLET, EXTENDED RELEASE;BUCCAL									
STRIANT									
	+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Apr	CAHN	
<u>TESTOSTERONE UNDECANOATE</u>									
INJECTABLE;INTRAMUSCULAR									
AVEED									
	+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014	Mar	NEWA	
<u>THEOPHYLLINE</u>									
SOLUTION, ELIXIR;ORAL									
ELIXOPHYLLIN									
	+	CARACO	80MG/15ML	A085186	001		Jun	CDFR	
	+	SUN PHARM INDS INC	80MG/15ML	A085186	001		Jul	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
THEOCHRON									
	@ CARACO	300MG	A087400	002	Jan 11, 1983	Jan	DISC		
AB	SUN PHARM INDS INC	100MG	A088320	001	Feb 21, 1985	Jul	CAHN		
AB		200MG	A088321	001	Feb 21, 1985	Jul	CAHN		
	@	300MG	A087400	002	Jan 11, 1983	Jul	CAHN		
<u>THIAMINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
THIAMINE HYDROCHLORIDE									
	@ WATSON LABS	100MG/ML	A080571	001		May	DISC		
	@	200MG/ML	A080571	002		May	DISC		
<u>THIORIDAZINE HYDROCHLORIDE</u>									
CONCENTRATE;ORAL									
THIORIDAZINE HYDROCHLORIDE									
	@ ANI PHARMS INC	100MG/ML	A089603	001	Nov 09, 1987	Feb	CAHN		
TABLET;ORAL									
THIORIDAZINE HYDROCHLORIDE									
	@ ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983	Feb	CAHN		
	@	10MG	A088493	001	May 17, 1985	Feb	CAHN		
	@	15MG	A088271	001	Apr 14, 1983	Feb	CAHN		
	@	25MG	A088272	001	Apr 14, 1983	Feb	CAHN		
	@	50MG	A088194	001	Apr 14, 1983	Feb	CAHN		
	@	100MG	A088273	001	Oct 03, 1983	Feb	CAHN		
	@	100MG	A088456	001	May 17, 1985	Feb	CAHN		

THIOTEPA

INJECTABLE; INJECTION
THIOTEPA

EUROHLTH INTL 15MG/VIAL A075547 001 Apr 02, 2001 Aug CAHN

THIOTHIXENE

CAPSULE; ORAL
THIOTHIXENE

@ WATSON LABS 2MG A070601 001 Jun 05, 1987 May DISC
@ 5MG A070602 001 Jun 05, 1987 May DISC

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HYDROCHLORIDE INTENSOL

@ CYCLE PHARMS LTD EQ 5MG BASE/ML A073494 001 Jun 30, 1992 Sep CAHN

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

AB SUN PHARM INDS INC 250MG A075526 001 Sep 26, 2002 Jul CAHN

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC
BETIMOL

+ OAK PHARMS INC EQ 0.25% BASE N020439 001 Mar 31, 1995 Apr CAHN
+ EQ 0.5% BASE N020439 002 Mar 31, 1995 Apr CAHN

TIOTROPIUM BROMIDE

POWDER; INHALATION
SPIRIVA

+ BOEHRINGER INGELHEIM EQ 0.018MG BASE/INH N021395 001 Jan 30, 2004 Sep CAIN

SPRAY, METERED; INHALATION
SPIRIVA RESPIMAT

+ BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH N021936 001 Sep 24, 2014 Sep NEWA

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL
TIZANIDINE HYDROCHLORIDE

AB SUN PHARM INDS INC EQ 2MG BASE A076416 001 Sep 29, 2003 Jul CAHN
AB EQ 4MG BASE A076416 002 Sep 29, 2003 Jul CAHN

TOBRAMYCIN

SOLUTION; INHALATION
BETHKIS

CHIESI USA INC 300MG/4ML N201820 001 Oct 12, 2012 Apr CAHN

TOBRAMYCIN

AN AKORN INC 300MG/5ML A201422 001 May 28, 2014 May NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP AKORN EQ 40MG BASE/ML A205179 001 Sep 16, 2014 Sep NEWA
@ WATSON LABS INC EQ 10MG BASE/ML A062945 001 Aug 09, 1989 May DISC
AP XELLIA PHARMS APS EQ 1.2GM BASE/VIAL A205685 001 Sep 16, 2014 Sep NEWA

TOPIRAMATE

CAPSULE, DELAYED RELEASE; ORAL
QUDEXY XR

UPSHER SMITH 25MG N205122 001 Mar 11, 2014 Mar NEWA
50MG N205122 002 Mar 11, 2014 Mar NEWA
100MG N205122 003 Mar 11, 2014 Mar NEWA
150MG N205122 004 Mar 11, 2014 Mar NEWA
+ 200MG N205122 005 Mar 11, 2014 Mar NEWA

CAPSULE, EXTENDED RELEASE; ORAL
QUDEXY XR

UPSHER SMITH 25MG N205122 001 Mar 11, 2014 Apr CDFR
50MG N205122 002 Mar 11, 2014 Apr CDFR
100MG N205122 003 Mar 11, 2014 Apr CDFR
150MG N205122 004 Mar 11, 2014 Apr CDFR
+ 200MG N205122 005 Mar 11, 2014 Apr CDFR

TABLET; ORAL

TOPIRAMATE

@ WATSON LABS	25MG	A077643	001	Mar 27, 2009	May DISC
@	50MG	A077643	002	Mar 27, 2009	May DISC
@	100MG	A077643	003	Mar 27, 2009	May DISC
@	200MG	A077643	004	Mar 27, 2009	May DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	ACTAVIS ELIZABETH	EQ 4MG BASE/VIAL	A090620	001	Dec 02, 2010	Aug CAHN
AP	ACTAVIS TOTOWA	EQ 4MG BASE/VIAL	A090620	001	Dec 02, 2010	Oct CAHN
>A> AP	CIPLA LTD	EQ 4MG BASE/VIAL	A091199	001	Dec 01, 2010	Nov CAHN
AP	INNOPHARMA LICENSING	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Apr CAHN
>D> AP	THREE RIVERS PHARMS	EQ 4MG BASE/VIAL	A091199	001	Dec 01, 2010	Nov CAHN

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

AP	+ EUROHLTH INTL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Aug CAHN
AP	+	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Aug CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ALLIED PHARMA INC	50MG	A202075	001	Nov 28, 2011	Apr CAHN
AB	AUROBINDO PHARMA LTD	50MG	A203494	001	Mar 31, 2014	Mar NEWA
AB	SUN PHARM INDS INC	50MG	A075964	001	Jun 19, 2002	Jul CAHN
	@ WATSON LABS	50MG	A075962	001	Jun 24, 2002	May DISC

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

@ COREPHARMA	1MG	A077256	001	Jun 12, 2007	Jun DISC
@	2MG	A077256	002	Jun 12, 2007	Jun DISC
@	4MG	A077256	003	Jun 12, 2007	Jun DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	ACIC FINE CHEMS	100MG/ML	A202436	001	Feb 11, 2014	Jan NEWA
AP	EMCURE PHARMS LTD	100MG/ML	A203521	001	Aug 12, 2014	Aug NEWA
	@ FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Oct DISC

TABLET; ORAL

TRANEXAMIC ACID

AB	APOTEX INC	650MG	A202286	001	Jan 27, 2014	Jan NEWA
----	------------	-------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

IZBA

+	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	May NEWA
	TRAVOPROST					
+	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb CRLD

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

@ WATSON LABS	50MG	A070857	001	Oct 10, 1986	May DISC
@	100MG	A070858	001	Oct 10, 1986	May DISC

TREPROSTINIL

SOLUTION; INHALATION

TYVASO

+	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009	Sep CPOT
---	---------------	----------	---------	-----	--------------	----------

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE; ORAL

ORENITRAM

	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013	Jun CAIN
		EQ 0.25MG BASE	N203496	002	Dec 20, 2013	Jun CAIN
		EQ 1MG BASE	N203496	003	Dec 20, 2013	Jun CAIN
+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Jun CAIN

TRETINOIN

CREAM; TOPICAL							
TRETINOIN							
AB	MATAWAN PHARMS	0.025%	A 075264	001	Dec 24, 1998	Sep	CAHN
AB1		0.05%	A 075265	001	Dec 24, 1998	Sep	CAHN
AB		0.1%	A 075213	001	Dec 24, 1998	Sep	CAHN
	+ WATSON LABS INC	0.0375%	A 090098	001	Mar 22, 2010	Sep	CAHN
		0.075%	A 202209	001	Oct 11, 2012	Sep	CAHN
GEL; TOPICAL							
RETIN-A-MICRO							
	+ VALEANT INTL	0.08%	N 020475	003	Jan 28, 2014	Jan	NEWA
TRETINOIN							
AB	MATAWAN PHARMS	0.01%	A 075589	001	Jun 11, 2002	Sep	CAHN
AB		0.025%	A 075529	001	Feb 22, 2000	Sep	CAHN
SOLUTION; TOPICAL							
RETIN-A							
	+ VALEANT INTL	0.05%	N 016921	001		Feb	CTEC
TRETINOIN							
	@ WOCKHARDT	0.05%	A 075260	001	Jan 25, 1999	Feb	DISC

TRIAMCINOLONE

TABLET; ORAL							
KENACORT							
	@ DELCOR ASSET CORP	1MG	N 011283	003		Sep	CAHN
	@	2MG	N 011283	008		Sep	CAHN
	@	4MG	N 011283	006		Sep	CAHN
	@	8MG	N 011283	010		Sep	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL							
KENALOG							
	@ DELCOR ASSET CORP	0.025%	N 011601	003		Jul	CAHN
	@	0.1%	N 011601	006		Jul	CAHN
	@	0.5%	A 083943	001		Sep	CAHN
KENALOG-H							
	@ DELCOR ASSET CORP	0.1%	A 086240	001		Sep	CAHN
INJECTABLE; INJECTION							
KENALOG-10							
	APOTHECON	10MG/ML	N 012041	001		May	CTEC
KENALOG-40							
	+ APOTHECON	40MG/ML	N 014901	001		May	CTEC
TRIAMCINOLONE ACETONIDE							
	@ SANDOZ	10MG/ML	A 090166	001	May 27, 2009	May	DISC
	@ SANDOZ CANADA INC	40MG/ML	A 090164	001	Jun 01, 2009	May	DISC
LOTION; TOPICAL							
KENALOG							
	@ DELCOR ASSET CORP	0.025%	A 084343	001		Sep	CAHN
	@	0.025%	N 011602	003		Sep	CAHN
	@	0.1%	A 084343	002		Sep	CAHN
	@	0.1%	N 011602	001		Sep	CAHN
TRIAMCINOLONE ACETONIDE							
	@ G AND W LABS INC	0.1%	A 089129	001	Aug 14, 1986	Aug	CAHN
	@ TARO	0.1%	A 089129	001	Aug 14, 1986	Mar	DISC
OINTMENT; TOPICAL							
KENALOG							
	@ DELCOR ASSET CORP	0.025%	N 011600	003		Jul	CAHN
	@	0.1%	N 011600	001		Jul	CAHN
	@	0.5%	A 083944	001		Sep	CAHN
PASTE; DENTAL							
KENALOG IN ORABASE							
	@ DELCOR ASSET CORP	0.1%	N 012097	001		Sep	CAHN

TRIAMCINOLONE DIACETATE

SYRUP; ORAL							
KENACORT							
	@ DELCOR ASSET CORP	EQ 4MG BASE/5ML	N 012515	001		Sep	CAHN

TRIAMTERENECAPSULE;ORAL
DYRENIUM

COVIS PHARMA SARL

50MG

N013174 001

Sep CAHN

+

100MG

N013174 002

Sep CAHN

TRIAZOLAMTABLET;ORAL
TRIAZOLAM

@ WATSON LABS

0.125MG

A074445 001 Oct 20, 1995 May DISC

@

0.25MG

A074445 002 Oct 20, 1995 May DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

@ WATSON LABS

2MG

A040184 001 Feb 06, 1998 May DISC

@

5MG

A040184 002 Feb 06, 1998 May DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

TIGAN

AP

+

PAR STERILE PRODUCTS

100MG/ML

N017530 001

May CAHN

UMECLIDINIUM BROMIDEPOWDER;INHALATION
INCRUSE ELLIPTA

+ GLAXO GRP ENGLAND

EQ 62.5MCG BASE/INH

N205382 001 Apr 30, 2014 Apr NEWA

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEPOWDER;INHALATION
ANORO ELLIPTA

+ GLAXOSMITHKLINE

EQ 0.0625MG BASE/INH;EQ 0.025MG
BASE/INH

N203975 001 Dec 18, 2013 Apr CAHN

UNOPROSTONE ISOPROPYLSOLUTION/DROPS;OPHTHALMIC
RESCULA

+ SUCAMPO PHARMS

0.15%

N021214 001 Aug 03, 2000 Aug CRLD

UREA C-13

FOR SOLUTION;ORAL

BREATHTEK UBT FOR H-PYLORI

@ OTSUKA AMERICA

EQ 75MG/POUCH

N020586 002 May 10, 2001 May DISC

URSODIOLTABLET;ORAL
URSO 250

AB

FOREST LABS INC

250MG

N020675 001 Dec 10, 1997 Apr CAHN

URSO FORTE

AB

+

FOREST LABS INC

500MG

N020675 002 Jul 21, 2004 Apr CAHN

URSODIOL

AB

IMPAX LABS INC

250MG

A200826 001 Dec 23, 2011 Jul CAHN

AB

500MG

A200826 002 Dec 23, 2011 Jul CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB

APOTEX INC

EQ 1GM BASE

A090500 002 Apr 04, 2014 Mar NEWA

AB

EQ 500MG BASE

A090500 001 Apr 04, 2014 Mar NEWA

AB

CIPLA LTD

EQ 1GM BASE

A077135 002 May 24, 2010 Jan CAHN

AB

EQ 500MG BASE

A077135 001 May 24, 2010 Jan CAHN

AB

JUBILANT GENERICS

EQ 1GM BASE

A201506 002 Apr 03, 2012 Aug CAHN

AB

EQ 500MG BASE

A201506 001 Apr 03, 2012 Aug CAHN

AB

WATSON LABS INC

EQ 1GM BASE

A090370 002 Mar 16, 2011 Apr CAHN

AB

EQ 500MG BASE

A090370 001 Mar 16, 2011 Apr CAHN

VALGANCICLOVIR HYDROCHLORIDETABLET; ORAL
VALCYTE

AB	+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29, 2001	Oct CFTG
VALGANCICLOVIR HYDROCHLORIDE							
AB		DR REDDYS LABS LTD	EQ 450MG BASE	A203511	001	Nov 04, 2014	Oct NEWA
AB		ENDO PHARMS INC	EQ 450MG BASE	A200790	001	Nov 04, 2014	Oct NEWA

VALPROIC ACIDSYRUP; ORAL
VALPROIC ACID

AA		ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan CAHN
----	--	----------------	-----------	---------	-----	--------------	----------

VALSARTANTABLET; ORAL
DIOVAN

AB		NOVARTIS	40MG	N021283	004	Aug 14, 2002	Jun CFTG
AB			80MG	N021283	001	Jul 18, 2001	Jun CFTG
AB			160MG	N021283	002	Jul 18, 2001	Jun CFTG
AB	+		320MG	N021283	003	Jul 18, 2001	Jun CFTG
VALSARTAN							
AB		OHM LABS INC	40MG	A077492	001	Jun 26, 2014	Jun NEWA
AB			80MG	A077492	002	Jun 26, 2014	Jun NEWA
AB			160MG	A077492	003	Jun 26, 2014	Jun NEWA
AB			320MG	A077492	004	Jun 26, 2014	Jun NEWA

VANCOMYCIN HYDROCHLORIDECAPSULE; ORAL
VANCOCIN HYDROCHLORIDE

AB		ANI PHARMS INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	Aug CAHN
AB	+		EQ 250MG BASE	N050606	002	Apr 15, 1986	Aug CAHN
AB		SHIRE VIROPHARM INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	May CAHN
AB	+		EQ 250MG BASE	N050606	002	Apr 15, 1986	May CAHN
VANCOMYCIN HYDROCHLORIDE							
AB		STRIDES PHARMA	EQ 125MG BASE	A065490	001	Apr 09, 2012	Aug CAHN
AB			EQ 250MG BASE	A065490	002	Apr 09, 2012	Aug CAHN

FOR SOLUTION; ORAL
VANCOCIN HYDROCHLORIDE

@	ANI PHARMS INC	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Aug CAHN
@		EQ 500MG BASE/6ML	A061667	001		Aug CAHN

INJECTABLE; INJECTION
VANCOCIN HYDROCHLORIDE

@	ANI PHARMS INC	EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Aug CAHN
@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Aug CAHN
@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Aug CAHN
@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Aug CAHN
@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Aug CAHN
@		EQ 500MG BASE/VIAL	A060180	001		Aug CAHN
@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Aug CAHN
@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Aug CAHN
@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Aug CAHN

VANCOMYCIN HYDROCHLORIDE

AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Feb CAHN
AP		MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP			EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
AP		SAGENT PHARMS	EQ 10GM BASE/VIAL	A200837	002	Sep 02, 2014	Aug NEWA

VASOPRESSINSOLUTION; IV (INFUSION)
VASOSTRICT

+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr NEWA
---	----------------------	-------------------------	---------	-----	--------------	----------

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

@	WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995	May DISC
@		20MG/VIAL	A074334	002	Aug 31, 1995	May DISC

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	EQ 25MG BASE	A078627	001	Jun 13, 2008	Jul CAHN
AB		EQ 37.5MG BASE	A078627	002	Jun 13, 2008	Jul CAHN
AB		EQ 50MG BASE	A078627	003	Jun 13, 2008	Jul CAHN
AB		EQ 75MG BASE	A078627	004	Jun 13, 2008	Jul CAHN
AB		EQ 100MG BASE	A078627	005	Jun 13, 2008	Jul CAHN

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	+	HOSPIRA	10MG/4ML (2.5MG/ML)	A070738	001	May 06, 1987	Oct CRLD
AP	+		5MG/2ML (2.5MG/ML)	A075136	001	Oct 20, 1998	Oct CRLD
AP	+		5MG/2ML (2.5MG/ML)	A070737	001	May 06, 1987	Oct CRLD
AP	+		10MG/4ML (2.5MG/ML)	A070737	002	May 06, 1987	Oct NEWA

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

AB	MYLAN	80MG	A071483	002	Feb 15, 1989	Apr CMS1
	@ WATSON LABS	40MG	A072923	001	Jun 29, 1993	May DISC
	@	80MG	A070855	001	Sep 24, 1986	May DISC
	@	80MG	A071366	001	Oct 01, 1986	May DISC
	@	120MG	A070856	001	Sep 24, 1986	May DISC
	@	120MG	A071367	001	Oct 01, 1986	May DISC

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

AB	ANI PHARMS INC	120MG	A090529	001	Dec 30, 2011	Jun CAHN
AB		180MG	A090529	002	Dec 30, 2011	Jun CAHN
AB		240MG	A090529	003	Dec 30, 2011	Jun CAHN
AB	SUN PHARM INDS INC	120MG	A090529	001	Dec 30, 2011	Jul CAHN
AB		180MG	A090529	002	Dec 30, 2011	Jul CAHN
AB		240MG	A090529	003	Dec 30, 2011	Jul CAHN

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

	+	EUROHLTH INTL	10MG/VIAL	A089395	001	Apr 09, 1987	Aug CAHN
--	---	---------------	-----------	---------	-----	--------------	----------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP	ACTAVIS ELIZABETH	EQ 10MG BASE/ML	A078011	001	Jul 22, 2009	Aug CAHN
AP	ACTAVIS TOTOWA	EQ 10MG BASE/ML	A078011	001	Jul 22, 2009	Oct CAHN
>D> AP	EBEWE PHARMA	EQ 10MG BASE/ML	A078408	001	Feb 13, 2008	Nov DISC
>A>	@	EQ 10MG BASE/ML	A078408	001	Feb 13, 2008	Nov DISC

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

	+	MERCK SHARP DOHME	EQ 2.08MG BASE	N204886	001	May 08, 2014	Jun CPOT
	+		EQ 2.5MG BASE	N204886	001	May 08, 2014	May NEWA

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

AB	+	PF PRISM CV	200MG/5ML	N021630	001	Dec 19, 2003	Sep CAHN
----	---	-------------	-----------	---------	-----	--------------	----------

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002	Sep CAHN
----	---	-------------	------------	---------	-----	--------------	----------

TABLET; ORAL

VFEND

AB	PF PRISM CV	50MG	N021266	001	May 24, 2002	Sep CAHN
AB	+	200MG	N021266	002	May 24, 2002	Sep CAHN

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

	@	BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995	Mar DISC
--	---	----------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

COUMADIN

AB	BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Apr	CMFD
	@	1MG	N009218	022	Mar 01, 1990	Mar	DISC
AB		2MG	N009218	013		Apr	CMFD
	@	2MG	N009218	013		Mar	DISC
AB		2.5MG	N009218	018		Apr	CMFD
	@	2.5MG	N009218	018		Mar	DISC
AB		3MG	N009218	025	Nov 18, 1996	Apr	CMFD
	@	3MG	N009218	025	Nov 18, 1996	Mar	DISC
AB		4MG	N009218	023	Aug 24, 1993	Apr	CMFD
	@	4MG	N009218	023	Aug 24, 1993	Mar	DISC
AB		5MG	N009218	007		Apr	CMFD
	@	5MG	N009218	007		Mar	DISC
AB		6MG	N009218	026	Nov 18, 1996	Apr	CMFD
	@	6MG	N009218	026	Nov 18, 1996	Mar	DISC
AB		7.5MG	N009218	016		Apr	CMFD
	@	7.5MG	N009218	016		Mar	DISC
AB	+	10MG	N009218	005		Apr	CMFD
	@	10MG	N009218	005		Mar	DISC

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

@	JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Feb	CAIN
---	------------------	------------------------	---------	-----	--------------	-----	------

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

@	LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013	Mar	DISC
---	------------------	---------	---------	-----	--------------	-----	------

ZILEUTON

TABLET; ORAL

ZYFLO

@	CHIESI USA INC	300MG	N020471	001	Dec 09, 1996	Apr	CAHN
+		600MG	N020471	003	Dec 09, 1996	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

ZYFLO CR

+	CHIESI USA INC	600MG	N022052	001	May 30, 2007	Apr	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOLEDRONIC ACID

	AP	AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Aug	NEWA
	AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	May	NEWA
>A>	AP	SAGENT PHARMS	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Nov	NEWA
	AP	+ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Oct	CTEC
	AP	USV NORTH AMERICA	EQ 4MG BASE/VIAL	A202923	001	Sep 04, 2014	Aug	NEWA

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

AB	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	NEWA
AB		5MG	A204284	002	Apr 09, 2014	Mar	NEWA
>A> AB	JUBILANT GENERICS	2.5MG	A202279	001	Nov 20, 2014	Nov	NEWA
>A> AB		5MG	A202279	002	Nov 20, 2014	Nov	NEWA
AB	SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014	Oct	NEWA
AB		5MG	A203476	002	Nov 13, 2014	Oct	NEWA
AB	TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb	NEWA
AB		5MG	A090861	002	Mar 04, 2014	Feb	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007	Jul	CAHN
AB		10MG	A077359	002	Apr 23, 2007	Jul	CAHN
	@	VIVIMED LABS	A076062	001	Apr 23, 2007	Apr	CAHN
	@		A076062	002	Apr 23, 2007	Apr	CAHN
	@	WATSON LABS	A077773	001	Apr 23, 2007	May	DISC
	@		A077773	002	Apr 23, 2007	May	DISC

ZONISAMIDE

	CAPSULE;ORAL							
	ZONISAMIDE							
	@ ANI PHARMS INC	25MG	A 077639	001	Dec 22, 2005	Sep	DISC	
AB		25MG	A 077639	001	Dec 22, 2005	Jan	CAHN	
	@	25MG	A 077641	003	Dec 22, 2005	Jan	CAHN	
	@	50MG	A 077639	002	Dec 22, 2005	Sep	DISC	
AB		50MG	A 077639	002	Dec 22, 2005	Jan	CAHN	
	@	50MG	A 077641	002	Dec 22, 2005	Jan	CAHN	
	@	100MG	A 077639	003	Dec 22, 2005	Sep	DISC	
AB		100MG	A 077639	003	Dec 22, 2005	Jan	CAHN	
	@	100MG	A 077641	001	Dec 22, 2005	Jan	CAHN	
	@ SANDOZ	25MG	A 077644	001	Dec 22, 2005	Feb	DISC	
	@	50MG	A 077644	002	Dec 22, 2005	Feb	DISC	
	@	100MG	A 077644	003	Dec 22, 2005	Feb	DISC	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DRIXORAL PLUS

@ SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987	Feb DISC
-------------------	----------------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC 5MG/5ML

A091327 001 Oct 17, 2011 Sep CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC 5MG/5ML

A091327 002 Oct 17, 2011 Sep CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

IPCA LABS LTD 5MG

A202277 002 Mar 11, 2014 Feb NEWA

10MG

A202277 004 Mar 11, 2014 Feb NEWA

SUN PHARM INDS INC 5MG

A077499 001 Dec 27, 2007 Jul CAHN

10MG

A077499 002 Dec 27, 2007 Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES

IPCA LABS LTD 5MG

A202277 001 Mar 11, 2014 Feb NEWA

10MG

A202277 003 Mar 11, 2014 Feb NEWA

SUN PHARM INDS INC 5MG

A077499 003 Dec 27, 2007 Jul CAHN

10MG

A077499 004 Dec 27, 2007 Jul CAHN

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CARACO 5MG

A077631 004 Jan 11, 2008 Feb DISC

@ 10MG

A077631 003 Jan 11, 2008 Feb DISC

@ SUN PHARM INDS INC 5MG

A077631 004 Jan 11, 2008 Jul CAHN

@ 10MG

A077631 003 Jan 11, 2008 Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CARACO 5MG

A077631 001 Jan 11, 2008 Feb DISC

@ 10MG

A077631 002 Jan 11, 2008 Feb DISC

@ SUN PHARM INDS INC 5MG

A077631 001 Jan 11, 2008 Jul CAHN

@ 10MG

A077631 002 Jan 11, 2008 Jul CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ WATSON LABS 200MG

A075425 001 Jul 29, 1999 May DISC

CLOTRIMAZOLE

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%,200MG

N020526 002 Jul 29, 1996 Sep CAHN

TABLET;VAGINAL

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG

N020525 001 Jul 29, 1996 Sep CAHN

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC 6MG;120MG

A078648 001 Feb 27, 2013 Jan CRLD

DISOPHROL

@ SCHERING PLOUGH 6MG;120MG

N013483 004 Sep 13, 1982 Jan DISC

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES PHARMA 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

A200888 001 Mar 05, 2012 Aug CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE 25MG;220MG

N205352 001 Jan 17, 2014 Jan NEWA

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED RELEASE;ORAL
NEXIUM

ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CMS2
	EQ 20MG BASE	N204655	001	Mar 28, 2014	Mar NEWA
NEXIUM 24HR					
+ ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CTNA

FAMOTIDINETABLET;ORAL
FAMOTIDINE

@ WATSON LABS	10MG	A075404	001	Nov 28, 2001	May DISC
---------------	------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

>A>	CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
>A>	ACTAVIS MID ATLANTIC 30MG/5ML	A203330	001	Nov 18, 2014	Nov NEWA
>A>	CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES				
>A>	ACTAVIS MID ATLANTIC 30MG/5ML	A203330	002	Nov 18, 2014	Nov NEWA

TABLET;ORAL

>A>	CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
	AUROLIFE PHARMA LLC 30MG	A202039	001	Nov 19, 2014	Nov NEWA
	FEXOFENADINE HYDROCHLORIDE ALLERGY				
>A>	AUROLIFE PHARMA LLC 60MG	A202039	002	Nov 19, 2014	Nov NEWA
>A>	180MG	A202039	003	Nov 19, 2014	Nov NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

>A>	FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
>A>	DR REDDYS LABS LTD 60MG;120MG	A076667	001	Nov 18, 2014	Nov NEWA

FLUTICASONE PROPIONATESPRAY, METERED;NASAL
FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014	Jul NEWA
------------------------	--------------	---------	-----	--------------	----------

IBUPROFENCAPSULE;ORAL
IBUPROFEN

P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Sep CAHN
-----------------	---------------------------------------	---------	-----	--------------	----------

SUSPENSION;ORAL

CHILDREN'S ELIXSURE					
MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004	May CAHN

TABLET;ORAL

IBUPROFEN					
AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Mar NEWA
@ WATSON LABS	200MG	A070435	001	Mar 05, 1986	May DISC

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE					
PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014	Jun NEWA

KETOCONAZOLESHAMPOO;TOPICAL
NIZORAL A-D

>A>	+ JOHNSON AND JOHNSON	1%	N020310	001	Oct 10, 1997	Nov CAHN
>D>	+ MCNEIL CONS	1%	N020310	001	Oct 10, 1997	Nov CAHN

LEVONORGESTREL

TABLET;ORAL

FALLBACK SOLO					
LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014	Jun NEWA
LEVONORGESTREL					
FAMY CARE LTD	1.5MG	A202739	001	Oct 31, 2014	Oct NEWA
@ LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Sep DISC
PERRIGO R AND D	1.5MG	A202334	001	Aug 20, 2014	Aug NEWA
OPCICON ONE-STEP					
SUN PHARM INDS LTD	1.5MG	A202635	001	Sep 11, 2014	Sep NEWA

LORATADINETABLET;ORAL
CLARITIN

+ BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002	Sep CAHN
CLARITIN HIVES RELIEF					
+ BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003	Sep CAHN
TABLET, ORALLY DISINTEGRATING;ORAL					
CLARITIN HIVES RELIEF REDITAB					
+ BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003	Sep CAHN
CLARITIN REDITABS					
+ BAYER HEALTHCARE LLC	10MG	N020704	002	Nov 27, 2002	Sep CAHN

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

MEDTECH PRODUCTS 2%,4%

N021261 003 Jun 17, 2003 Oct CAHN

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ MEDTECH PRODUCTS 2%,4%

N021261 001 Feb 02, 2001 Oct CAHN

CREAM;VAGINAL

MONISTAT 3

+ MEDTECH PRODUCTS 4%

N020827 001 Mar 30, 1998 Oct CAHN

MONISTAT 7

+ MEDTECH PRODUCTS 2%

N017450 002 Feb 15, 1991 Oct CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 1 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,1.2GM

N021308 001 Jun 29, 2001 Oct CAHN

MONISTAT 7 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,100MG

N020288 002 Apr 26, 1993 Oct CAHN

MONISTAT-3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,200MG

N020670 002 Apr 16, 1996 Oct CAHN

SUPPOSITORY;VAGINAL

MONISTAT 7

+ MEDTECH PRODUCTS 100MG

N018520 002 Feb 15, 1991 Oct CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014 Feb NEWA

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

>A> ACTAVIS LABS NY INC EQ 2MG BASE

A076569 001 Jul 29, 2004 Nov CAHN

>A> EQ 2MG BASE

A078699 001 Dec 29, 2008 Nov CAHN

>A> EQ 2MG BASE

A079216 001 Jul 08, 2009 Nov CAHN

>A> @ EQ 4MG BASE

A076569 002 Jul 29, 2004 Nov CAHN

>A> EQ 4MG BASE

A078697 001 Dec 29, 2008 Nov CAHN

>D> WATSON LABS EQ 2MG BASE

A076569 001 Jul 29, 2004 Nov CAHN

>D> EQ 2MG BASE

A078699 001 Dec 29, 2008 Nov CAHN

>D> EQ 2MG BASE

A079216 001 Jul 08, 2009 Nov CAHN

>D> @ EQ 4MG BASE

A076569 002 Jul 29, 2004 Nov CAHN

>D> EQ 4MG BASE

A078697 001 Dec 29, 2008 Nov CAHN

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+ MAYER LABS INC 1GM

N018683 001 Apr 01, 1983 Aug CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ BAYER HEALTHCARE LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Sep CAHN

PERMETHRIN

LOTION;TOPICAL

NIX

+ MEDTECH PRODUCTS 1%

N019918 001 May 02, 1990 Oct CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ WOCKHARDT EQ 150MG BASE

A078653 001 Nov 26, 2007 Oct DISC

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

NASACORT ALLERGY 24 HOUR

+ SANOFI AVENTIS US 0.055MG/SPRAY

N020468 002 Oct 11, 2013 Jul CRLD

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2014

NO NOVEMBER 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	5905082	May 18, 2016	DS DP		NCE	Aug 12, 2018
	5905082*PED	Nov 18, 2016				
	6294540	May 14, 2018	DS DP U-1572			
	6294540*PED	Nov 14, 2018				
	6417191	Mar 28, 2016	DP U-1572			
	8129385	Oct 05, 2027	DS DP			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027	U-1579			
	8822438	Aug 24, 2027	U-1580			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001	8592434	Jun 16, 2030	DP U-1460			
	8747896	Jun 03, 2027	DP U-1460			
	8791127	Mar 23, 2027	DP U-1460			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - ADAPALENE</u>						
A 200298 001					PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8709392	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8809305	Dec 23, 2022	U-1078			
<u>ADENOSINE - ADENOSINE</u>						
A 077425 001					PC	Mar 22, 2014
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	8834849	Jun 04, 2017	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	8664215	Oct 05, 2029	U-1493			
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8112290	Jul 31, 2030	U-1443			
	8645160	Jun 18, 2029	U-1485			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	8758418	May 01, 2018	U-289			
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 001					PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 002					PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 004					PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090144 001					PC	Mar 29, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 001					>A> PC	May 30, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	002				>A> PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	003				>A> PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	004				>A> PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	005				>A> PC	May 30, 2015
<u>APIXABAN - ELIQUIS</u>						
N 202155	001	6413980	Dec 22, 2019	DS DP U-1200	I-661	Aug 21, 2017
		6413980	Dec 22, 2019	DS DP U-1301	I-681	Mar 03, 2017
		6413980	Dec 22, 2019	DS DP U-1302	I-690	Aug 21, 2017
		6413980	Dec 22, 2019	DS DP U-1501	I-691	Aug 21, 2017
		6967208	Feb 03, 2023	DS DP U-1167		
		6967208	Feb 03, 2023	DS DP U-1200		
		6967208	Feb 03, 2023	DS DP U-1301		
		6967208	Feb 03, 2023	DS DP U-1302		
		6967208	Feb 03, 2023	DS DP U-1323		
		6967208	Feb 03, 2023	DS DP U-1501		
		6967208	Feb 03, 2023	DS DP U-1502		
<u>APIXABAN - ELIQUIS</u>						
N 202155	002				I-661	Aug 21, 2017
					I-690	Aug 21, 2017
					I-691	Aug 21, 2017
<u>APREMILAST - OTEZLA</u>						
N 205437	001	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
<u>APREMILAST - OTEZLA</u>						
N 205437	002	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
<u>APREMILAST - OTEZLA</u>						
N 205437	003	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	001	8642600	Jan 28, 2022	U-1492	M-137	Jun 09, 2017
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027	U-1529		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001					M-137	Jun 09, 2017
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Apr 20, 2015	DS DP U-1530		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Apr 20, 2015	DS DP U-1530		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	8022228	Apr 06, 2026	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	8022228	Apr 06, 2026	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	6087383	Dec 21, 2018	DS DP			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>AVANAFIL - STENDRA</u>						
N 202276 001					D-140	Sep 17, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 002					D-140	Sep 17, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 003					D-140	Sep 17, 2017
<u>AXITINIB - INLYTA</u>						
N 202324 001	8791140	Aug 05, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Aug 05, 2030	DS			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	8815934	May 06, 2019	DP		NP	Oct 03, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	8546428	Mar 19, 2029	DS DP U-1321			
<u>BELINOSTAT - BELEODAO</u>						
N 206256 001	6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
	8835501	Oct 27, 2027	DP		ODE	Jul 03, 2021
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	>A> 8895756	Jan 12, 2026	DP			
	>A> 8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	>A> 8895756	Jan 12, 2026	DP			
	>A> 8895756*PED	Jul 12, 2026				
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8663699	Jun 03, 2029	U-124			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	>A> 8288434	Aug 05, 2029	DP U-124			
	>A> 8288434	Aug 05, 2029	DP U-134			
	>A> 8288434	Aug 05, 2029	DP U-818			
	>A> 8288434	Aug 05, 2029	DP U-916			
	>A> 8288434	Aug 05, 2029	DP U-921			
	>A> 8288434	Aug 05, 2029	DP U-1033			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	8784789	Sep 05, 2024	DP			
	>A> 8877168	Jul 30, 2023	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					PC	Sep 27, 2014
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001					NPP	Aug 29, 2017
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8772338	Mar 16, 2025	DP U-1528			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277		M-140	Sep 04, 2017
	8632760	Jan 15, 2023	U-1487			
	8758733	Jan 15, 2023	U-1487			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	>A> 5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	>A> 6713446	Jan 25, 2022	DS DP		D-142	Oct 08, 2017
	>A> 6958319	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
					M-139	Aug 08, 2017
					ODE	Jun 20, 2015
					ODE	Oct 08, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	8858961	Sep 02, 2023	DP			
	8858961*PED	Mar 02, 2024				
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	8859551	May 25, 2024	U-1428			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	8748425	Apr 19, 2022	DP U-1524			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	8784888	Jun 09, 2020	DP			
	>A> 8895064	Sep 07, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001					NP	Oct 07, 2017
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	8834921	Sep 18, 2018	DP U-1587			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	8834921	Sep 18, 2018	DP U-1587			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	7375111	Mar 26, 2025	DP		NC	Sep 10, 2017
	7462626	Jul 20, 2024	U-1583			
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027	U-1584			
	8722085	Nov 08, 2027	U-1585			
	8815889	Jul 20, 2024	U-1586			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001 >A>	8877776	Oct 08, 2030	DS DP U-1617			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002 >A>	8877776	Oct 08, 2030	DS DP U-1617			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280			
	8269128	May 26, 2026	DP U-1280			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8703787	Feb 02, 2032	U-1179			
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	8846650	Jun 04, 2025	DP U-1578			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331 003					>A> M-149	Nov 20, 2017
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331 004					>A> M-149	Nov 20, 2017
<u>COBICISTAT - TYBOST</u>						
N 203094 001	8148374	Sep 03, 2029	DS DP U-1279		NP	Sep 24, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
	8716264	Jan 13, 2024	DP U-257			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	8785632	Mar 01, 2025	DS			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	8003353	Jun 11, 2024	U-817			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					ODE	Apr 30, 2020
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002					ODE	Apr 30, 2020
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002					I-682	Apr 04, 2017
					I-683	Apr 04, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-678 ODE	Jan 08, 2017 Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-678 ODE	Jan 08, 2017 Jan 09, 2021
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
	7115564	Nov 14, 2023	DP		GAIN	May 23, 2024
	7119061	Nov 14, 2023	DP			
	8143212	Nov 14, 2023	U-1517			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	8663685	Jan 18, 2025	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	7758890	Jul 01, 2025	DP			
	8110225	Dec 24, 2022	DP			
	8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	>A> 6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	>A> 6515117	Oct 04, 2020	DS DP U-493			
	>A> 6936590	Oct 04, 2020	U-493			
	>A> 7919598	Dec 16, 2029	DS			
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8685934	May 26, 2030	U-1522			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	>A> 6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	>A> 6515117	Oct 04, 2020	DS DP U-493			
	>A> 6936590	Oct 04, 2020	U-493			
	>A> 7919598	Dec 16, 2029	DS			
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8685934	May 26, 2030	U-1522			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	>A> 6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	>A> 6515117	Oct 04, 2020	DS DP U-493			
	>A> 6936590	Oct 04, 2020	U-493			
	>A> 7919598	Dec 16, 2029	DS			
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8685934	May 26, 2030	U-1522			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	>A> 6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	>A> 6515117	Oct 04, 2020	DS DP U-493			
	>A> 6936590	Oct 04, 2020	U-493			
	>A> 7919598	Dec 16, 2029	DS			
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8685934	May 26, 2030	U-1522			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	8680103	Feb 04, 2025	DP			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001					I-686	Jun 29, 2017
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	>A> 8871273	Jan 11, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
>A>	8871273	Jan 11, 2028	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992 003					PC	May 18, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	RE38115	Jan 26, 2016	DP	Y		
<u>DICLOFENAC - ZORVOLEX</u>						
N 024592 001	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
<u>DICLOFENAC - ZORVOLEX</u>						
N 024592 002	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
A 202027 001					PC	Nov 23, 2014
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 024623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
>A>	8871809	Oct 17, 2027	U-1614			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 024063 001	8759393	Oct 29, 2019	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 024063 002	8759393	Oct 29, 2019	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	>A> 8883849	Jan 17, 2022	U-1618			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	8715724	Feb 03, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	8715724	Feb 03, 2028	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					NPP NPP	Oct 16, 2017 Oct 16, 2017
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					NPP NPP	Oct 16, 2017 Oct 16, 2017
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					NPP NPP	Oct 16, 2017 Oct 16, 2017
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8716264	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	U-1571		NCE	Aug 19, 2019
	7196205	Apr 29, 2022	DS		ODE	Aug 19, 2021
	7615573	Apr 29, 2022	U-1571			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	8716264	Jan 13, 2024	DP U-257			
	8841310	Dec 09, 2025	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	8716264	Jan 13, 2024	DP U-257			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-185			
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 001					PC	Feb 21, 2015
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 002					PC	Feb 21, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	May 15, 2026	U-1281		I-693	Sep 10, 2017
	8183274	May 15, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	8870827	Sep 11, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	8870827	Sep 11, 2025	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509		RTO	Mar 28, 2017
	5714504	Feb 03, 2015	DP U-1509			
	5877192	May 27, 2014	U-1509			
	5900424	May 04, 2016	DS U-1509			
	6369085	May 25, 2018	DS DP U-1509			
	6428810	Nov 03, 2019	DP U-1509			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6978945	Jul 31, 2022	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190 001					ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	8722037	Sep 28, 2027	DP			
	>A> 8888745	Aug 28, 2026	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001					>A> M-148	Nov 24, 2017
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002					>A> M-148	Nov 24, 2017
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8216180	Jan 12, 2028	DP			
	8439864	Mar 25, 2028	DP			
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FERRIC CITRATE - FERRIC CITRATE</u>						
N 205874 001	5753706	Feb 03, 2017	DP U-1577			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8859510	Jul 31, 2027	U-319			
<u>FLORBETABEN F-18 - NEURACEO</u>						
N 204677 001	7907135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	6217895	Mar 22, 2019	DP U-1597		NP	Sep 26, 2017
	6375972	Apr 26, 2020	DP U-1597			
	6548078	Mar 22, 2019	DP U-1597			
	8252307	Jun 27, 2019	DP			
	8871241	Aug 12, 2027	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001					M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002					M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003					M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004					M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005					M-142	Oct 10, 2017
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8691185	Jan 24, 2023	U-336			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8691185	Jan 24, 2023	U-336			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	5873360	Feb 23, 2016	DP		NP	Aug 20, 2017
	7101866	Aug 03, 2021	DS DP U-1559			
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	5873360	Feb 23, 2016	DP		NP	Aug 20, 2017
	7101866	Aug 03, 2021	DS DP U-1559			
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8746242	Oct 11, 2030	DP		NP	May 10, 2016
	RE44874	Mar 23, 2023	DS DP U-1548			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF</u>						
N 205434 001					>A> M-147	Jul 23, 2017
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	6743413	Jun 01, 2021	U-1591			
	6743413*PED	Dec 01, 2021				
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	6743413	Jun 01, 2021	U-1591			
	6743413*PED	Dec 01, 2021				
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	6743413	Jun 01, 2021	U-1591			
	6743413*PED	Dec 01, 2021				
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	8623922	Jun 22, 2021	DP			
<u>GABAPENTIN - GRALISE</u>						
N 022544 001					ODE	Jan 28, 2018
<u>GABAPENTIN - GRALISE</u>						
N 022544 002					ODE	Jan 28, 2018
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	6054430	May 24, 2014	DS		NP	Jan 28, 2017
	6342476	May 24, 2014	U-441			
	6362161	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
	8232250	Aug 19, 2030	U-441			
	8367605	May 24, 2014	DS			
	8399413	Aug 19, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8642012	Sep 22, 2030	U-1383			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001	5854290	Sep 21, 2015	U-494	Y	I-635	Feb 25, 2014
	5854290*PED	Mar 21, 2016			PED	Aug 25, 2014
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002	5854290	Sep 21, 2015	U-494	Y	I-635	Feb 25, 2014
	5854290*PED	Mar 21, 2016			PED	Aug 25, 2014
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003	5854290	Sep 21, 2015	U-494	Y	I-635	Feb 25, 2014
	5854290*PED	Mar 21, 2016			PED	Aug 25, 2014
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004	5854290	Sep 21, 2015	U-494	Y	I-635	Feb 25, 2014
	5854290*PED	Mar 21, 2016			PED	Aug 25, 2014
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001 >A>	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002 >A>	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003 >A>	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004 >A>	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005 >A>	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006 >A>	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007 >A>	8808740	Dec 21, 2031	DP U-1556			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-680	Feb 12, 2017
	8476284	Dec 28, 2026	U-1491		I-689	Jul 28, 2017
	8497277	Dec 28, 2026	U-1456		ODE	Feb 12, 2021
	8497277	Dec 28, 2026	U-1491		ODE	Jul 28, 2021
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8735452	Sep 30, 2029	U-981			
	8871810	Aug 27, 2030	U-1599			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2015	DS DP U-1187			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NP	Jul 26, 2015
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
>A>	8865730	Mar 05, 2033	DS DP U-1615			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
>A>	8865730	Mar 05, 2033	DS DP U-1615			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002					ODE	Dec 19, 2015
<u>INDOMETHACIN - TIVORBEX</u>						
N 024768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 024768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 020833 001	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 020833 002	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8679069	Apr 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2015	DS			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8754224	Dec 28, 2026	DS DP			
<u>IVERMECTIN - SKLICE</u>						
N 202736 001	8791153	Oct 12, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8648107	May 28, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001	RE38551	Mar 17, 2022	DS DP U-1565		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1568		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	8840925	Jul 02, 2028	DP U-1596			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	8821927	Jun 12, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Oct 10, 2019
	8088368	May 12, 2030	DS DP			
	8273341	May 12, 2030	U-1470			
	8334270	Mar 21, 2028	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8822430	May 12, 2030	DS DP U-1470			
	8841278	May 12, 2030	DP U-1470			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696 001	6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696 002	6036976	Dec 13, 2016	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001	8765153	Dec 08, 2023	DP			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 001	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 002	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 003	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 004	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001 >A>	8865937	May 23, 2032	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002 >A>	8865937	May 23, 2032	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003 >A>	8865937	May 23, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	>A> 8865937	May 23, 2032	DS DP			
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	8759401	Jul 24, 2026	DP U-1523			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	8802628	Jul 24, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	8802628	Jul 24, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	Aug 23, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	Aug 23, 2027	U-1503		M-146	Jul 30, 2017
	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	Aug 23, 2027	U-1503		M-146	Jul 30, 2017
	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	Aug 23, 2027	U-1503		M-146	Jul 30, 2017
	8846695	Jun 04, 2030	U-1503			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-645	Jan 31, 2015
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8697686	Dec 20, 2025	DS DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679	Oct 26, 2021	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8748481	Sep 01, 2025	U-1520			
	8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	8729085	May 26, 2026	DP			
	>A> 8883794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	8729085	May 26, 2026	DP			
	>A> 8883794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	8729085	May 26, 2026	DP			
	>A> 8883794	May 26, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	8729085	May 26, 2026	DP			
	>A> 8883794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	5532372	Jul 02, 2018	DS			
	8729085	May 26, 2026	DP			
	>A> 8883794	May 26, 2026	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 002	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>MENOTROPINS (FSH;LH) - MENOPUR</u>						
N 021663 001					D-139	Feb 19, 2017
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	8809615	Jan 03, 2030	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	8809615	Jan 03, 2030	DP			
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919 001					ODE	Apr 28, 2021
<u>MESALAMINE - APRISO</u>						
N 022301 001	8865688	May 01, 2030	U-1310			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	>A> 6746429	Apr 12, 2020	DP			
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8480631	Mar 19, 2030	DP U-1442			
	>A> 8562564	Jan 24, 2026	DP			
	>A> 8579865	Mar 19, 2030	DP U-1442			
	>A> RE44846	Aug 10, 2019	DP			
	>A> RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 005	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 006	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 007	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 008	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 009	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 010	8664231	Jun 01, 2029	U-1442			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8778390	Feb 15, 2031	DP U-1543			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	8722650	Jun 24, 2025	U-1078			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	>A> 8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	>A> 8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	>A> 8877247	Jun 19, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
>A>	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
>A>	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
>A>	8877247	Jun 19, 2027	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	8778365	Jan 31, 2033	DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7662365	Oct 18, 2022	DS DP		NCE	Sep 16, 2019
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7662365	Oct 18, 2022	DS DP		NCE	Sep 16, 2019
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	5202333	Apr 13, 2015	DS DP U-528		NCE	Oct 10, 2019
	6297375	Feb 22, 2020	DS			
	8623826	Nov 18, 2030		U-528		
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8663680	Feb 13, 2020	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	8293756	Sep 25, 2027	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	8293756	Sep 25, 2027	DP			
<u>NINTEDANIB - OFEV</u>						
N 205832 001	6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
<u>NINTEDANIB - OFEV</u>						
N 205832 002	6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8776794	Jan 06, 2031	DP U-1226		M-132	Dec 21, 2013
	8776794*PED	Jul 06, 2031			PED	Jun 21, 2014
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8776794	Jan 06, 2031	DP U-1226		M-132	Dec 21, 2013
	8776794*PED	Jul 06, 2031			PED	Jun 21, 2014
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001	5840757	Nov 24, 2015	DP		NP	Oct 03, 2016
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	5964416	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP U-1547			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1547			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1547			
	8044046	Nov 10, 2023	U-1547			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	RE45128	Mar 16, 2019	DS DP U-1576			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2016	DP			
	5948818	May 13, 2016	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP U-1511			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	RE45198	Jul 16, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	RE45198	Jul 16, 2016	U-588			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2015	DS DP U-1569		NCE	Aug 06, 2019
	5998581	Nov 12, 2017	DS		GAIN	Aug 06, 2024
	8420592	Aug 29, 2029	U-1570			
<u>OSPemifene - OSPHENA</u>						
N 203505 001	8642079	Mar 01, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	8821930	Apr 13, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	8821930	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	>A> 8894987	Mar 29, 2030	DP			
	>A> 8894988	Aug 25, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	>A> 8894987	Mar 29, 2030	DP			
	>A> 8894988	Aug 25, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	>A> 8894987	Mar 29, 2030	DP			
	>A> 8894988	Aug 25, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	>A> 8894987	Mar 29, 2030	DP			
	>A> 8894988	Aug 25, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	>A> 8894988	Aug 25, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	>A> 8894988	Aug 25, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	>A> 8894988	Aug 25, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8637540	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 001	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 002	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 003	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 005	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	8853260	Aug 14, 2020	DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001					>A> I-698	Nov 12, 2017
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002					>A> I-698	Nov 12, 2017
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003					>A> I-698	Nov 12, 2017
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004					>A> I-698	Nov 12, 2017
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005					>A> I-698	Nov 12, 2017
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
	>A> 8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
	>A> 8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
	>A> 8562981	Feb 20, 2028	U-1274			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
	>A> 8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
	>A> 8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 007	>A> 8221747	Feb 20, 2028	DP			
	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
	>A> 8562981	Feb 20, 2028	U-1274			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 004	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015	U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 005	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015	U-507			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Apr 20, 2019	DP			
	8685441	Jan 13, 2019	U-665			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	6071537	Jun 23, 2017	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	6071537	Jun 23, 2017	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	6071537	Jun 23, 2017	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	6071537	Jun 23, 2017	U-1262			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 001	8859623	Nov 14, 2033	U-1594			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 002	8859623	Nov 14, 2033	U-1594			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	>A> 7566729	Apr 22, 2029	U-1600		NCE	Oct 16, 2019
	>A> 7635707	Apr 22, 2029	U-1609		ODE	Oct 15, 2021
	>A> 7696326	Dec 18, 2027	U-1601			
	>A> 7767225	Sep 22, 2026	DP U-1602			
	>A> 7767700	Dec 18, 2027	U-1601			
	>A> 7816383	Jan 08, 2030	U-1603			
	>A> 7910610	Jan 08, 2030	U-1604			
	>A> 7988994	Sep 22, 2026	DP U-1602			
	>A> 8013002	Jan 08, 2030	U-1603			
	>A> 8084475	Jan 08, 2030	U-1605			
	>A> 8318780	Jan 08, 2030	U-1606			
	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8420674	Dec 18, 2027	DP U-1608			
	>A> 8592462	Apr 22, 2029	U-1609			
	>A> 8609701	Apr 22, 2029	U-1610			
	>A> 8648098	Jan 08, 2030	U-1611			
	>A> 8753679	Sep 22, 2026	DP U-1602			
	>A> 8754109	Jan 08, 2030	U-1612			
	>A> 8778947	Aug 30, 2033	U-1613			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	8734833	May 26, 2020	DS DP			
	RE40640	Oct 14, 2015	DS DP U-1462			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	8679533	Sep 08, 2029	DP U-219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	>A> 8404703	Jan 02, 2023	U-1381			
	>A> 8569325	Jan 02, 2023	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	>A> 8404703	Jan 02, 2023	U-1381			
	>A> 8569325	Jan 02, 2023	U-1381			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001					I-685	May 29, 2017
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002					I-685	May 29, 2017
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
	8680124	Jul 20, 2028	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS U-1526			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS U-1526			
	8829017	Jul 24, 2029	U-1562			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8691878	Aug 25, 2024	U-688			
	8691878*PED	Feb 25, 2025				
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			
<u>ROPIVACAIN HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989		PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156	Y		
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	7566714	Nov 17, 2024	U-1589			
	7612073	Nov 17, 2024	U-1010			
	8067416	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-134	May 24, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	8741926	Jul 28, 2026	DS U-1467		>A> I-697	Nov 05, 2017
	8754106	Jul 28, 2026	DS U-1467			
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676 003					PC	Jul 15, 2014
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8731963	Dec 17, 2022	U-1110			
	8772306	Mar 15, 2033	U-1532			
	8859619	Dec 22, 2019	DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8889159	Mar 26, 2029	DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 007	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8618141	Feb 11, 2023	U-1480			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					NCE	Oct 10, 2019
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	8241243	Aug 10, 2023	DP			
	8491524	Nov 21, 2022	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8741620	Feb 24, 2024	DS DP		NPP	Aug 27, 2017
	8790641	Oct 18, 2025	U-1564			
	8790641	Oct 18, 2025	U-1574			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
	8785492	Jan 25, 2033	U-1486		ODE	Jan 31, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-718		NCE	Jul 07, 2019
	7767657	May 22, 2027	DP			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	8808716	Feb 24, 2030	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					I-687 ODE	Jun 13, 2017 Jun 13, 2021
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 001					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 002					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 003					PC	Jul 07, 2014
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	8623868	Feb 21, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y		
	5362718*PED	Aug 15, 2019				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	8791097	May 10, 2032		U-1550		
	8791097	May 10, 2032		U-1551		
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	8802735	Sep 14, 2030	DP			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	8802735	Sep 14, 2030	DP			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	7517334	Mar 25, 2025	DP			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 002	7517334	Mar 25, 2025	DP			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2020	DS DP U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020		U-1103		
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020		U-1103		
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	>A> 8877230	Feb 04, 2024	U-1616			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026	U-1500			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	8626531	Oct 23, 2020	U-1465			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	8425934	Apr 17, 2030	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 16, 2018	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NP	Sep 24, 2017
	6149054	Dec 16, 2016	DP			
	6176242	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-1593			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	8715623	Dec 19, 2022	DP U-909			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020	U-978			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 001					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 002					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 003					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 004					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 005					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 006					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 001					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 002					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844 003					NPP	Mar 28, 2017
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
>A>	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
>A>	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
>A>	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
>A>	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			
>A>	8889190	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8791160	Mar 04, 2025	DP U-1182			
	8809394	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8722735	Oct 10, 2029	DP		NP	May 15, 2017
	8754123	May 19, 2029	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001					M-145	May 20, 2017
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Oct 08, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8735380	Feb 20, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8746242	Oct 11, 2030	DP		NP	Dec 18, 2016
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALSARTAN - VALSARTAN</u>						
A 077492 001					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 002					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 003					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 004					PC	Jan 03, 2015
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 001 >A>	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 002 >A>	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 003 >A>	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 004 >A>	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-143	Oct 15, 2017
					M-144	Oct 15, 2017
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-143	Oct 15, 2017
					M-144	Oct 15, 2017
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8741920	Jul 27, 2030	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	8673921	Jun 05, 2022	DS DP			
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
	7304078	Apr 06, 2024	DS DP U-1512			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	8450372	Mar 18, 2028	U-892			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Nov 11, 2030	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>